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ABSTRACT 
NEW PERSISTENT AND CHRONIC OPIOID USE IN CANCER SURVIVORS AFTER 
CURATIVE INTENT RADIATION 
 
By Elena Valerie Fernández, BS, PharmD, PhD Candidate 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University, 2020 
 
Advisor: Norman V. Carroll, PhD, RPh, Professor of Pharmacoeconomics and Health 
Outcomes, Department of Pharmacotherapy & Outcomes Science 
 
Background:  Emerging evidence suggests that as more patients are surviving cancer, new 
persistent opioid use (no prior exposure to opioids before cancer therapy but requiring opioid 
prescriptions after curative intent treatment; NPOU) is of greater concern. In patients receiving 
curative intent radiation (definitive radiation therapy and as treatment for cure; CIR), the extent 
to which patients develop NPOU or continue opioid use (COU) following CIR is not known. 
Neither are factors associated with NPOU or COU, opioid doses, or time to discontinuation 
(TTD) of opioids in 5CS known. Objectives: Describe longitudinal trends opioid use in cancer 
survivors who received CIR, examine the association of NPOU and COU to patient specific 
factors as well as opioid dose levels and TTD of opioids.  Methods: Electronic medical record 
data from individuals receiving CIR for any indication at Virginia Commonwealth University’s 
Massey Cancer Center in the last 11 years was used to create a longitudinal record of the oral 
morphine equivalent (OME) of prescriptions to determine NPOU and COU. Descriptive 
statistics as well as incidence, binomial logistic regressions, panel data models, mixed linear 
models, Kaplan Meyer survival curves and Cox proportional hazard models were used. 
Results: Based on our analysis, 5CS at this institution were prescribed high 30-day average 
daily OME doses (mean: 94, SD: 131) which increased from late 2009 to 2012, then 
decreased after 2012. Men, those of white compared to black race, those with public 
insurance, and patients with additional chemotherapy or no additional surgery appeared to be 
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prescribed higher 30-day average daily OME doses between 2008 and 2018. Of 5CS who 
received CIR, 19.7% developed NPOU and 54.8% COU. Head and neck cancer, stage 3 
disease, additional chemotherapy, African American race, certain insurance types, and 
comorbid conditions conferred increased odds of NPOU. Indigent insurance, anxiety, back 
pain, hypertension, and nicotine use were associated with increased odds of COU. Most 5CS 
do not utilize opioids long-term before or after CIR. 5CS with opioid prescriptions prior to 
radiation had sustained daily doses of 68.2 - 68.3 OMEs higher than those without opioid 
prescriptions. 5CS with public insurance, anxiety, depression, and other drug use were 
associated with higher average daily OMEs while diabetes and hypertension were associated 
with lower average daily OMEs. We predict that 5CS that undergo CIR will use at least some 
level of opioids, on average 4.1 daily OMEs one year after end of radiation. 5CS continue 
receiving opioid prescriptions for a median of 16.8 months after completion of CIR. Median 
TTD of opioids was shorter for patients without opioid exposure prior to therapy (NPOU; 13.0 
months) compared to patients with opioid exposure prior to therapy (COU; 21.4 months). 
Factors associated with shorter TTD included NPOU and head and neck cancers. Conversely, 
additional surgery, death more than five years after diagnosis, as well as alcohol and nicotine 
use were associated with longer TTD of opioids. Discussion: Presence of comorbidities, 
substance use, and indigent or public insurance were associated with greater opioid burden, 
use, dose and length of time of opioid use. . Socioeconomic and health differences (African 
American race, indigent charity insurance, Medicaid, chronic conditions and substance use) in 
patients receiving CIR also result in increased opioid use, odds of NPOU and COU, opioid 
dose, and longer TTD of opioids. Conclusions: Our results have demonstrated substantial 
opioid use in cancer survivors. There are currently no evidence-based guidelines for opioid 
prescribing in cancer survivors. Guidelines to prevent misuse and opioid related deaths are 
warranted to prevent potential misuse due to high numbers of patients that continue to use 
opioids long after CIR, risk of NPOU, COU, and high OMEs utilized. 
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CHAPTER 1: INTRODUCTION 
Background and Significance 
Five-year survival from cancer diagnosis has increased from less than 50% to a mean 
of 67% (with a large range based on cancer site) over the last several decades.1,2 This 
increase in survival, in part due to improvements in antineoplastic therapy, has led to an 
increase in both the aggregate number of cancer survivors, but also the duration of time 
patients spend in the survivorship period.  These patients have either experienced cancer-free 
survival or have managed chronic or intermittent illness without recurrence.1–3 There are more 
than 100 types of cancers each with its own treatment options and evidence based guidelines 
to direct therapy depending on disease severity, location, and provider and patient therapeutic 
goals.4  
Approximately 50% of cancer patients will receive radiation therapy as a component of 
their treatment.5  Radiation therapy can be used alone and in combination with surgery or 
chemotherapy. Radiation can be used neoadjuvantly (before surgery to reduce the size of the 
tumor) or adjuvantly (after surgery). Radiation therapy is widely used in many cancer types 
including eye, bladder, brain, breast, esophageal, gynecologic, lung, liver, prostate, and skin. 
Undergoing radiation therapy can subject patients to significant morbidity that can vary by 
treatment site, with patients treated for head and neck cancer tending to have a significant 
burden of radiation-related acute and late toxicity.3,6,7   
Pain management is an important consideration for patients undergoing cancer disease 
treatment.  Opioids are a cornerstone of pain management in patients with cancers, as 
malignancies themselves can lead to significant pain in addition to pain resulting from invasive 
surgery, chemotherapy, and radiation.3,8,9 Additionally, pain management guidelines are 
lacking for patients nearing the end of life, or for cancers treated with palliative intent.10–12 
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For these reasons, there is a distinct divide in pain management for patients that have 
cancer versus those who do not. The former are often excluded from most pain studies. 
Cancer and non-cancer pain is treated differently in the literature and the focus of opioid 
prescribing guidelines, overuse, misuse, abuse, and adverse consequences leading to death 
has mostly focused on non-cancer pain.8,10 In studies that have investigated pain in patients 
with cancer, it has been documented that pain has been significantly undertreated.8,13–16 
Specifically from 1994 to 2007, a systematic review found 43% of patients with cancer were 
potentially undertreated for pain.8,17  Later studies from 2007-2013 suggest lower, but still 
significant prevalence of undertreatment of pain in 32% of patients.8,14,17–21  
However, there is growing awareness of opioid use and misuse in patients with 
cancer.8,22–26  It has been suggested that opioid utilization patterns (chronic opioid use by total 
daily dose, dose escalations, and dose reductions) are similar between patients with cancer 
pain and patients with non-cancer pain although patients were not matched.27,28 Additionally, in 
Canada, trends in opioid prescribing in noncancer and cancer patients remained relatively 
stable between 2004 and 2013.25 A propensity score matched study published in 2019 
reported that respondents with cancer were significantly more likely to use prescription opioids 
than matched controls (OR: 2.43, 95% CI: 1.68-3.57).24 One study utilizing validated self-report 
instruments (the Screener and Opioid Assessment for Patients With Pain (SOAPP), and the 
Cut Down-Annoyed-Guilty-Eye Opener (CAGE) questionnaire adapted to include drug use 
(CAGE-AID)) conducted at a single supportive care clinic for patients with cancer found that 
“men and patients who have anxiety, financial distress, and a prior history of alcoholism/illicit 
drug use are at increased risk of aberrant opioid and drug use behaviors” and suggests that 
roughly 20% of patients with cancer are at elevated risk for aberrant opioid and drug use 
behaviors.23   
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Cancer survivors are an important demographic to consider as opioid use and abuse 
have reached epidemic proportions in the United States.  There are over 200 million opioid 
prescriptions utilized in the United States annually, but it is not known how many of those are 
for patients with cancer pain.29 Per Substance Abuse and Mental Health Services 
Administration (SAMHSA) in 2015, 11.5 million Americans reported misusing prescription 
opioids and 1.9 million met diagnostic criteria for prescription opioid abuse.30  There has also 
been a surge of opioid deaths from 4,200 in 1999 to 15,300 in 2013 and over 64,000 in 
2016.8,31 Further, three times the number of opioids were prescribed 2015 compared to 
1999.8,31 
For patients with cancer, pain is often managed by the patient’s surgical, radiation, or 
medical oncologist, who may not have optimal training in pain management and palliative 
care.32  There is emerging evidence of high rates of opioid misuse (use of opioids contrary to 
the directed or prescribed pattern of use, regardless of presence or absence of harm) in 
patients with cancer.33–38 One study found that 58% of patients with cancer were noncompliant 
with their prescribed opioid therapy and were more likely to have higher morphine equivalent 
daily doses.34 Another study found that more than 50% of urine drug tests (UDT) were 
abnormal in patients with cancer and the most common opioid findings were absent prescribed 
opioids (27%) and present unprescribed opioids (25%).38  A study of 209 emergency 
department patients with cancer showed depression and illicit substance use were significantly 
associated with high risk of opioid misuse.37  Ultimately, an estimated 29% of patients with 
cancer are at high-risk for misuse.8,39   
Historically, there are five groups of pain types for patients with cancer: acute cancer-
related pain, chronic cancer-related pain, preexisting chronic pain and cancer-related pain, 
history of drug addiction and cancer-related pain, and end-stage cancer-related pain.40 
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However, there is emerging evidence of a new group of patients with new persistent opioid 
use, defined as those who were opioid naïve (not exposed to opioids before cancer therapy) 
and who continue to fill opioid prescriptions beyond six months of curative intent treatment.41,42  
As more patients are surviving cancer, new persistent and continued chronic opioid use are of 
greater concern, especially as pain in this population is poorly characterized and there is little 
to no consensus on the therapeutic framework of treating pain for these patients.21 Recent 
evidence suggests that cancer-directed therapies (especially surgery and radiation directed to 
the head and neck) may promote opioid use long after the cancer therapy is concluded.7,42–44   
Additionally, there is anecdotal evidence that patients having certain cancers may be at 
higher risk for high opioid use after curative intent radiation (CIR, treatment with intent to cure, 
which is generally the case for all non-palliative cancer) due to differences in cancer site or 
demographics.42  However, it has been suggested that radiation treatment alone is least likely 
to be associated with opioid use during treatment compared to other treatment modalities 
(surgery, chemotherapy, combinations).45 Neither the extent to which cancer survivors who 
receive CIR develop new persistent opioid use nor what factors may put them at risk for 
developing new persistent and continued chronic opioid use is known.  Understanding the 
factors associated with developing new persistent and continued chronic opioid use after 
radiotherapy may help identify patients that may have difficulty weaning off opioid regimens. 
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Specific Aims 
1. In cancer survivors who received curative intent radiation (definitive radiation therapy as 
treatment for cure; CIR) for their malignancy, describe longitudinal trends in continued opioid 
use by 30-day average daily oral morphine equivalent (OME) opioid dose  
a. Describe variations over time in 30-day average daily OME dose overall and by cancer 
type 
b. Describe opioid-related public health initiatives that may have influenced trends in 30-
day average daily OME dose over time 
2. In cancer survivors who received CIR for their malignancy, examine incidence and 
characteristics associated with the risk of new persistent and continued chronic opioid use  
a. Identify the rate of new persistent and continued chronic opioid use  
b. Examine the association of new persistent and continued chronic opioid use with 
radiation specific factors such as modality 
c. Examine the association of new persistent and continued chronic opioid use with 
radiation specific clinical factors such as disease site, stage, and other treatment 
modalities (including surgery, chemotherapy, and immune therapy) 
d. Examine the association of new persistent and continued chronic opioid use with other 
non-radiation specific clinical factors such as disease stage and comorbidities 
e. Examine the association of new persistent and continued chronic opioid use with 
sociodemographic characteristics such as age, gender, race, and insurance status 
f. Using the significant associations found in prior analyses (2b-e) estimate the risk of 
continued chronic opioid use and developing new persistent opioid use 
3. In cancer survivors who received CIR, examine new persistent opioid use and 30-day average 
daily OME dose after radiation therapy 
a. Describe 30-day average daily OME dose over time and at one year after CIR 
b. Examine variations in average daily OME dose over time before and after CIR 
c. Predict average daily OME dose between new persistent and continued chronic opioid 
use in the year following CIR 
d. Describe opioid use by time to discontinuation between new persistent opioid use in the 
months following CIR 
4. In cancer survivors who received CIR for their malignancy, examine health disparities that may 
exist in sex, race, and socioeconomic status in patients with new persistent opioid use 
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Systematic Literature Review: Opioid Utilization in Cancer Survivors  
Abstract 
Background:  With advancement of cancer treatment, cancer survivors are an important 
demographic to consider as opioid use and abuse have reached epidemic proportions in the 
United States. There has also been an increase in both the aggregate number of cancer 
survivors and the duration of time patients spend in the survivorship period. Pain management 
is an important consideration for patients undergoing cancer treatment but patients with cancer 
are often excluded from most pain studies and guidelines.  Therefore, literature about the 
opioid use landscape in patients with cancer is far less known than for patients without cancer. 
Objective: To describe opioid utilization within cancer survivors from the literature. Methods: A 
systematic literature review was conducted in Pubmed/MEDLINE. A total of 80 articles were 
assessed for inclusion based on cancer survivorship sample and exclusion of narrative articles 
or main topics of opioid safety, efficacy, outcomes, or dosing. Results: 13 articles were 
included in this review, all but one article were published in North America and in the last three 
years.  The majority of articles used samples of a specific cancer type or treatment modality.  
Discussion: A significant number of cancer survivors utilize opioids before, during, and after 
cancer treatment.  Opioid use within cancer survivors appears to vary based on clinical 
characteristics such as cancer type, comorbid conditions, and treatment modality. Conclusion: 
Patients with cancer are at risk of high opioid use and certain characteristics such as cancer 
type or treatment modality may carry increased risk, although literature on the subject is still 
new. Future studies are needed to identify underlying risk factors for new persistent and 
chronic opioid use in cancer survivors of all types of cancer.  
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Background 
Pain management is an important consideration for patients undergoing cancer disease 
treatment.  Opioids are a cornerstone of pain management in patients with cancers, as 
malignancies themselves can lead to significant pain in addition to pain resulting from invasive 
treatments (surgery), chemotherapy, and radiation.3,8,9 Additionally, pain management 
guidelines are lacking for patients nearing the end of life, or for cancers treated with palliative 
intent.10–12  There is a distinct divide in pain management for patients that have cancer versus 
those who do not. The former are often excluded from most pain studies. Cancer and non-
cancer pain is treated differently in the literature and the focus of opioid prescribing guidelines, 
overuse, misuse, abuse, and adverse consequences leading to death has mostly focused on 
non-cancer pain.8,10 In studies that have investigated pain in patients with cancer, it has been 
documented that pain has been significantly undertreated.8,13–16 Later studies from 2007-2013 
suggest lower, but still significant prevalence of undertreatment of pain in 32% (range 4% to 
68%) of patients.8,14,17–21  
There is growing awareness of opioid use and misuse in patients with cancer.8,22–25  It 
has been suggested that opioid utilization patterns (chronic opioid use by total daily dose, dose 
escalations, and dose reductions) are similar between patients with cancer pain and patients 
with non-cancer pain although patients were not matched.27,28 A propensity score matched 
study published in 2019 reported that respondents with cancer were significantly more likely to 
use prescription opioids than matched controls (OR: 2.43, 95% CI: 1.68-3.57).24  
Five-year survival from cancer diagnosis has increased from less than 50% to a mean 
of 67% (with a large range based on cancer site) over the last several decades.1,2 This 
increase in survival, in part due to improvements in antineoplastic therapy, has led to an 
increase in both the aggregate number of cancer survivors, but also the duration of time 
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patients spend in the survivorship period.  Cancer survivors are an important demographic to 
consider as opioid use and abuse have reached epidemic proportions in the United States.  
There are over 200 million opioid prescriptions utilized in the United States (US) annually, but it 
is not known how many of those are for patients with cancer pain.29  This literature review aims 
to describe opioid utilization within cancer survivors. 
 
 
Methods 
In order to assess the landscape of opioid use in cancer survivors, a systematic 
literature review was conducted. Pubmed/MEDLINE was used to extract literature data.  A 
broad search strategy of relevant terms was used to find evidence of opioid use in cancer 
survivors. The search strategy was as follows: ("Cancer Survivors/classification"[Mesh] OR 
“cancer survivors” OR “patients with cancer”) AND ("Analgesics, Opioids/administration and 
dosage"[Mesh] OR "Analgesics, Opioids/adverse effects"[Mesh] OR "Analgesics, 
Opioids/classification"[Mesh] OR “Analgesics, Opioids/economics"[Mesh] OR "Analgesics, 
Opioids/organization and administration"[Mesh] OR "Analgesics, Opioids/poisoning"[Mesh] OR 
"Analgesics, Opioids/standards "[Mesh] OR "Analgesics, Opioids/therapeutic use"[Mesh]  OR 
"Analgesics, Opioids/toxicity"[Mesh] OR “opioid use” OR “opioid prescribing”) AND 
Humans[Mesh] AND English[lang]. 
Following PRISMA guidelines for reporting systematic reviews, the search resulted in 62 
articles.  Articles were also pulled from the reference lists of resulting literature and 
independent searches of key words (n = 11). A total of 80 articles were then assessed for 
inclusion and exclusion criteria by examining titles and abstracts (Figure 1.1).46 Articles were 
included if they assessed opioid utilization in cancer survivors.  Articles were excluded if the 
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patient population did not have cancer or were in end-of-life care; main topics of excluded 
articles involved opioid safety, efficacy, outcomes, or dosing; or were narrative articles.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Prisma Flow Chart of Opioids in Cancer Survivors Literature Review 
 
Results 
The resulting studies with lead author and title are summarized in Table 1.1.  Three 
studies identified in this literature review were conducted outside of the USA.  A 2010 
retrospective population-wide matched cohort study examined patients 18-64 years of age and 
more than 5 years after cancer diagnosis in the Ontario Health Insurance Plan and Drug 
Benefits Program.  Results indicated that the opioid prescribing rate was 1.22 times higher 
among cancer survivors compared to matched controls without cancer.47 These higher 
prescribing rates were associated with lower income, younger patients, living in more rural 
communities, and more comorbidities.47  Additionally, over the course of the 36 month time 
frame of the study, the mean cumulative number of opioid prescriptions increased at a higher 
Database: PubMed 
Limits: English-language articles and human 
subjects only (n = 69) 
Search results combined (n = 80) 
Articles screened on basis of title and abstract 
Included (n = 13) 
Excluded articles (n = 67): 
-Not patients with cancer (n = 4) 
-Opioid safety/efficacy/outcomes (n = 10) 
-Opioid dosage form (n = 6) 
-Palliative care / end-of-life (n = 14) 
-Cancer pain management (n = 20) 
-Economic outcomes (n = 2) 
-Opioid utilization in cancer therapy (n = 5) 
-Pharmacokinetics/Pharmacodynamics (n = 1) 
-Narrative Case Study (n = 1) 
-Comment (n = 3) 
-Not opioids (n = 1) 
Independent searches of key words, authors, 
relevant topics, and referenced articles (n = 11) 
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rate for cancer survivors over matched controls.  This study did not discuss the role of type of 
treatment. 
 Another study conducted in Canada utilized linked provincial administrative data from 
the government funded Pharmacare program from 2010-2015.  Patients aged 24 to 70 years 
with cancer 5 years from diagnosis (index date) were examined to determine the opioid 
prescription rate.48  This study found that continuous opioid use between diagnosis and index 
date was most strongly associated with higher rate of opioid use after index date.  Other 
factors associated with higher rate of opioid use after index date included: opioid use before 
diagnosis, history of depression, comorbidity, and greater than two years of diabetes.  
Additionally, there were significant interactions between prior opioid use and opioid use 
between diagnosis and index date and most prescriptions from family physicians.48  This study 
was limited to patients receiving surgery and did not discuss patients receiving radiation for 
their malignancy treatment. 
 The last article identified outside of the USA utilized a Norwegian prescription database 
to determine use of opioids 10 years after cancer diagnosis.49 In this study, the one year 
periodic prevalence of any opioid use was higher in long-term cancer survivors than general 
population, as was the prevalence of persistent opioid use and prevalence of high-dose 
opioids.49 
 Ten studies were conducted inside the USA. Three of these articles would have been 
excluded from the review, due to the study population not being cancer survivors. However, 
these will be discussed due to their pertinence of comparing different treatment modalities. 
First, Silver et al. examined 198 patients with oropharyngeal cancer who underwent 
radiotherapy from 2012 to 2017 to assess risk factors for chronic opioid use and effect on 
overall survival.43  It was determined that chronic opioid use was observed in 53% of patients 
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and associations with chronic use included pre-treatment opioid use and presence of a 
preexisting chronic pain condition at time of diagnosis. Multivariate analysis associations 
included tumor stage and anxiety/depression. Overall survival was worse for patients who had 
chronic opioid use, but was not significant when controlled for recurrence.43  While this study 
investigated patients receiving radiation, it was limited to oropharyngeal cancer and patients 
with recurrence, which does not fit the definition of cancer survivors. 
Secondly, a retrospective analysis at MD Anderson’s supportive care clinic determined 
that half of patients who received definitive chemoradiotherapy for head and neck cancer were 
unable to discontinue their prescribed opioids.6 While this study involved radiation as definitive 
cancer treatment, patients were limited to head and neck cancers and to those whose pain 
medications were managed by palliative care specialists, rather than their treating oncologists. 
Third, electronic health records of 750 palliative care clinic patients at MD Anderson 
Cancer Center were reviewed between 2010 to 2015 for changes in type and dose of opioid 
prescriptions.50  This study showed a decrease in median morphine equivalent daily dose from 
78 mg per day (IQR: 30-150) in 2010 to 40 mg per day (IQR: 19-80) in 2015.  However, 
morphine equivalent daily dose remained higher for males, those of white race, and a positive 
Cut-down, Annoyed, Guilty, Eye-opener (CAGE) questionnaire score for alcoholism.  
Additionally, this study identified hydrocodone as the most commonly prescribed opioid  
followed by oxycodone and transdermal fentanyl.50 
The remaining seven articles were determined to be the most relevant articles for this 
research. Salz et al. conducted a Surveillance, Epidemiology and End Results (SEER) 
Medicare multilevel logistic regression analysis for chronic opioid use among opioid-naïve 
survivors of colorectal, lung, and breast cancers diagnosed from 2008 to 2013 with matched 
non-cancer controls.51 In this study, one year after a survivor’s diagnosis date, chronic opioid 
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use among lung and colorectal cancer survivors exceeded controls, but differences between 
survivors and controls declined each year for six years after diagnosis.  Conversely, the rate of 
chronic opioid use among breast cancer survivors was lower than that of controls, suggesting 
that type of cancer was driving at least part of this relationship.  On the whole, however, cancer 
survivors with chronic opioid use were more likely to have a higher daily dose of opioids than 
controls.51  This study only examined opioid use of patients with colorectal, lung, and breast 
cancers and did not discriminate based on cancer treatment modality. 
 A cohort study from Kaiser Permanente Washington of 4,216 women greater or equal to 
18 years, diagnosed with stage 1 or 2 breast cancer between January 1, 1990, and December 
31, 2008 was conducted to estimate the association between chronic opioid use and risk of 
second breast cancer events.52 Women in this study were considered chronic opioid users if, 
after 6 months from when they first accumulated 75 days of opioid possession in a 90-day 
window, they remained exposed to opioid therapy through follow up or the end of the study.52  
Cox proportional hazards models determined that the risk of second breast cancer events was 
not significantly higher among chronic opioid users versus non-chronic opioid users.52 While 
the primary objective was to assess second breast cancer events, almost 10% of patients met 
the criteria for chronic use and almost a third of users were taking opioids for greater than 3 
years.52 This study was limited to patients with breast cancer before the surge of opioid deaths 
in 2016 and did not account for radiation. 
Lee et al. conducted a Truven MarketScan database analysis in opioid naïve patients 
with cancer undergoing curative surgical treatment.41  This study determined that 10% of these 
patients develop new persistent opioid use that required 30 mg or more of hydrocodone daily, 
which is similar to doses with chronic opioid use.  Additionally, of those with new persistent 
opioid use, patients receiving adjuvant chemotherapy for any cancer investigated (breast, 
 15 
melanoma, colorectal, gastric, thoracic) utilized higher doses of opioids than those that did not 
receive chemotherapy or those that received neoadjuvant chemotherapy.41  Lee et al. did not 
investigate these effects in patients receiving radiation.  
In a study of 311 opioid naive patients that received curative intent radiation (CIR) at the 
Icahn School of Medicine at Mount Sinai for head and neck cancers between January 1, 2011 
and September 1, 2017, 12.9% continued to use opioids 6 months following radiation 
therapy.42 In multivariable analysis, delivery of induction chemotherapy (OR 2.86, CI (95%) 
1.32–6.21) and alcohol abuse (OR 3.75, CI (95%) 1.66–8.47) were statistically significant risk 
factors for prolonged opioid use.42 Univariate analysis found various other positive associations 
with prolonged opioid use including current smoking, radiation therapy dose, concurrent 
chemotherapy, and daily milligram morphine equivalents, whereas prior surgery was 
negatively associated.42  While this article most closely attempts to answer our research 
question, patients were only included if they were opioid naïve and received radiation for head 
and neck cancer. 
A study published in 2019 of 976 Medicare patients from the Surveillance, Epidemiology 
and End Results (SEER)- Medicare database with non-distant metastatic head and neck 
cancer were evaluated for risk of acute and chronic opioid use. This study determined that 
patients were least likely to use opioids during therapy with radiation alone in comparison to 
other treatment modalities.  Additionally, multivariable logistic analyses determined that 
tobacco use (OR 3.84, CI (95%) 1.44-10.24) and opioids prescribed prior to treatment (OR 
3.56, CI (95%) 1.95-6.50) resulted in increased risk of opioid use six months following 
treatment.45 This study suggests that patients with head and neck cancer are at high risk for 
opioid use, however the study did not evaluate other cancers and did not find statistical 
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differences in opioid use at 3 or 6 months based on treatment type (chemotherapy, surgery, 
radiation).45 
 Schumacher et al. did investigate long term use of opioids from electronic medical 
record data between 2013 and 2017 at a single institution in 276 head/neck cancer patients 
one year after CIR and found that 7.2% of patients developed long-term opioid use.53  
However, this study only evaluated opioid use status at one year of follow-up, which may not 
constitute cancer survivorship and the authors did not evaluate prior to therapy opioid use and 
thus could not differentiate between chronic and new persistent use of opioids post CIR.53 
 Another study at a single institution investigated continued use of opioids in 199 patients 
diagnosed with any cancer after curative intent therapy over a 3 year period.54  Cass et al. 
reported that 38% of patients continued to receive opioid prescriptions with an average of 4.8 
prescriptions per patient of mean milli morphine equivalents per prescription of 319 mg over an 
average of 9.5 months following curative intent therapy.54  Additionally, from logistic 
regression, patients who received chemotherapy (OR: 7.25; 95% CI: 2.09-25.17), used pain-
modifying medications (OR, 4.61; 95% CI, 2.25-9.44), and had lower stages of cancers 
(compared to stage 3) (Stage 0 -  OR: 13.5; 95% CI: 2.07- 88.07) (stage 1- OR: 4.01; 95% CI: 
1.26-12.79) (stage 2 - OR, 4.05; 95% CI: 1.26-13.06) were significantly more likely to continue 
to receive prescriptions for opioids and continue opioid use long-term.54 
 
Table 1.1: Summary of Literature Review Articles  
Authors Title 
 1  Sutradhar et al. (2017)47 Cancer survivorship and opioid prescribing rates: A population-based matched 
cohort study among individuals with and without a history of cancer 
 2  Barbera et al. (2019)48 Factors associated with opioid use in long-term cancer survivors 
 3  Fredheim et al. (2019)49 A complete national cohort study of prescriptions of analgesics and 
benzodiazepines to cancer survivors in Norway 
 4  Silver et al. (2019)43 Chronic opioid use in patients undergoing treatment for oropharyngeal cancer 
 5  Kwon et al. (2013)6  Predictors of long-term opioid treatment among patients who receive 
chemoradiation for head and neck cancer  
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 6 Haider et al. (2017)50 Opioid prescription trends among patients with cancer referred to outpatient 
palliative care over a 6-year period 
 7  Salz et al. (2019) 51 Trends in opioid use among older survivors of colorectal, lung, and breast 
cancers 
 8  Boudreau et al. (2019)52 Risk of second breast cancer events with chronic opioid use in breast cancer 
survivors 
 9  Lee et al. (2017)41 New persistent opioid use among patients with cancer after curative-intent 
surgery 
10 Smith et al. (2019)42 Risk of prolonged opioid use among cancer patients undergoing curative intent 
radiation therapy for head and neck malignancies 
11 McDermott et al. (2019)45 Short- and long-term opioid use in patients with oral and oropharynx cancer 
12 Schumacher et al. 
(2019)53 
Long-term opioid use in curative-intent radiotherapy: One-year outcomes in 
head/neck cancer patients 
13 Cass et al. (2018)54 Analysis of opioid use following curative cancer treatment at a 
large urban safety-net hospital 
 
Discussion 
This systematic literature review reports that there are a significant number of cancer 
survivors that heavily utilize opioids, even long after cancer therapy, compared to the general 
population.6,41–43,45,47–49,51,53,54  Additionally, it is suggested that half of patients that use opioids 
during cancer treatment have difficulty or do not stop opioid use.50 
Opioid use in cancer survivors seems to vary based on cancer type or location.  This 
may be due to variations in how caustic various cancer are, or that a majority of the studies 
presented focus on one or few cancer types (breast, head and neck, colorectal, lung, 
melanoma, gastric, thoracic). Studies that utilized samples with varied cancer types suggest 
that type of cancer may play a role in the relationship of opioid use in cancer 
survivorship.41,45,47,51  From the presented studies, five focused solely on head and neck 
cancers, which may have the highest observed pain burden and ultimately greatest risk for 
continued opioid use, but this was not conclusive from the articles presented. 
Articles presented in this review suggest that various patient clinical characteristics 
increase risk of opioid use.  Comorbid conditions such as pre-existing chronic pain conditions, 
anxiety, depression, alcohol and tobacco use as well as status cancer/tumor stage and pre-
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treatment of opioids were reported to increase risk of chronic opioid utilization. Additionally, 
treatment modality may be associated with increased opioid utilization in cancer survivors post 
treatment, but several of the studies reported in this review did not differentiate by treatment 
modality, or isolated their patient sample by specific treatment modality (i.e. only surgery 
patients).41,47,48,51,53 
 In this review, we described three articles that compared opioid use in patients with 
cancer receiving palliative treatment and varying cancer treatment modalities.6,43,50 Palliative 
care patients may experience more pain than those without advanced disease, and may 
receive higher doses of opioids to manage their pain.21 The purpose of this review was to 
address opioid use within cancer survivors, however these studies shed light on differences in 
opioid use with different treatment modalities. 
Lastly, while this study was not limited to patient samples from the United States, the 
majority of studies presented were conducted in North America with only one article from 
Europe.  This may be due to higher attention to this topic in the United States.55 However, 
there was some evidence that as attention to opioid use has increased, opioid dosage may be 
decreasing over time.50  
A major limitation of this review is that any research conducted in this area is recent, as 
all of the articles cited in this review were published in the last six years, and all but one in the 
last three years.  Several of the studies presented focused on one type of cancer treatment or 
one treatment modality.  To date, there is not a study that establishes risk of new persistent 
opioid use in cancer survivors of different treatment modalities and cancer types.  Another 
limitation of this review is that several articles were conducted at single institutions that may 
not be representative of cancer treatment in the general population.6,42,50,54 Lastly, several 
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studies reported utilizing medical record prescription data rather than pharmacy claims data. 
This could result in an overestimation of opioid use in cancer survivors.48,53  
 
Conclusion 
Patients with cancer are at risk of developing new persistent and continued chronic 
opioid use behaviors, although has not been studied well and literature on the topic is only 3 
years old.  Opioid use in several cancer types such as head and neck are better studied than 
others.  Even less studied is the potential for patients with cancer to develop new-persistent 
opioid use. Future studies are needed to identify underlying risk factors for new persistent and 
chronic opioid use in cancer survivors of any type of cancer. 
 
Human Subjects Research   
 This research was approved under the VCU IRB: HM20014385. In order to ensure the 
protection of human subjects as well as data safety, the following steps were taken.  First, 
results were, or will be, only disseminated in aggregate; no identifiable information was or will 
be disseminated.  In order to de-identify the data, medical record number (MRN) and treatment 
data were extracted from the VCU ARIA database, cancer registry, relevant data from the 
Cerner database (clinical and demographic information), and merged. After pharmacy data, 
clinical data from radiation treatment records, and clinical data from the registry were 
extracted, combined, and merged by the researchers, a randomly generated key code was 
used in lieu of the patient's medical record number to identify individuals in the data. A key file 
linking the randomly generated key code to the MRNs was stored in a different computer than 
the primary database, and the key file was kept in a password protected file. Original 
identifying information was stripped from the primary database. Only those conducting the 
analysis had access to the data after de-identification.  
 20 
References 
1.  Yazdani S, Abdi S. Brief review: Pain management for cancer survivors: challenges and 
opportunities. Can J Anesth Can d’anesthésie. 2014;61(8):745-753. doi:10.1007/s12630-
014-0170-5 
2.  Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 
2019. CA Cancer J Clin. June 2019:caac.21565. doi:10.3322/caac.21565 
3.  Brown M, Farquhar-Smith P. Pain in cancer survivors; filling in the gaps. Br J Anaesth. 
2017;119(4):723-736. doi:10.1093/bja/aex202 
4.  About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 
https://www.nccn.org/professionals/default.aspx. Accessed July 1, 2019. 
5.  American Cancer Society. Radiation Therapy Basics. 
https://www.cancer.org/treatment/treatments-and-side-effects/treatment-
types/radiation/basics.html. Accessed August 21, 2019. 
6.  Kwon JH, Hui D, Chisholm G, Bruera E. Predictors of long-term opioid treatment among 
patients who receive chemoradiation for head and neck cancer. Oncologist. 
2013;18(6):768-774. doi:10.1634/theoncologist.2013-0001 
7.  Muzumder S, Nirmala S, Avinash H, Sebastian Mgj, Kainthaje P. Analgesic and opioid 
use in pain associated with head-and-neck radiation therapy. Indian J Palliat Care. 
2018;24(2):176. doi:10.4103/IJPC.IJPC_145_17 
8.  Manchikanti L, Manchikanti KN, Kaye ADAM, Kaye ADAM, Hirsch JA. Challenges and 
concerns of persistent opioid use in cancer patients. Expert Rev Anticancer Ther. 
2018;18(7):705-718. doi:10.1080/14737140.2018.1474103 
9.  Glare PA, Davies PS, Finlay E, et al. Pain in Cancer Survivors. J Clin Oncol. 
2014;32(16):1739-1747. doi:10.1200/JCO.2013.52.4629 
10.  Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic 
Pain — United States, 2016. MMWR Recomm Reports. 2016;65(1):1-49. 
doi:10.15585/mmwr.rr6501e1er 
11.  Sager ZS, Buss MK, Hill KP, Driver JA, Skarf LM. Managing Opioid Use Disorder in the 
Setting of a Terminal Disease: Opportunities and Challenges. J Palliat Med. July 
2019:jpm.2019.0101. doi:10.1089/jpm.2019.0101 
12.  Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc 
Netw. 2013;11(8):992-1022. http://www.ncbi.nlm.nih.gov/pubmed/23946177. Accessed 
 21 
July 18, 2019. 
13.  Paice JA, Portenoy R, Lacchetti C, et al. Management of Chronic Pain in Survivors of 
Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin 
Oncol. 2016;34(27):3325-3345. doi:10.1200/JCO.2016.68.5206 
14.  Greco MT, Roberto A, Corli O, et al. Quality of Cancer Pain Management: An Update of 
a Systematic Review of Undertreatment of Patients With Cancer. J Clin Oncol. 
2014;32(36):4149-4154. doi:10.1200/JCO.2014.56.0383 
15.  Bennett M, Paice JA, Wallace M. Pain and Opioids in Cancer Care: Benefits, Risks, and 
Alternatives. Am Soc Clin Oncol Educ B. 2017;37(37):705-713. 
doi:10.1200/EDBK_180469 
16.  King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of 
opioid medication for those with moderate to severe cancer pain and renal impairment: a 
European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 
2011;25(5):525-552. doi:10.1177/0269216311406313 
17.  Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer 
pain. A review of published literature. Ann Oncol. 2008;19(12):1985-1991. 
doi:10.1093/annonc/mdn419 
18.  Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain 
management. Results from the Cancer Pain Outcome Research Study Group. Br J 
Cancer. 2009;100(10):1566-1574. doi:10.1038/sj.bjc.6605053 
19.  Fisch MJ, Lee J-W, Weiss M, et al. Prospective, observational study of pain and 
analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or 
prostate cancer. J Clin Oncol. 2012;30(16):1980-1988. doi:10.1200/JCO.2011.39.2381 
20.  Mitera G, Zeiadin N, Kirou-Mauro A, et al. Retrospective assessment of cancer pain 
management in an outpatient palliative radiotherapy clinic using the Pain Management 
Index. J Pain Symptom Manage. 2010;39(2):259-267. 
doi:10.1016/j.jpainsymman.2009.07.005 
21.  Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247. 
doi:10.1016/S0140-6736(11)60236-5 
22.  Del Fabbro E, Carmichael A-N, Morgan L. Identifying and assessing the risk of opioid 
abuse in patients with cancer: an integrative review. Subst Abuse Rehabil. 2016;7:71. 
doi:10.2147/SAR.S85409 
 22 
23.  Yennurajalingam S, Edwards T, Arthur JA, et al. Predicting the risk for aberrant opioid 
use behavior in patients receiving outpatient supportive care consultation at a 
comprehensive cancer center. Cancer. 2018;124(19):3942-3949. 
doi:10.1002/cncr.31670 
24.  Tringale KR, Huynh-Le M, Salans M, Marshall DC, Shi Y, Hattangadi-Gluth JA. The role 
of cancer in marijuana and prescription opioid use in the United States: A population-
based analysis from 2005 to 2014. Cancer. April 2019:cncr.32059. 
doi:10.1002/cncr.32059 
25.  Barbera L, Sutradhar R, Chu A, et al. Comparison of Opioid Prescribing Among Cancer 
and Noncancer Patients Aged 18–64: Analysis Using Administrative Data. J Pain 
Symptom Manage. 2018;56(1):72-79. doi:10.1016/j.jpainsymman.2018.03.010 
26.  Dalal S, Bruera E. Pain Management for Patients With Advanced Cancer in the Opioid 
Epidemic Era. Am Soc Clin Oncol Educ B. 2019;39(39):24-35. 
doi:10.1200/EDBK_100020 
27.  Datto, MD, MS CJ, Hu, MD, PhD Y, Wittbrodt, PharmD, MPH E, Fine, MD PG. Opioid 
utilization patterns among patients with cancer and non-cancer pain. J Opioid Manag. 
2019;15(1):11. doi:10.5055/jom.2019.0481 
28.  Datto CJ, Hu Y, Wittbrodt E, Fine PG. Cancer and non-cancer pain opioid utilization in 
Medicare and Medicaid populations. J Clin Oncol. 2018;36(7_suppl):139-139. 
doi:10.1200/JCO.2018.36.7_suppl.139 
29.  Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, Safe, and Effective 
Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional 
Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20(2S):S3-S92. 
http://www.ncbi.nlm.nih.gov/pubmed/28226332. Accessed July 19, 2019. 
30.  SAMHSA - Substance Abuse and Mental Health Services Administration. 
https://www.samhsa.gov/. Accessed April 15, 2019. 
31.  Han B, Compton WM, Jones CM, Cai R. Nonmedical Prescription Opioid Use and Use 
Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. 
JAMA. 2015;314(14):1468-1478. doi:10.1001/jama.2015.11859 
32.  Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical Oncologists’ Attitudes and 
Practice in Cancer Pain Management: A National Survey. J Clin Oncol. 
2011;29(36):4769-4775. doi:10.1200/JCO.2011.35.0561 
 23 
33.  Koyyalagunta D, Bruera E, Aigner C, Nusrat H, Driver L, Novy D. Risk stratification of 
opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med. 
2013;14(5):667-675. doi:10.1111/pme.12100 
34.  Koyyalagunta D, Bruera E, Engle MP, et al. Compliance with Opioid Therapy: 
Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer 
Pain. Pain Med. 2018;19(7):1469-1477. doi:10.1093/pm/pnx178 
35.  Novy DM, Lam C, Gritz ER, Hernandez M, Driver LC, Koyyalagunta D. Distinguishing 
features of cancer patients who smoke: pain, symptom burden, and risk for opioid 
misuse. J Pain. 2012;13(11):1058-1067. doi:10.1016/j.jpain.2012.07.012 
36.  Koyyalagunta D, Burton AW, Toro MP, Driver L, Novy DM. Opioid abuse in cancer pain: 
report of two cases and presentation of an algorithm of multidisciplinary care. Pain 
Physician. 14(4):E361-71. http://www.ncbi.nlm.nih.gov/pubmed/21785486. Accessed 
July 19, 2019. 
37.  Reyes-Gibby CC, Anderson KO, Todd KH. Risk for Opioid Misuse Among Emergency 
Department Cancer Patients. Miner J, ed. Acad Emerg Med. 2016;23(2):151-158. 
doi:10.1111/acem.12861 
38.  Arthur JA, Edwards T, Lu Z, et al. Frequency, predictors, and outcomes of urine drug 
testing among patients with advanced cancer on chronic opioid therapy at an outpatient 
supportive care clinic. Cancer. 2016;122(23):3732-3739. doi:10.1002/cncr.30240 
39.  Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of 
opioid misuse, abuse, and addiction in chronic pain: a systematic review and data 
synthesis. Pain. 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1 
40.  Foley KM. The Treatment of Cancer Pain. N Engl J Med. 1985;313(2):84-95. 
doi:10.1056/NEJM198507113130205 
41.  Lee JS-J, Hu HM, Edelman AL, et al. New Persistent Opioid Use Among Patients With 
Cancer After Curative-Intent Surgery. J Clin Oncol. 2017;35(36):4042-4049. 
doi:10.1200/JCO.2017.74.1363 
42.  Smith WH, Luskin I, Resende Salgado L, et al. Risk of prolonged opioid use among 
cancer patients undergoing curative intent radiation therapy for head and neck 
malignancies. Oral Oncol. 2019;92:1-5. doi:10.1016/j.oraloncology.2019.03.007 
43.  Silver N, Dourado J, Hitchcock K, et al. Chronic opioid use in patients undergoing 
treatment for oropharyngeal cancer. Laryngoscope. 2019;129(9):2087-2093. 
 24 
doi:10.1002/lary.27791 
44.  Tan PD, Barclay JS, Blackhall LJ. Do Palliative Care Clinics Screen for Substance 
Abuse and Diversion? Results of a National Survey. J Palliat Med. 2015;18(9):752-757. 
doi:10.1089/jpm.2015.0098 
45.  McDermott JD, Eguchi M, Stokes WA, et al. Short- and Long-term Opioid Use in Patients 
with Oral and Oropharynx Cancer. Otolaryngol Neck Surg. 2019;160(3):409-419. 
doi:10.1177/0194599818808513 
46.  Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic 
reviews and meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34. 
doi:10.1016/j.jclinepi.2009.06.006 
47.  Sutradhar R, Lokku A, Barbera L. Cancer survivorship and opioid prescribing rates: A 
population-based matched cohort study among individuals with and without a history of 
cancer. Cancer. 2017;123(21):4286-4293. doi:10.1002/cncr.30839 
48.  Barbera L, Sutradhar R, Howell D, et al. Factors associated with opioid use in long term 
cancer survivors. J Pain Symptom Manage. March 2019. 
doi:10.1016/j.jpainsymman.2019.02.024 
49.  Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of 
prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years 
after diagnosis. Pain. 2019;160(4):852-859. doi:10.1097/j.pain.0000000000001459 
50.  Haider A, Zhukovsky DS, Meng YC, et al. Opioid Prescription Trends Among Patients 
With Cancer Referred to Outpatient Palliative Care Over a 6-Year Period. J Oncol Pract. 
2017;13(12):e972-e981. doi:10.1200/JOP.2017.024901 
51.  Salz T, Lavery JA, Lipitz-Snyderman AN, et al. Trends in Opioid Use Among Older 
Survivors of Colorectal, Lung, and Breast Cancers. J Clin Oncol. February 
2019:JCO.18.00938. doi:10.1200/JCO.18.00938 
52.  Boudreau DM, Chen L, Yu O, Bowles EJA, Chubak J. Risk of second breast cancer 
events with chronic opioid use in breast cancer survivors. Pharmacoepidemiol Drug Saf. 
April 2019:pds.4779. doi:10.1002/pds.4779 
53.  Schumacher LD, Sargi ZB, Masforroll M, et al. Long-term opioid use in curative-intent 
radiotherapy: One-Year outcomes in head/neck cancer patients. Head Neck. November 
2019:hed.26034. doi:10.1002/hed.26034 
 25 
54.  Cass AS, Alese JT, Kim C, et al. Analysis of Opioid Use Following Curative Cancer 
Treatment at a Large Urban Safety-Net Hospital. Clin J Pain. 2018;34(10):1. 
doi:10.1097/AJP.0000000000000612 
55.  DeWeerdt S. Tracing the US opioid crisis to its roots. Nature. 2019;573(7773):S10-S12. 
doi:10.1038/d41586-019-02686-2 
 
 26 
CHAPTER 2: LONGITUDINAL OPIOID PRESCRIPTION USE IN PATIENTS WITH CANCER 
RECEIVING RADIOTHERAPY FROM 2008 TO 2018 AT A SINGLE CANCER CENTER 
 
Abstract 
Background: Cancer survivors receiving potentially caustic radiation for their malignancies are 
an important demographic to consider as opioid use and abuse have reached epidemic 
proportions in the United States.  Objective: This study described opioid prescriptions overall, 
and by various subgroups, from 2008-2018 prescribed at a single cancer center. Methods: A 
retrospective longitudinal analysis of opioid prescriptions by oral morphine equivalent (OME) 
doses in cancer survivors overall, and by subgroups of cancer type, additional cancer therapy 
(chemotherapy or surgery), opioid medication, and basic demographic information (sex, race, 
insurance type) was conducted. Results: Overall, there was an increase in 30-day average 
daily OME dose prescribing from late 2009 to 2012, which decreased after 2012. Men, those of 
white compared to black race, and patients with additional chemotherapy or no additional 
surgery appeared to be prescribed higher 30-day average daily OME doses between 2008 and 
2018.  Discussion: This study suggests that patients with cancer at this institution received 
higher rates of opioid prescriptions per patient and 30-day average daily OME doses than in 
the general American, non-cancer public. Changes in opioid prescribing over the course of the 
study could be due to addressing under treatment of cancer pain (until 2012) or from various 
public health or institution-specific initiatives to decrease opioid use (after 2012).  This was the 
first study to describe patient characteristics that result in differences in the 30-day average 
daily OME doses in patients with cancer receiving radiation in the last decade. Conclusion: 
Opioid prescription use for patients with cancer receiving radiation followed similar trends, but 
showed higher per patient prescriptions and 30-day average daily OME dose quantities, 
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compared to other previously reported trends in patients without cancer and outside of the 
United States. 
 
Background 
Five-year survival from cancer diagnosis has increased from less than 50% to a mean 
of 67% (with a large range based on cancer site) over the last several decades.1,2 This 
improvement in survival has led to an increase in both the aggregate number of cancer 
survivors and the duration of time patients spend in the survivorship period. Consequently, 
long-term management of this population is of increasing concern.  
Approximately 50% of patients with cancer will receive radiation therapy as a 
component of their treatment.3  Undergoing radiation therapy can subject patients to significant 
morbidity that can vary by treatment site, with patients treated for head and neck cancer 
tending to have a significant burden of radiation-related acute and late toxicity.4,5  Therefore, 
opioid use for pain management is a mainstay of cancer treatment regimens. It has been 
suggested that curative intent radiation (CIR) treatment alone is least likely to be associated 
with opioid use compared to other treatment modalities (surgery, chemotherapy, 
combinations), but, certain cancers may be at higher risk for high opioid use after CIR.6,7  
Notably, pain is generally managed by the patient’s surgical, radiation, or medical oncologist, 
who may not have optimal training in pain management and palliative care.8   
Cancer and non-cancer pain are treated differently in the literature. Opioid prescribing 
guidelines and discussions of overuse, misuse, abuse, and adverse consequences leading to 
death have been focused on patients treated for non-cancer pain.9,10 Pain has been 
significantly under treated in studies that have investigated treatment patterns in patients with 
cancer.9,11–14 Specifically, from 1994 to 2007, a systematic review found that 43% of patients 
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with cancer were potentially under treated for pain.9,15  Later studies from 2007-2013 suggest a 
lower, but still significant prevalence of under treatment of pain in 32% of patients.9,12,15–19 At 
the same time, opioid use and misuse has been increasingly characterized in patients with 
cancer.9,20–23   
There are over 200 million opioid prescriptions utilized in the United States annually, but 
it is not known how many of those are for patients with cancer pain.24 Further, three times the 
number of opioids were prescribed 2015 compared to 1999.9,25 Two studies have suggested 
that opioid utilization patterns are similar between patients with cancer pain and patients with 
non-cancer pain, although patients were not matched.26,27 In Canada, trends in opioid 
prescribing in non-cancer and cancer patients remained relatively stable between 2004 and 
2013, although opioid prescription rates were consistently higher for patients with cancer.23 A 
propensity score matched study published in 2019 reported that respondents with cancer were 
significantly more likely to use prescription opioids than matched controls (OR: 2.43, 95% CI: 
1.68-3.57).22 There is also emerging evidence of high rates of opioid misuse in patients with 
cancer.28–33 Ultimately, an estimated 29% of patients with cancer are at high-risk for misuse.9,34 
Cancer survivors are an important demographic to consider given substantial opioid use 
and the increase in survivorship that has transformed many cancers into chronic diseases. The 
objective of this study is to describe opioid prescription use overall and by various 
demographics including cancer type, gender, race, ethnicity, and primary insurance payer from 
2008-2018 at a single cancer center. The objectives of this study are to address Specific Aim 1 
(Table 2.1), which includes describing longitudinal trends and public health initiatives that may 
have influenced trends in continued opioid use in cancer survivors who received CIR. 
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Table 2.1: Methods for Specific Aim 1 
Specific Aim 1 
In cancer survivors who received curative intent radiation therapy (treatment for cure) for 
their malignancy, describe longitudinal trends in continued opioid use by 30-day average 
daily oral morphine equivalent (OME) opioid dose 
Method 
1a Describe variations over time in 30-day average daily OME dose overall and by cancer type Descriptive 
time series 
1b Describe opioid-related public health initiatives that may have influenced trends in 30-day 
average daily OME dose over time 
Descriptive 
time series 
 
 
Methods 
A retrospective longitudinal analysis of chronic opioid prescription use in individuals 
classified as cancer survivors (no death within 5 years, no recurrence of disease within 5 
years, or no presence of metastatic disease; 5CS) who received first-line radiation treatment at 
Virginia Commonwealth University Massey Cancer Center for a cancer diagnosis between 
January 1, 2008 and December 31, 2018 was conducted. Electronic medical record data from 
patients 18 years of age or older with any cancer type and stage receiving radiation with or 
without additional treatment modalities (surgery, chemotherapy) and at least a 14-day supply 
of opioids were included. Prisoners were excluded. Additionally, patients receiving 
radioisotopes or radium as their primary radiation therapy were excluded. Data on cancer type, 
medications, and basic demographic information (e.g. sex, race, ethnicity and insurance 
status) were used. Descriptive statistics and graphical analysis were conducted using Stata 
v15.1 and Microsoft Excel. 
 
Opioid Prescription Equivalencies 
Medication prescribing data was coded to create a monthly longitudinal record of the 
average daily oral morphine equivalent (OME) dose for each opioid prescription and then 
average OME dose of prescriptions per month by the following equation to create comparable 
OME dose based on established conversion factors (Table 2.2):  
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𝐷𝑎𝑖𝑙𝑦	𝑂𝑀𝐸 = 𝑀𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛	𝑀𝑖𝑙𝑙𝑖𝑔𝑟𝑎𝑚	(𝑀𝑔)	𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ	 × 	𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝐷𝑜𝑠𝑒𝑠	 × 	𝐷𝑎𝑖𝑙𝑦	𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦	
× 	𝑂𝑀𝐸	𝐶𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛	𝐹𝑎𝑐𝑡𝑜𝑟	(𝑇𝑎𝑏𝑙𝑒	2.2) 
 
 
Daily OME dose was averaged for all prescriptions written in the same month overall for 
30-day average daily OME dose, as well as monthly by various subgroups. Due to the differing 
approach to pain treatment acutely, inpatient opioids were excluded. Additionally, this study’s 
objective was to investigate long-term opioid use, therefore, only prescriptions written for 
greater than a 14-day supply were included. Prescriptions from five patients were removed 
from the analysis for presumption of outliers due to their calculated OME dosages being far 
greater than upper quartile plus 1.5 the interquartile range.35 
 
Table 2.2: Opioid Dose Oral Morphine Equivalencies36 
Opioid (strength in mg except where noted) OME Conversion Factor 
Buprenorphine, transdermal patch (MCG/HR) N/A 
Buprenorphine, tablet and film N/A 
Buprenorphine, film (MCG) N/A 
Butorphanol 7 
Codeine 0.15 
Dihydrocodeine 0.25 
Fentanyl, buccal/SL tablet or lozenge/troche (MCG) 0.13 
Fentanyl, film or oral spray (MCG) 0.18 
Fentanyl, nasal spray (MCG) 0.16 
Fentanyl, transdermal patch (MCG/HR) 7.2 
Hydrocodone 1 
Hydromorphone 4 
Levomethadyl acetate 8 
Levorphanol tartrate 11 
Meperidine  0.1 
Methadone 3 
Morphine 1 
Opium 1 
Oxycodone 1.5 
Oxymorphone 3 
Pentazocine 0.37 
Tapentadol 0.4 
Tramadol 0.1 
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Patient Subgroups 
Patients were sub-grouped based on cancer type, additional cancer therapy 
(chemotherapy or surgery), type of opioid medication, and basic demographic information (sex, 
insurance type). It was expected that patients would have different 30-day average daily OME 
doses for different cancer types due to varying cancer treatment algorithms and evidence-
based guidelines (i.e. surgery or chemotherapy). Once OME dose was averaged monthly and 
by patient subgroups, 30-day average daily OME dose was plotted over time. Trends were 
described and were compared to opioid-related public health initiatives that may have provided 
external influences on longitudinal trends. 
 
Results 
 Summary statistics for all opioid prescriptions each year after exclusion criteria were 
applied are presented in Table 2.3. Summary statistics for individual prescription daily OME 
doses are presented in Table 2.4. Of the opioid prescriptions in the sample, there were 3,791 
unique patients who received radiation and outpatient opioid prescriptions with a greater than 
14-day supply. An average of 2.7 prescriptions per patient (standard deviation: 6.7 
prescriptions, median: 1 prescription, range 1-79 prescriptions, interquartile range: 0) were 
written for these patients.  There were 10,352 unique outpatient opioid prescriptions, of which 
4,186 had sufficient data to calculate a daily OME dose. 
 
Table 2.3: Summary Statistics of Opioid Prescriptions by Year 
Year Number of Newly 
Diagnosed Patients 
Total Rx 
Prescribed 
Mean Rxs 
per Patient 
Standard Deviation 
of Rxs per Patient 
Median Rxs 
per Patient 
IQR Range 
2008 352 42 2.1 1.8 1 1.3 1-7 
2009 414 354 3.5 3.8 2 3 1-18 
2010 415 595 5.3 6.2 2 6 1-29 
2011 377 748 4.3 5.6 2 3 1-27 
2012 378 829 3.5 4.3 2 3 1-30 
2013 383 732 3.4 5.0 1 2 1-35 
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2014 379 715 3.0 3.4 1 2 1-17 
2015 383 892 3.6 4.4 2 3 1-27 
2016 485 947 3.6 4.5 2 3 1-34 
2017 483 1073 3.7 4.5 2 3 1-25 
2018 74 802 4.6 5.4 2 5 1-29 
Rxs: Prescriptions; IQR: Interquartile Range 
 
Table 2.4: Summary Statistics of Opioid Prescription Daily OME Dose 
N Range Mean Standard Deviation Median Interquartile Range 
4,186 2-1440 94 131 60 60 
 
 
Overall 30-Day Average Daily OME Dose Over Time  
 Figure 2.1 presents 30-day average daily OME doses per month that were plotted over 
11 years from 2008-2018. Overall, 30-day average daily OME dose increased from 2008 to 
2011, at which point 30-day average daily OME dose peaked in 2012 and then decreased 
gradually over the remaining course of the study. In addition to 30-day average daily OME 
dose decreasing after 2012, the variation in 30-day average daily OME dose also gradually 
decreased.   
 
Figure 2.1: 30-Day Average Daily OME Dose for 5CS from 2008-2018. Months on x-axis are in 
chronological order (i.e. m7 = July). 
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Subgroup Analyses 
 The first subgroup analysis indicates that (Figure 2.2a: gender) males and females 
generally follow similar trends for the overall 30-day average daily OME dose prescriptions. 
For both males and females, 30-day average daily OME doses initially increase and then 
decrease or plateau with decreasing variability. However, it appears that males were 
prescribed much higher overall 30-day average daily OME doses with greater variation in 
overall 30-day average daily OME dose than for females until around 2016. Female 30-day 
average daily OME dose peaked between 2009 and 2010, and after 2011, the OME dose 
remained relatively stable. 
 The sample included 1,329 African American patients with a total of 4,369 prescriptions, 
of which 1,814 had a calculated OME dose.  There were 2,389 white patients with a total of 
5,530 prescriptions, of which 2,204 had a calculated OME dose.  These two groups made up 
the majority of the sample (Figure 2.2b.). There were only 168 patients of other 
races/ethnicities with 453 total prescriptions and 168 calculated OME doses (Figure 2.2bi).  
Over the 10 years of data, white patients were generally prescribed higher 30-day average 
daily OME doses compared to African American patients, but the 30-day average daily OME 
doses for white and African American patients converge over time as the variation in dose 
decreases.  
Notably, and upon further review, there was one patient that identified as multiracial that 
caused the “other” patient group to have extremely high 30-day average daily OME dose 
between 2010 and 2012 (Figure 2.2b).  Also, in mid 2012, there may have been a change in 
the electronic medical record documentation options for race to include ethnicity. Figure 2.2b 
shows that patient inclusion in the “Other” group ends in mid 2012, while patient inclusion in a 
group of “Other of Hispanic or Latino or Spanish Origin” begins around that time.  
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 Figure 2.2c shows that, unsurprisingly, laryngeal cancer resulted in the highest 30-day 
average daily OME doses over time as head and neck cancers are notoriously caustic. Of the 
4,186 prescriptions with calculated daily OME dose, almost 25% were written for patients with 
breast cancer (n = 1,037).  For these prescriptions, Figure 2.2c shows that 30-day average 
daily OME dose was high and highly variable before 2012, then subsequently leveled off after 
2012.  Lung and bronchial cancers (n = 359 prescriptions with calculated daily OME dose) 
followed the trend seen in breast cancer 30-day average daily OME doses, with a high 30-day 
average daily OME dose in the first half of the study followed by a leveling off at lower 30-day 
average daily OME doses. 
 A majority of opioid prescriptions were written for patients receiving additional treatment 
modalities. Of the opioid prescriptions written, 72% were for patients that received additional 
chemotherapy and 51% that received additional definitive surgery. Unsurprisingly, over the 
course of this study, patients receiving additional chemotherapy were prescribed higher 30-day 
average daily OME doses than those that did not receive chemotherapy (Figure 2.2d). This is 
most likely due to the caustic nature of multiple rounds of chemotherapy. Notably, at the end of 
2013, there was a spike in 30-day average daily OME dose for patients that did not receive 
chemotherapy.  Upon further review, two individual patients contributed to excessively high 
daily OME dose at this time. On the other hand, patients who received additional definitive 
surgery were prescribed consistently lower 30-day average daily OME doses (Figure 2.2e). 
Additionally, the trend in 30-day average daily OME dose for patients that received additional 
definitive surgery follows very closely to what is seen in the 30-day average daily OME dose 
overall. 
 Of the prescribed medications, oxycodone was by far the most commonly prescribed in 
patients with complete information (n = 2,600 prescriptions with calculated daily OME doses). 
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In general, 30-day average daily OME doses for oxycodone had less variation than other 
medications in the 11 years studied, although 30-day average daily OME doses were higher 
towards the beginning of the study (Figure 2.2f). For the next most commonly prescribed 
medication with complete information, morphine (n = 571 prescriptions with calculated daily 
OME doses), 30-day average daily OME doses were high and highly variable throughout the 
course of the study. Tramadol (n = 451 prescriptions with calculated daily OME doses), a less 
potent opioid, had consistently low 30-day average daily OME doses throughout the course of 
the study. For ease of visualization, these three medications (oxycodone, morphine, and 
tramadol) were plotted separately in Figure 2.2fi.  Interestingly, hydromorphone 30-day 
average daily OME doses were high before 2013, and after 2013 dramatically decreased and 
remained stable. On the other hand, methadone 30-day average daily OME doses dramatically 
increased after 2013.  For ease of visualization, hydromorphone and methadone were plotted 
separately in Figure 2.2fii. Unfortunately, while widely prescribed, fentanyl and hydrocodone 
prescriptions were almost all missing at least one essential variable to accurately calculate a 
daily OME dose (98.3% and 99.7%, respectively) and we were thus not able to describe 30-
day average daily OME doses over time for these medications. 
 Lastly, prescriptions were sub-grouped by primary payer to observe variations of 30-day 
average daily OME doses by insurance. Before 2014, there were large 30-day average daily 
OME doses with large variations for all insurance types, except commercial and Medicare 
(Figure 2.2g). Commercial and Medicare 30-day average daily OME doses were relatively 
stable across the study time, except for a single peak in late 2013 and early 2014 in the 
Medicare subgroup. The remaining insurance types (indigent, Medicaid, insurance that was 
not specified, and self-paid) were relatively stable despite having moderate variations after 
2014.  Of all of the insurance types, commercial insurance and patients who paid out of pocket 
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(self-pay) consistently had lower prescribed 30-day average daily OME doses. Because the 
results from individual insurance types were complex, groups were divided into Public 
(Indigent, Military, Medicaid, and Medicare) or Private (commercial and self-pay) options based 
on the payer (Figure 2.2gi). Patients with public insurance were generally prescribed higher 
30-day average daily OME doses. However, a similar trend was seen in public versus private 
insurance as for white and African American patients, where 30-day average daily OME doses 
converge over time as the variation decreases. 
 
Figure 2.2a: 30-Day Average Daily OME Dose by Gender from 2008-2018 
 
 
Figure 2.2b: 30-Day Average Daily OME Dose by Race from 2008-2018 
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Figure 2.2bi: 30-Day Average Daily OME Dose by Race from 2008-2018 (Black or African 
American and White only) 
 
 
Figure 2.2c: 30-Day Average Daily OME Dose by Cancer Type from 2008-2018 
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Figure 2.2d: 30-Day Average Daily OME Dose by Additional Chemotherapy from 2008-2018 
 
 
Figure 2.2e: 30-Day Average Daily OME Dose by Additional Definitive Surgery from 2008-
2018 
 
 
 39 
 
Figure 2.2f: 30-Day Average Daily OME Dose by Opioid Medication from 2008-2018 
 
Figure 2.2fi: 30-Day Average Daily OME Dose by Opioid Medications (Morphine, Oxycodone, 
and Tramadol) from 2008-2018 
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Figure 2.2fii: 30-Day Average Daily OME Dose by Opioid Medications (Hydromorphone and 
Methadone) from 2008-2018 
 
 
Figure 2.2g: 30-Day Average Daily OME Dose by Payer from 2008-2018 
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Figure 2.2gi: 30-Day Average Daily OME Dose by Public or Private Payer from 2008-2018 
 
 
Discussion 
 Patients with cancer receiving radiation in the sample studied received an average of 2 - 
5 opioid prescriptions over the time period analyzed. In comparison, a study from the CDC 
reported 11 years of overall (not limited to outpatient medications of at least 14-day supply) 
opioid prescribing trends in non-cancer patients. The CDC study indicated that there was 
almost one prescription per American before 2012, declining to less than 6 prescriptions per 10 
Americans in 2014 (Figure 2.3).37  Our study suggests that patients with cancer at this 
academic institution received higher rates of opioid prescriptions per patient than in the general 
American, non-cancer public. It has been reported that patients with cancer utilize significantly 
higher amounts of opioids compared to non-cancer patients due to the caustic nature of the 
disease, treatment, and regular management. A 2019 propensity score matched study 
reported 2.4 increased odds of opioid prescription use for patients with cancer compared with 
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matched controls.22 Additionally, a Canadian time series analysis reported patients with cancer 
greater than five years had statistically significant 1.44 more opioid prescriptions compared 
with patients without cancer from 2004-2013.38  
In this study, we observed an increase in prescriptions per patient at this institution over 
the time period of the study. It is possible the increase arose because the number of patients 
with high opioid prescription burden increased as more patients were accepted to the 
institution for treatment or from increases in patient survival due to advances in cancer 
management. It is also possible that opioid prescribing became increasingly part of patient 
disease management. It has been well documented that pain in patients with cancer has 
historically been significantly under treated.9,11–14 As reported previously, 43% of patients with 
cancer from 1994-2007 and 32% of patients with cancer from 2007-2013 were potentially 
under treated for pain.9,12,15–19 These studies may have influenced prescribers managing 
patients with cancer to increase opioid prescribing. The Canadian study previously referenced 
also saw an increase in patients and opioid prescriptions for patients with cancer greater than 
5 years, however, even larger increases in opioid prescriptions were noticed from evaluating 
specific medication subclasses.38  
 From the CDC prescribing trends in the general, non-cancer American public, opioid 
prescribing rate trends suggest that an external influence or event occurred between 2010 and 
2012 to change the behavior of providers prescribing opioids.37  Guy Jr et al. note that 
decreases during this time followed the “publication of two national guidelines defining high-
dose opioid prescribing as >200 MME/day […, and] coincided with studies demonstrating 
progressively increasing overdose risk at prescribed opioid dosages exceeding 20, 50, and 
100 [OME] per day and publications highlighting associations of prescribed opioids with 
overdose deaths.”39 Notably, these guidelines excluded patients with cancer.10 Additionally, 
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there has been significant attention dedicated in recent years to opioid utilization, as there has 
been a surge of opioid deaths from 4,200 in 1999, to 15,300 in 2013, and over 64,000 in 
2016.9,25 In response, many public health initiatives were enacted in the health care community 
by agencies like the U.S. Food and Drug Administration (FDA), Centers for Disease Control 
and Prevention (CDC), Drug Enforcement Administration (DEA), and various medical 
organizations to highlight and address issues related to the opioid epidemic (Table 2.5). While 
this study did not investigate if a single event contributed to changes in opioid prescribing 
practices, it can be seen from the trends that initiatives not specifically targeted to patients with 
cancer may have influenced providers of cancer patients to closely monitor and decrease 
overall daily OME doses when possible. Future evaluation of this data with interrupted time 
series analysis could determine if specific public health initiatives (or potential institutional 
policy or protocol changes) may have resulted in opioid prescribing changes at this institution. 
 This study identified very high 30-day average daily OME doses prescribed for patients 
with cancer receiving radiation over the course of the study.  While there are evidence based 
recommendations for opioid formulations to use for patients with cancer undergoing therapy, 
there are no daily OME dose recommendations for patients with cancer.40  The 2016 chronic 
opioid prescribing guidelines for non-cancer pain (cancer pain explicitly excluded) 
recommends avoiding daily OME doses greater than 90 and for prescribers to use caution with 
daily OME doses greater than 50.10  In this study, we regularly saw 30-day average daily OME 
doses over 100 (although doses decreased over time after 2010-2011), and after 2009, all 30-
day average daily OME doses were over 50. These 30-day average daily OME prescribed 
doses are notably higher than what is recommended in non-cancer pain guidelines, but are not 
outside the norm of general practice. A HealthCore Integrated Research Environment (HIRE) 
database study from 2006 to 2014 of a commercially insured population in the United States 
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reported quartiles of daily OME in which the “fourth quartile mean ± SD doses were 162.9 ± 
168.4 and 100.7 ± 91.5 in the cancer pain and non-cancer pain cohorts, respectively.”26 
This is the first descriptive study to investigate patient characteristics that result in 
differences in the 30-day average daily OME doses in patients with cancer receiving radiation 
in the last decade. Over the course of this study of patients with cancer receiving radiation, 
males, those of white race, those that received additional chemotherapy or did not receive 
additional definitive surgery, and those with public insurance had higher 30-day average daily 
OME doses. The difference observed with gender could be real, or it could be attributed to 
weight-based dosing that is clinically indicated for some opioid medications (namely long 
acting opioid medications). However, the trends of 30-day average daily OME doses for males 
and females converging over time suggests that the observed difference, at least in earlier 
years of the study, was likely due to more than differences in weights between males and 
females.  
Surgery is a painful component of many cancer treatment regimens.  Our study found 
that patients that receive surgery in addition to radiation generally have lower 30-day average 
daily OME doses than those that do not. This is likely due to the fact that additional definitive 
surgery, while painful in the short term, resulted in pain source control.  Further, this suggests 
that additional surgery, when indicated, may allow for lower daily OME doses to be prescribed. 
Future time series analysis is needed to determine if changes in prescribing practices 
were significant over time or if differences in prescribing practices were significant between 
subgroup characteristics. Additional studies from medication subgroups are also warranted. A 
Canadian study published in 2017 reported differences in opioid prescribing trends based on 
medication type, but focused mainly on long acting versus short acting opioid medications.38 
The electronic medical record from which this data was pulled only captured the medication 
 45 
active ingredient, not formulation. While methadone is not generally used for pain management 
alone, it can be used for pain management in the context of opioid use disorder. Future 
investigations should identify if patients were switched from other high dose opioids to 
methadone in the context of opioid use disorder management, which may coincide with an 
increase in awareness of the opioid epidemic and opioid dependence. Additionally, 
determination of formulation based on dosing frequency should be explored to determine use 
of long acting versus short acting opioids. Lastly, further studies could be done to determine if 
insurance pressures exist on prescribers, including formulary restrictions and dose quantity or 
day supply limits.   
 
Figure 2.3: Trends in Annual Opioid Prescribing Rates from the CDC by Overall and High-
Dosage Prescriptions Adapted for 2008-201737 
 
Table 2.5: Selected Events Related to the Opioid Epidemic between June 2008 and May 2018, 
adapted from the Timeline of Selected FDA Activities and Significant Events Addressing 
Opioid Misuse and Abuse41 
Date Event  
5/2010 FDA approved new formulation of OxyContin 
4/2011 White House Office of National Drug Control Policy report: Responding to America’s Prescription 
Drug Abuse Crisis, comprehensive action plan to address national prescription drug abuse released 
3/2012 The single-shared TIRF REMS went live 
2/2013 February 20, JAMA Article “Pharmaceutical Overdose Deaths, Unites States, 2010” published42 
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3/2013 March 1, FDA and health professional organizations asked prescribers of opioids to ensure 
knowledge of FDA-approved product labeling for opioids, adequate training in opioid therapy, and 
encouraged all prescribers to help curb nation's opioid epidemic 
4/2013 April 16, FDA took multiple actions related to OxyContin 
4/2014 April 3, FDA approved Evzio (naloxone hydrochloride injection) for emergency treatment of opioid 
overdose as the 1st auto-injector designed to deliver naloxone outside of a healthcare setting 
7/2014 CDC published “Opioid Painkiller Prescribing” citing 46 people die per day from prescription opioid 
overdose43 
10/2014 October 6, DEA reschedules hydrocodone combination products from schedule III to schedule II 
1/2015 AMA starts Opioid Task Force 
10/2015 October 13, JAMA article “Nonmedical Prescription Opioid Use and Use Disorders Among Adults 
Aged 18 Through 64 Years in the United States, 2003-2013” published25 
11/2015 November 18, FDA approved Narcan nasal spray, the 1st approved nasal spray version of naloxone 
3/2016 March 22, FDA required class-wide safety labeling changes for IR opioid pain medications including 
new boxed warning about serious risks of misuse and abuse, leading to addiction, overdose and 
death  
4/2016 April 19, CDC Guidelines for Chronic Pain Released10 
8/2016 August 16, US Surgeon General Vivek H. Murthy calls on physicians to raise awareness and further 
efforts to end opioid overdose epidemic 
August 31, FDA required class-wide changes to drug labeling to help inform health care providers and 
patients of serious risks associated with combined use of opioid medications and benzodiazepines  
12/2016 December 7, Senate passed “21st Century Cures Act” with $1 billion to curb opioid epidemic 
3/2017 March 14, Virginia Board of Medicine provides Regulations on Opioid Prescribing and Buprenorphine  
7/2017 July 6, the JAMA article by Scott Gottlieb and Janet Woodcock, “Marshaling FDA Benefit-Risk 
Expertise to Address the Current Opioid Abuse Epidemic," published 
July 6, following FDA’s request, Endo announced voluntarily removal of Opana ER from the market 
8/2017 AMA provides guidance to physicians to co-prescribe naloxone 
10/2017 October 23, The New Yorker article “The Family that Build an Empire of Pain” published44 
October 26, Trump declares opioid epidemic a public health emergency 
11/2017 November 1, President’s commission on combating drug addiction and the opioid crisis report 
released45 
1/2018 January 4, MMWR article “Drug and Opioid Involved Deaths – Unites States, 2013-2017” published46 
AMA: American Medical Association; CDC: Centers for Disease Control and Prevention; DEA: 
Drug Enforcement Administration; FDA: Food and Drug Administration; JAMA: Journal of the 
American Medical Association; MMWR: Morbidity and Mortality Weekly Report 
 
Limitations 
 The major limitation of this study was from the descriptive nature of the objectives that 
resulted in a lack of definitive statistical analysis. Future analyses should determine if statistical 
differences existed in 30-day average daily OME doses prescribing overall and if there were 
significant statistical differences between subgroup characteristics. 
Another limitation was from a large amount of missing prescription data information to 
calculate accurate daily OME doses. In order to accurately calculate a daily OME dose, a 
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medication name, medication strength, tablet or quantity amount (number of dose), daily 
frequency, and the OME conversion factor were needed. Due to the inherent limitations of 
documentation of the prescriptions from the electronic medical record, 59.6% of prescriptions 
were missing at least one component of the OME dose calculation. This may have led to bias 
in the calculated 30-day average daily OME dose, especially since some medications seemed 
to have more missing data than others (i.e. data were not missing at random). The authors 
considered imputing missing data to address this issue, however, it was ultimately decided that 
imputation was not necessarily due the large sample size of available prescriptions for which 
all data was available to calculate 30-day average daily OME dose.  
Another limitation was due to the inherent flexibility that prescribers often use when 
writing prescriptions for patients, particularly for “as needed” (i.e. PRN) dosing. Ranges were 
often provided in prescriptions for dose and frequency (i.e. 1-2 tablets every 4-6 hours per 
day). Therefore, daily OME doses were calculated based on patients using the highest 
possible dose at the greatest frequency for the ranges given in a prescription.  Therefore, it is 
possible that 30-day average daily OME doses may be overestimated. However, minimum 
daily OME doses were also calculated for all prescriptions and differences in results were 
negligible. 
Lastly, due to the nature of electronic medical record documentation, only one race was 
recorded for each patient. It is possible that a transition of documentation within the electronic 
medical record occurred to allow for addition of ethnicity to be included at some point in the 
study. Patients initially reporting “Multiple” for race could have changed their responses fall into 
a different group. 
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Conclusion 
Cancer survivors are an important demographic to consider for opioid utilization, as 
opioids are the mainstay to manage disease- and treatment-related pain. This longitudinal 
study described opioid prescriptions for patients with cancer receiving radiation overall, as well 
as variations in demographics including cancer type, gender, race, ethnicity, and primary 
insurance payer from 2008-2018 at a single academic cancer center. Opioid prescription 
trends followed similar trends, but higher 30-day average daily OME dose quantities compared 
to other previously reported trends in patients without cancer and outside of the United States. 
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CHAPTER 3: INCIDENCE AND ASSOCIATED RISKS OF NEW PERSISTENT AND 
CONTINUED OPIOID USE IN PATIENTS WITH CANCER RECEIVING RADIOTHERAPY 
 
Abstract 
Background: Improvements in cancer therapy have led to an increase in the aggregate 
number of cancer survivors and the duration of time spent in the survivorship period. There is 
growing awareness of opioid use in cancer survivors as this population increases. Pain 
management is an important consideration for patients with cancer, as malignancies, invasive 
surgery, chemotherapy, and radiation can all lead to significant pain. Approximately 50% of 
cancer patients will receive radiation therapy as a component of their treatment. For these 
patients, new persistent opioid use (NPOU; opioid naïve before cancer therapy, but fill opioid 
prescriptions beyond curative intent treatment) as well as continued chronic opioid use (COU; 
filled opioid prescriptions before cancer therapy and continued to be prescribed opioids beyond 
curative intent treatment) is of increasing concern. Neither the extent to which cancer survivors 
who receive curative intent radiation (CIR) develop NPOU or COU, nor factors that put them at 
risk for developing NPOU or COU, are known. Objective: Calculate incidence of and examine 
characteristics associated with COU and NPOU. Methods: Electronic medical record clinical 
and prescribing data from cancer survivors receiving radiotherapy for any indication from a 
single academic cancer center from January 1, 2008 through December 31, 2018 was utilized 
to determine NPOU and COU incidence. Associations of radiation-related, non-radiation 
related clinical, and sociodemographic variables on NPOU development and COU were 
assessed by bivariate analysis and multivariable binary logistic regression. Subgroup and 
sensitivity analyses were then conducted. Results: Of patients with cancer receiving 
radiation,19.7% of opioid naïve patients developed NPOU and 54.8% patients with opioid 
exposure prior to radiation continued opioid use. Certain cancer types, including head and 
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neck cancer (OR 3.90, 95% CI, 2.59-5.86), stage 3 disease (OR 1.75, 95% CI, 1.01-3.05), and 
additional chemotherapy (OR 1.58, 95% CI, 1.21-1.98) conferred increased odds of NPOU. 
Sociodemographic factors that conferred increased risk of NPOU included African American 
race (OR 1.38, 95% CI, 1.11-1.71), certain insurance types, and comorbid conditions including 
anxiety (OR 1.52, 95% CI, 1.11-2.08), arthritis (OR 1.58, 95% CI, 1.16-2.15), back pain (OR 
1.94, 95% CI, 1.46-2.58), depression (OR 1.56, 95% CI, 1.08-2.25), lung disease (OR 1.84, 
95% CI, 1.39-2.43), other opioid use (OR 3.05, 95% CI, 1.02-9.13), and nicotine use (OR 1.51, 
95% CI, 1.21-2.08). Indigent provided health insurance (OR 2.39, 95% CI, 1.00-5.73), anxiety 
(OR 2.00, 95% CI, 1.11-3.60), back pain (OR 2.86, 95% CI, 1.65-4.86), hypertension (OR 
1.77, 95% CI, 1.06-2.96), and nicotine use (OR 2.60, 95% CI, 1.46-4.64) were significantly 
associated with increased odds of COU after radiation. Discussion: Roughly one in five 
patients with cancer receiving CIR without prior exposure to opioids developed NPOU and 
more than half of patients with prior opioid exposure were COU. Patients with head and neck 
cancers may be at highest risk of NPOU, but other cancers such as colorectal, gastrointestinal, 
female genital, and respiratory also carry significant risk. This study identified socioeconomic 
and health differences in patients receiving radiation that result in increased odds of NPOU 
and COU. Conclusion: This study demonstrated substantial NPOU and COU in cancer 
survivors receiving radiation therapy with health disparities. Opioid use in these patients 
warrants evidence-based recommendations and guidelines to prevent misuse and opioid 
related deaths. 
 
 
Background 
Five-year survival from cancer diagnosis has increased from less than 50% to a mean 
of 67% (with a large range based on cancer site) over the last several decades.1,2 This 
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increase in survival, in part due to improvements in antineoplastic therapy, has led to an 
increase in both the aggregate number of cancer survivors and the duration of time patients 
spend in the survivorship period. Approximately 50% of cancer patients will receive radiation 
therapy as a component of their treatment.3 Undergoing radiation therapy can subject patients 
to significant morbidity that can vary by treatment site, with patients treated for head and neck 
cancer tending to have a significant burden of radiation-related toxicity.4–6   
Opioids are a cornerstone of pain management in patients with cancer, as malignancies 
themselves can lead to significant pain, in addition to pain resulting from invasive surgery, 
chemotherapy, and radiation.6–8 Cancer and non-cancer pain is treated differently in the 
literature and opioid prescribing guidelines have mostly focused on non-cancer pain.7,9 In 
studies that have investigated pain in patients with cancer, it has been documented that pain 
has been significantly undertreated.7,10–13 For patients with cancer, pain is often managed by 
the patient’s surgical, radiation, or medical oncologist, who may not have optimal training in 
pain management and palliative care. Specifically, radiation oncologist prescribing patterns 
have been explicitly described.14 Factors associated with increased written opioid prescriptions 
by radiation oncologists were: male sex, ≥25 years since graduation, group practice greater 
than ten, participation in the Physician Quality Reporting System, and southern location.14 
Historically, there have been five groups of pain types for patients with cancer: acute 
cancer-related pain, chronic cancer-related pain, preexisting chronic pain and cancer-related 
pain, history of drug addiction and cancer-related pain, and end-stage cancer-related pain.15 
However, there is emerging evidence of a new group of patients with new persistent opioid use 
(NPOU), defined as those who were opioid naïve (not exposed to opioids before cancer 
therapy) and who continue to fill opioid prescriptions after curative intent treatment.16,17  As 
more patients are surviving cancer, NPOU is of greater concern, especially as pain in this 
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population is poorly characterized and there is little-to-no consensus on the therapeutic 
framework of treating pain in patients with cancer.18  
Two studies have suggested that opioid use in patients with cancer is associated with 
worse survival.19,20 Hence, there is growing awareness of opioid use and misuse in patients 
with cancer.7,21–25  A propensity score matched study published in 2019 reported that 
respondents with cancer were significantly more likely to use prescription opioids than 
matched controls (OR: 2.43, 95% CI: 1.68-3.57).23  There is also emerging evidence of high 
rates of opioid misuse (use of opioids contrary to the directed or prescribed pattern of use, 
regardless of presence or absence of harm) in patients with cancer.26–31 One study found that 
58% of patients with cancer were non-compliant with their prescribed opioid therapy and were 
more likely to have higher morphine equivalent daily doses.27 Another study found that more 
than 50% of urine drug tests (UDT) were abnormal in patients with cancer and the most 
common opioid findings were absence of prescribed opioids (27%) and presence of 
unprescribed opioids (25%).31  A study of 209 emergency department patients with cancer 
showed depression and illicit substance use were significantly associated with a high risk of 
opioid misuse.30  Ultimately, an estimated 29% of patients with cancer are at high-risk for 
misuse.7,32   
Neither the extent to which cancer survivors who receive curative intent radiation (CIR) 
develop NPOU and COU, nor the factors that put them at risk are known. Understanding the 
factors associated with COU or developing NPOU after radiotherapy may help identify patients 
receiving radiation that may have difficulty weaning off opioid regimens. The objective of this 
study was to calculate the incidence of and examine characteristics associated with NPOU and 
COU. 
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Methods   
Data Source, Patient Identification, and Patient Covariates 
We utilized electronic medical record data from cancer survivors who received 
radiotherapy for any indication at Virginia Commonwealth University Massey Cancer Center 
between January 1, 2008 and December 31, 2018.  Patients 18 years of age or older with any 
cancer type and stage receiving radiation with or without additional treatment modalities (i.e. 
surgery, chemotherapy) were included. We only included patients that classified as cancer 
survivors (5CS), defined as the absence of metastatic disease or recurrence within 5 years of 
diagnosis. Prisoners were excluded. Covariate information on the date of cancer diagnosis, 
cancer type, stage, treatment type, treatment details, comorbid conditions, germane social 
history (including alcohol, tobacco, or illicit drug use), and demographic information (e.g., age, 
race, ethnicity and insurance status and type - including Virginia Coordinated Care [VCC], the 
institution sponsored health insurance for which all medical records should be available for 
these patients) was used. Prescribed opioid medications were included if written for the 
outpatient setting for at least a 14-day supply.  
 
Patient Grouping and Categorization 
Patients were grouped based on variations in treatment and by cancer type. As cancer 
treatment algorithms and evidence-based guidelines vary for different cancer types, it was 
expected that patients that fall in different subgroups (i.e. receive surgery versus those that do 
not), have different pain levels and overall potential risk of COU or developing NPOU.  In order 
to classify patients by COU and NPOU criteria, patients were grouped by previously published 
methods and as follows.16,33 Patients and written prescriptions were first indexed by days since 
radiation, where 0 was start of radiation, -30 was 30 days before start of radiation, and 30 was 
30 days after start of radiation. Because prescriptions were written with varying day-supply 
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greater than 14 days with or without ongoing refills, prescription rules were established to 
classify prescriptions based on day-prescribed and day-supply in comparison to start of 
radiation therapy as follows: (1) before radiation (2) during radiation (3) after radiation (4) 
continuous (Figure 3.1). Based on prescription classifications, patients were initially stratified 
by opioid exposure as opioid naïve (ON) or opioid exposed (OE) to determine final 
categorizations of: NPOU, Never Opioid User (NOU), and Chronic Opioid User (COU) (Table 
3.1).16,17 Due to the inherent limitations of documentation of the prescriptions from the 
electronic medical record, 5.2% of prescriptions were missing components required to 
determine when the prescriptions were ordered in relation to radiation treatment and thus were 
classified as UTOE: “Unknown Timing of Opioid Exposure” 
 
Figure 3.1: Prescription Index Rules 
 
  1: Prescription used before radiation  
2: Prescription used during radiation  
3: Prescription used after radiation  
4: Prescription used continuously 
>/= : greater than or equal to; </= : less than or equal to 
* Note: If the prescription fill overlapped more than one category, the 
prescription was assigned to whichever category in which majority of the 
prescription was contained  
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Table 3.1: Summary of Patient Groups by Opioid Exposure 
 Group  Abbreviation Definition  
Pre-Radiation Treatment 
 Opioid Naïve ON No known prescribed opioids ≥30 days before treatment 
 Opioid Exposed OE Known opioids prescribed ≥30 days before treatment 
Pre- and Post-Radiation Treatment 
 Chronic Opioid User COU Prescribed at least one opioid prescription 30 days before treatment 
(OE) and at least one opioid prescription 30 days after treatment 
 Never Opioid User NOU Had no known opioid prescription history before (ON) or after 
treatment 
 New Persistent Opioid 
User 
NPOU Previously ON who was prescribed at least one opioid prescription 
30 after treatment 
 Previous Opioid User POU Prescribed at least one opioid prescription 30 days before treatment 
(OE) and no known opioid prescription history after treatment 
 During Treatment Only 
User 
DTOU Prescribed opioids only between 30 days before treatment and 30 
days after treatment 
 
Statistical Analyses: Incidence and Binomial Logistic Regression 
The percent of ON patients who received CIR that develop new persistent opioid use 
was determined by incidence (Specific Aim 2a, Table 3.2) as follows:  
 
𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑁𝑃𝑂𝑈
𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑂𝑁 
The percent of OE patients who received CIR that continued chronic opioid use was 
determined by incidence (Specific Aim 2a, Table 9) as follows:  
 
𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝐶𝑂𝑈
𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑂𝐸 
In order to examine characteristics associated with COU and NPOU, associations of 
radiation-related, non-radiation related clinical, and sociodemographic variables with opioid 
exposure were assessed by bivariate analysis. Descriptive statistics including means, 
medians, standard deviations, and interquartile ranges were calculated for patient clinical, 
radiation, and sociodemographic characteristics, as well as opioid prescriptions. One-way 
ANOVA was conducted for continuous variables against opioid exposure status. Chi-squared 
tests were used on categorical variables with Fisher’s exact test used when expected cell 
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counts were less than 5.  P-values of <0.05 were considered statistically significant. Statistical 
analyses were conducted using Stata v15.1 and SAS v9.4 (SAS Institute, Cary, NC). 
 
Table 3.2: Methods for Specific Aim 2 
 
Binomial logistic regression for patient groups by opioid exposure against the radiation-
related, non-radiation related clinical, and sociodemographic variables was conducted. 
Binomial logistic regression was chosen over multinomial logistic regression to provide odds of 
developing NPOU compared to NOU and COU compared to POU for 5CS.  Odds ratios (OR) 
and 95% confidence intervals (95% CI) were reported (Specific Aims 2b-2e, Table 3.2). Table 
3.3 lists the models used for multivariable binary logistic regression. A stepwise binary logistic 
model was run to determine the best fitting model. The SAS automated input of p-value less 
than 0.05 to be included in the stepwise model was utilized. A final binary logistic regression 
model was then built with significant associations from the stepwise model and important 
theoretical characteristics (Specific aims 2b-2e, Table 3.2) to determine the risk of developing 
COU and NPOU (Specific Aim 2f, Table 3.2). As an extension of Specific Aim 2f, Specific Aim 
4 determined explicit health disparities in risk of NPOU, including gender and race. Type 3 
analysis of effects for significance of variables in each model overall was reported in 
Specific Aim 2 
In cancer survivors who received curative intent radiation therapy for their 
malignancy, examine incidence and characteristics associated with the risk of new 
persistent and continued chronic opioid use 
Method 
2a Identify the rate of new persistent and continued chronic opioid use  Incidence 
2b Examine the association of new persistent and continued chronic opioid use with 
radiation modality 
Binary logistic 
regression 
2c Examine the association of new persistent and continued chronic opioid use with 
radiation specific clinical factors such as disease site, stage, and other treatment 
modalities (including surgery, chemotherapy, and immune therapy) 
Binary logistic 
regression 
2d Examine the association of new persistent and continued chronic opioid use with 
other non-radiation specific clinical factors such as disease stage and comorbidities 
Binary logistic 
regression 
2e Examine the association of new persistent and continued chronic opioid use with 
sociodemographic characteristics such as age, gender, race, and insurance status 
Binary logistic 
regression 
2f Using significant associations found in prior analyses (2b-e) estimate the risk of 
developing new persistent and continued chronic opioid use 
Binary logistic 
regression 
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Supplemental Table 3.1. Supplemental multinomial logistic regressions for each model type 
were also conducted.   
 
Table 3.3: Logit Transformed Multivariable Binomial Logistic Regression Models for each COU 
(POU reference group) and NPOU (NOU reference group) 
Regression Model 
Radiation Specific log ! p
1-p
"=β0+ β1(Radiation Modality)+ε
a  
Radiation Specific, 
Clinical 
log ! p
1-p
"= β0 
+ β1(Cancer Type)	+ β2(Clinical Stage)	+ β3(Additional Chemotherapy)	+β4 
(Additional Surgery)	+ β5 (Additional Hormonal Therapy)	+ β6 
(Additional Immunotherapy)	+ β7 (Additional Other Therapy)	+ ε
a  
Non-Radiation 
Specific, Clinical 
log ! p
1-p
"= β0 + β1(Cancer Type)	+ β2(Clinical Stage)	+ β3(Comorbid Anxiety)	+β4 
(Comorbid Arthritis)	+ β5 (Comorbid Back Pain)	+ β6 (Comorbid Depression)	+ β7 
(Comorbid Diabetes)	+ β8 (Comorbid Heart Disease)	+ β9 
(Comorbid Hypertension)	+ β10 (Comorbid  Lung Disease)	+ β11 
(Comorbid Psychosis)	+ β12 (Comorbid Stroke)	+ β13 
(Death After More Than 5 years of Diagnosis)	+ β12 
(Recurrence After More Than 5 years of Diagnosis)	+ εa  
Socio-
demographic 
log ! p
1-p
"= β0 + β1(Age)	+ β2(Race)	+ β3(Gender)	+	β4 (Insurance Type)	+ β5 
(Alcohol Use)	+ β6 (Nicotine Use)	+ β7 (Opioid Use)	+ β8 (Other Drug Use)	+ ε
a  
Opioid Medication 
Specific log &
p
1-p'= β0 
+ β1(Number of Opioid Prescriptions)	+ β2(Buprenorphine Prescription)		 
+ β3(Codeine Prescription)
+ β4(Dihydrocodeine Prescription)	+ β5 (Fentanyl Prescription)	+ β6 
(Hydrocodone Prescription)	+ β7 (Hydromorphone Prescription)	+ β8 
(Meperidine Prescription)	+ β9 (Methadone Prescription)	+ β10 
(Morphine Prescription)	+ β11 (Oxycodone Prescription)	+ β12 
(Oxymorphone Prescription)	+ β13 (Tapentadol Prescription)	+ β14 
(Tramadol Prescription)+ εa 
Stepwise Model log &
p
1-p'= β0 + β1-4
(Radiation Specific Significant Factors) +β5-11 
(Radiation Specific, Clinical Significant Factors)+ β12-23 
(Non-Radiation Specific, Clinical Significant Factors)+ β24-31 
(Sociodemographic Significant Factors )+ εa 
Final Model 
(Stepwise + 
Theoretical) 
log &
p
1-p'= β0 + β1-4
(Radiation Specific Significant Factors) +β5-11 
(Radiation Specific, Clinical Significant Factors)+ β12-23 
(Non-Radiation Specific, Clinical Significant Factors)+ β24-31 
(Sociodemographic Significant Factors )+ β32-n(Theoretical Factors) +	ε
a 
NPOU: New Persistent Opioid User; NOU: Never Opioid User; COU: Chronic Opioid User; POU: 
Previous Opioid User 
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Subgroup and Sensitivity Analyses 
In order to assess the rigor of our results, we conducted a subgroup analysis and two 
sensitivity analyses. First, a subgroup analysis for patients with VCC was conducted to 
compare to patients without VCC to determine if differences existed due to potentially missed 
pre- or post- radiation opioid prescriptions in patients without VCC. Then, we conducted 
sensitivity analysis with patients with cancer that received radiation that lived without 
recurrence, metastatic disease, or death for at least 3 years (3-year cancer survivors; 3CS) 
and for at least 1 year (1-year cancer survivors; 1CS) after diagnosis. 
 
Results 
Between January 1, 2008 and December 31, 2018, 7,767 patients over the age of 18 
underwent radiation therapy for their malignancies at a single institution (Figure 3.2).  Of these 
patients, 3,887 survived without metastasis or recurrence of their disease beyond 5 years (5-
year cancer survivors; 5CS).  The majority of patients (84.1%) were opioid naïve prior to start 
of radiation therapy.  Only 10.7% (n = 414) of patients had known opioid prescriptions with at 
least a 14 day-supply written 30 days or more prior to radiation therapy.  
Table 3.4 describes sample sizes, patient demographics, and clinical factors grouped by 
opioid exposure status.  After grouping patients by opioid exposure before and after radiation, 
the majority of 5CSs (67.5%) were classified into the NOU group.  Of all opioid naïve 5CSs (n 
= 3,269), 19.7% developed NPOU. However, of 5CSs prescribed opioids prior to radiation 
therapy (n = 414), 54.8% continued opioid use after radiation. Only 5.2% (n =204) of 5CSs had 
documented opioid prescriptions for which timing in relation to radiation therapy could not be 
determined.  
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From bivariate analysis, all clinical and sociodemographic factors were associated with 
statistically significant differences in opioid exposure groups, except for death 5 or more years 
after diagnosis. NPOU and COU 5CSs were slightly younger than NOU and POU 5CSs and 
had higher numbers of opioids prescribed.  In any opioid exposure group, 5CSs were more 
likely to be female, have breast cancer, have commercial insurance or Medicare, and be white 
(except in COU for which there were more African American 5CSs). In addition to radiation 
therapy, almost half of 5CSs (44.9%) had additional chemotherapy, 70.4% had additional 
surgery, and 40.3% had additional hormonal therapy. Lastly, more than 85% of 5CSs reported 
no substance use. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Consort Diagram 
 
 
Patients >18 years old with cancer undergoing radiation 
therapy from January 2008 to December 2018 (N = 7,767) 
Opioid naïve  
(n = 3,269) 
Known opioid user 
prior to radiation  
(n = 414) 
Included in Analysis (n = 3,887) 
Clinical Exclusions (n = 3,880): 
- Died within 5 years (n = 2,793) 
- Had disease recurrence within 5 years (n = 233) 
- Metastatic Disease (n = 470) 
- Patient receiving radioisotopes and radium (n = 384) 
Unknown time of opioid use in 
relation to radiation 
(n = 204) 
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Table 3.4: 5CS Demographics Overall and by Opioid Exposure 
 Overall  
(n = 3,887) 
 COU  
(n = 227, 
5.8%) 
NPOU 
(n = 645, 
16.6%) 
POU 
(n = 187, 
4.8%) 
NOU 
(n = 2,624, 
67.5%) 
P-value 
Covariates Mean (Std) Median (IQR) Mean (Std) Mean (Std) Mean (Std) Mean (Std) 
 
Age 58.8 (12) 59 (16) 55.5 (11.8) 56.7 (12.4) 57.7 (12.9) 59.6 (11.9) <0.0001 
Number of Opioid 
Prescriptions** 7.5 (13.9) 2 (5) 18.6 (20.6) 7.6 (12.8) 1.4 (0.9) 0.0 (<0.1) <0.0001 
  N % N (%) N (%) N (%) N (%)  
Died After 5 or more 
years of Diagnosis 
       
 Yes 145 3.7 11 (4.9) 27 (4.0) 6 (3.2) 97 (3.7) 0.7305 
 No 3742 96.3 216 (95.2) 619 (96.0) 181 (96.8) 2527 (96.3)  
Recurrence of 
Disease After 5 or 
more years of 
Diagnosis 
       
 Yes 25 0.6 0 (0) 3 (0.5) 0 (0) 22 (0.8) 0.0018† 
 No 3862 99.4 227 (100) 642 (99.5) 187 (100) 2,602 (99.2)  
Gender        
 Female 2,796 72.0 156 (68.7) 390 (60.5) 154 (82.4) 1,948 (74.3) <0.0001 
 Male 1,090 28.0 71 (31.3) 255 (39.5) 33 (17.7) 675 (25.7)  
Race        
 White 2,368 60.9 101 (44.5) 354 (54.88) 103 (55.1) 1,675 (63.9) <0.0001 
 Black or African 
American 1,326 34.1 111 (48.9) 267 (41.4) 76 (40.6) 817 (31.2) 
 
 Other 192 4.9 15 (6.6) 24 (3.7) 8 (4.3) 131 (5.0)  
Insurance        
 Commercial 1,603 41.3 64 (28.2) 201 (31.2) 79 (42.3) 1,186 (45.2) <0.0001† 
 VCC 223 5.7 34 (15.0) 55 (8.5) 11 (5.9) 119 (4.5)  
 Insurance, Not 
Specified 297 7.6 18 (7.9) 61 (9.5) 15 (8.0) 185 (7.1) 
 
 Medicaid 203 5.2 28 (12.3) 58 (9.0) 12 (6.4) 93 (3.6)  
 Medicare 1,286 33.1 57 (25.1) 193 (30.0) 60 (32.1) 892 (34.0)  
 Military 51 1.3 2 (0.9) 5 (0.8) 3 (1.6) 40 (1.5)  
 Self-Pay 202 5.2 22 (9.7) 65 (10.1) 5 (2.7) 99 (3.8)  
 Unknown 21 0.5 2 (0.9) 7 (1.1) 2 (1.1) 9 (0.3)  
Cancer Type       <0.0001† 
 Breast 2,053 52.8 103 (45.4) 180 (27.9) 122 (65.2) 1,535 (59.4)  
 Colorectal 204 5.3 11 (4.8) 67 (10.4) 3 (1.6) 111 (4.3)  
 Female Genital 158 4.1 4 (1.8) 47 (7.3) 6 (3.2) 94 (3.6)  
 Gastrointestinal 95 2.4 12 (5.3) 22 (3.4) 4 (2.1) 45 (1.7)  
 Head and Neck 386 9.9 25 (11.0) 121 (18.8) 9 (4.8) 191 (7.4)  
 
Leukemia, 
Lymphoma, Other 
Hematopoietic 
147 3.8 8 (3.5) 24 (3.7) 13 (7.0) 98 (3.8)  
 Lung and 
Bronchus 259 6.7 18 (7.9) 78 (12.1) 10 (5.4) 127 (4.9) 
 
 Other 272 7.0 28 (12.3) 80 (12.4) 12 (6.4) 132 (5.1)  
 Prostate 312 8.0 18 (7.9) 26 (4.0) 8 (4.3) 252 (9.7)  
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Clinical Stage        
 0 327 8.5 9 (4.0) 24 (3.8) 5 (2.7) 265 (10.1) <0.0001 
 1 1,083 28.0 52 (23.0) 137 (21.5) 58 (31.0) 772 (29.9)  
 2 989 25.6 80 (35.4) 142 (22.3) 62 (33.2) 642 (24.9)  
 3 500 12.9 38 (16.8) 160 (25.1) 18 (9.6) 239 (9.2)  
 Unknown 969 25.1 47 (20.8) 174 (27.3) 44 (23.9) 660 (25.6)  
Radiation Modality        
 Brachytherapy 455 11.7 12 (5.3) 42 (6.5) 12 (6.4) 367 (14.2) <0.0001† 
 Conformal or 3-D 403 10.4 33 (14.5) 56 (8.7) 29 (15.5) 250 (9.7)  
 External Beam 567 14.6 25 (11.0) 93 (14.4) 18 (9.6) 399 (15.4)  
 IMRT 641 16.5 46 (20.3) 175 (47.1) 22 (11.8) 350 (13.5)  
 Photons  1,588 40.9 92 (40.5) 240 (37.2) 90 (48.1) 1,082 (41.9)  
 Photons and 
Electrons 73 1.9 5 (2.2) 6 (0.9) 7 (3.7) 47 (1.8) 
 
 Stereotactic 
Radiosurgery 114 3.0 12 (5.3) 26 (4.0) 8 (4.3) 58 (2.2) 
 
 Other 45 1.2 2 (0.9) 7 (1.1) 1 (0.5) 32 (1.2)  
Additional 
Chemotherapy 
       
 Yes 1,744 44.9 129 (56.8) 390 (60.5) 119 (63.6) 1,010 (38.5) <0.0001 
 No 2,143 55.1 98 (43.2) 255 (39.5) 68 (36.4) 1,614 (61.5)  
Additional Surgery        
 Yes 2,735 70.4 149 (65.6) 356 (55.2) 147 (78.6) 1,936 (73.8) <0.0001 
 No 1,152 29.6 78 (34.4) 289 (44.8) 40 (21.4) 688 (26.2)  
Additional Hormonal 
Therapy 
       
 Yes 1,566 40.3 70 (30.8) 153 (23.7) 89 (47.6) 1,174 (44.7) <0.0001 
 No 2,321 59.7 157 (69.2) 492 (76.3) 98 (52.4) 1,450 (55.3)  
Additional 
Immunotherapy 
       
 Yes 182 4.7 13 (5.7) 30 (4.7) 23 (12.3) 107 (4.1) <0.0001 
 No 3,705 95.3 214 (94.3) 615 (95.4) 164 (87.7) 2,517 (95.9)  
Additional Other 
Therapy 
       
 Yes 33 0.9 3 (1.3) 5 (0.8) 1 (0.5) 21 (0.8) 0.0018† 
 No 3854 99.2 224 (98.7) 640 (99.2) 186 (99.5) 2,603 (99.2)  
Comorbid Conditions        
 Anxiety + 442 11.4 74 (32.6) 118 (18.3) 29 (15.5) 205 (7.8) <0.0001 
 Anxiety - 3,444 88.6 153 (67.4) 527 (81.7) 158 (84.5) 2,418 (92.2)  
         
 Arthritis + 466 12.0 83 (36.6) 97 (15.0) 40 (21.4) 232 (8.8) <0.0001 
 Arthritis - 3,420 88.0 144 (63.4) 548 (85.0) 147 (78.6) 2,391 (91.2)           
 Back Pain + 486 12.5 96 (42.3) 140 (21.7) 33 (17.7) 204 (7.8) <0.0001 
 Back Pain - 3,400 87.5 131 (57.7) 505 (78.3) 154 (82.4) 2,419 (92.2)           
 Depression + 321 8.3 63 (27.8) 84 (13.0) 28 (15.0) 138 (5.3) <0.0001 
 Depression - 3,565 91.7 164 (72.3) 561 (87.0) 159 (85.0) 2,485 (94.7)  
         
 Diabetes + 463 11.9 52 (22.9) 97 (15.0) 34 (18.2) 266 (10.1) <0.0001 
 Diabetes - 3,423 88.1 175 (77.1) 548 (85.0) 153 (81.8) 2,357 (89.9)           
 Heart Disease + 769 19.8 94 (41.4) 185 (28.7) 48 (25.7) 427 (16.3) <0.0001 
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 Heart Disease - 3,117 80.2 133 (58.6) 460 (71.3) 139 (74.3) 2,196 (83.7)           
 Hypertension + 1,313 33.8 138 (60.8) 285 (44.2) 78 (41.7) 781 (29.8) <0.0001 
 Hypertension - 2,573 66.2 89 (39.2) 360 (55.8) 109 (58.3) 1,842 (70.2)           
 Lung Disease + 513 13.2 76 (33.5) 165 (25.6) 30 (16.0) 227 (8.7) <0.0001 
 Lung Disease - 3,373 86.8 151 (66.5) 480 (74.4) 157 (84.0) 23,96 (91.4)  
Substance Use        
 Alcohol + 121 3.1 31 (13.7) 33 (5.1) 9 (4.8) 44 (1.7) <0.0001 
 Alcohol - 37,65 96.9 196 (86.3) 612 (94.9) 178 (95.2) 2,579 (98.3)           
 Nicotine + 594 15.3 109 (48.0) 186 (28.8) 35 (18.7) 249 (9.5) <0.0001 
 Nicotine - 3,292 84.7 118 (52.0) 459 (71.2) 152 (81.3) 2,374 (90.5)           
 Other Opioid + 30 0.8 5 (2.2) 18 (2.8) 2 (1.1) 5 (0.2) <0.0001†   Other Opioid - 3,856 99.2 222 (97.8) 627 (97.2) 185 (98.9) 2,618 (99.8)           
 Other Drug + 103 2.7 26 (11.5) 38 (5.9) 7 (3.7) 31 (1.2) <0.0001 
 Other Drug - 3,783 97.4 201 (88.6) 607 (94.1) 180 (96.3) 2,592 (98.8)  
n = 3,886, missing clinical data for 1 patient; 204 patients had unknown opioid exposure timing (UTOE); 
Chi Squared test used unless stated; ** Number of prescriptions includes prescriptions written during 
radiation therapy that were not included in this analysis; †: Fisher’s Exact Test; 5CS: 5-year Cancer 
Survivors; Std: Standard Deviation; IQR: Interquartile Range; COU: Chronic Opioid User; NPOU: New 
Persistent Opioid User; POU: Previous Opioid User; NOU: Never Opioid User; IMRT: Intensity 
Modulated Radiation Therapy; VCC: Virginia Coordinated Care 
 
 
Characteristics Associated with NPOU and COU 
 Six multivariable binary logistic models were built to examine the associations of NPOU 
and COU with: radiation modality (Specific Aim 2b), radiation specific clinical factors (Specific 
Aim 2c), non-radiation specific clinical factors (Specific Aim 2d), sociodemographic 
characteristics (Specific Aim 2e), a stepwise model estimating the risk of NPOU and COU, and 
lastly, a theoretical model from significant associations of the stepwise regression with other 
significant and relevant characteristics identified in previous models (Specific Aim 2f).    
In the final theoretical model for likelihood of development of NPOU (Table 3.5), patients 
of African American race, certain insurance types, certain cancer types, stage 3 disease 
(meaning more advanced disease spreading beyond the primary tumor, but not to distant 
sites), additional chemotherapy, certain comorbid conditions, and nicotine and other opioid use 
were significantly more likely to develop NPOU controlling for other factors, compared to 
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patients that had no known opioid prescriptions.  Conversely, there was a significant decrease 
in risk of NPOU with increase in age controlling for other factors. 
 From individual binary logistic models addressing specific groups of characteristics, 
other covariates were additionally found be associated with increased risk of NPOU 
development. When examining only sociodemographic factors, men were found to carry 
increased risk of NPOU when controlling for other factors. Radiation specific factors resulted in 
decreased risk of NPOU based on certain radiation modalities, but were not found to be 
significant in the stepwise model. Gender and additional surgery did not meet the p-value of 
significance to be included in the stepwise model, but were included in the final theoretical 
model, as they are important clinical factors. 
 In the final model for 5CSs exposed to opioids prior to radiation (Table 3.6), use of VCC 
insurance, comorbid anxiety, back pain, hypertension, and nicotine use were significantly 
associated with increased odds of continuing opioid use after radiation.  Some covariates were 
found to be significant in individual binary logistic models addressing specific groups of 
characteristics (including colorectal, gastrointestinal, and head and neck cancers), but these 
were not found to be significant in the final model. 
 
Table 3.5: NPOU Binary Logistic Regressions for 5CS Not Exposed to Opioids Prior to 
Radiation 
NPOU, NOU = reference 
(n = 3,215) Sociodemographic 
Radiation 
Specific 
Radiation 
Specific, Clinical 
Non-Radiation 
Specific, Clinical Stepwise 
Stepwise + 
Theoretical 
Covariates OR (95% CI) 
Age 0.98 (0.97, 0.99)    0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 
Race  
 African American 1.23 (1.01, 1.49)    1.38 (1.11, 1.71) 1.38 (1.11, 1.71) 
 Other 0.80 (0.50, 1.28)    0.75 (0.46, 1.23) 0.75 (0.46, 1.22) 
 White Reference 
Gender  
 Male 1.64 (1.35, 2.00)     1.01 (0.76, 1.34) 
 Female Reference 
Insurance Type  
 Commercial Reference 
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 VCC 1.99 (1.36, 2.90)    1.61 (1.07, 2.44) 1.60 (1.06, 2.42) 
 Insurance, Not Specified 1.68 (1.20, 2.36)    1.47 (1.02, 2.12) 1.47 (1.02, 2.12) 
 Medicaid 2.53 (1.70, 3.75)    2.08 (1.35, 3.23) 2.08 (1.34, 3.21) 
 Medicare 1.83 (1.39, 2.41)    1.53 (1.14, 2.04) 1.52 (1.14, 2.03) 
 Military 0.69 (0.26, 1.80)    0.92 (0.34, 2.49) 0.93 (0.34, 2.52) 
 Self-Pay 2.57 (1.75, 3.77)    1.97 (1.30, 2.98) 1.96 (1.30, 2.97) 
Cancer Type  
 Breast Reference 
 Colorectal   3.25 (2.14, 4.94) 3.99 (2.74, 5.80) 3.26 (2.21, 4.81) 3.09 (2.03, 4.69) 
 Female Genital   4.13 (2.62, 6.52) 3.29 (2.16, 5.02) 2.72 (1.74, 4.26) 2.57 (1.62, 4.08) 
 Gastrointestinal   2.80 (1.52, 5.14) 3.06 (1.71, 5.48) 3.48 (1.90, 6.37) 3.24 (1.70, 6.19) 
 Head and Neck   4.61 (3.14, 6.77) 4.49 (3.31, 6.10) 4.27 (3.10, 5.89) 3.90 (2.59, 5.86) 
 Leukemia, Lymphoma, 
Other Hematopoietic  
 
1.58 (0.92, 2.70) 1.93 (1.16, 3.19) 1.69 (1.01, 2.84) 1.48 (0.82, 2.66) 
 Lung and Bronchus   3.53 (2.21, 5.64) 3.07 (2.12, 4.46) 2.91 (1.96, 4.31) 2.52 (1.55, 4.10) 
 Other   5.09 (3.41, 7.61) 4.49 (3.14, 6.42) 4.84 (3.33, 7.02) 4.48 (2.93, 6.85) 
 Prostate   0.91 (0.52, 1.57) 0.66 (0.42, 1.06) 0.85 (0.51, 1.40) 0.72 (0.38, 1.37) 
Clinical Stage  
 0 Reference 
 1   1.10 (0.68, 1.77) 1.12 (0.70, 1.81) 1.06 (0.65, 1.74) 1.07 (0.66, 1.75) 
 2   1.18 (0.71, 1.96) 1.60 (0.98, 2.61) 1.16 (0.69, 1.96) 1.18 (0.70, 1.98) 
 3   1.77 (1.04, 3.02) 2.69 (1.61, 4.48) 1.74 (1.00, 3.03) 1.75 (1.01, 3.05) 
Additional Chemotherapy   1.75 (1.39, 2.21)  1.58 (1.23, 2.02) 1.55 (1.21, 1.98) 
Additional Surgery   0.82 (0.63, 1.07)   0.86 (0.65, 1.14) 
Additional Hormonal 
Therapy 
  1.11 (0.84, 1.47) 
  
 
Additional Immunotherapy   1.05 (0.66, 1.66)    
Additional Other Therapy   1.24 (0.45, 3.48)    
Death After 5 or more 
years of Diagnosis 
   1.05 (0.65, 1.70) 
  
Recurrence After 5 or 
more years of Diagnosis 
   0.43 (0.11, 1.66) 
  
Comorbid conditions  
 Anxiety    1.59 (1.17, 2.15) 1.52 (1.11, 2.08) 1.52 (1.11, 2.08) 
 Arthritis    1.36 (1.00, 1.84) 1.56 (1.15, 2.13) 1.58 (1.16, 2.15) 
 Back Pain    2.06 (1.56, 2.72) 1.94 (1.46, 2.58) 1.94 (1.46, 2.58) 
 Depression    1.68 (1.17, 2.40) 1.55 (1.08, 2.23) 1.56 (1.08, 2.25) 
 Diabetes    0.89 (0.65, 1.21)   
 Heart Disease    1.18 (0.92, 1.51)   
 Hypertension    1.29 (1.03, 1.62)   
 Lung Disease    2.23 (1.70, 2.92) 1.84 (1.39, 2.43) 1.84 (1.39, 2.43) 
Substance Use  
 Alcohol Use 1.18 (0.69, 2.01)      
 Nicotine Use 2.65 (2.07, 3.38)    1.59 (1.21, 2.08) 1.58 (1.21, 2.08) 
 Other Opioid Use 4.81 (1.67, 13.85)    3.14 (1.05, 9.38) 3.05 (1.02, 9.13) 
 Other Drug Use 1.05 (0.59, 1.86)      
Radiation Modality  
 Brachytherapy  0.29 (0.15, 0.57)     
 Conformal or 3-D  0.46 (0.32, 0.64)     
 External Beam  0.46 (0.34, 0.62)     
 IMRT  Reference     
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 Other   0.46 (0.20, 1.05)     
 Photons   0.45 (0.36, 0.57)     
 Photons and Electrons  0.26 (0.11, 0.61)     
 Stereotactic Radiosurgery  0.91 (0.56, 1.50)     
Bold denotes statistical significance; 5CS: 5-year Cancer Survivors; NPOU: New Persistent Opioid 
User; NOU: Never Opioid User; OR: Odds Ratio; 95% CI: 95% Confidence Interval; IMRT: Intensity 
Modulated Radiation Therapy; VCC: Virginia Coordinated Care 
 
 
Table 3.6: COU Binary Logistic Regressions for 5CS Exposed to Opioids Prior to Radiation 
COU, POU = 
reference (n = 413) Sociodemographic 
Radiation 
Specific 
Radiation 
Specific, Clinical 
Non-Radiation 
Specific, Clinical Stepwise 
Stepwise + 
Theoretical 
Covariates OR (95% CI) 
Age 0.99 (0.97, 1.02)     0.98 (0.96, 1.01) 
Race  
 African American 1.36 (0.87, 2.13)     1.29 (0.76, 2.18) 
 Other 1.78 (0.67, 4.72)     1.88 (0.64, 5.50) 
 White Reference 
Gender       
 Male 1.52 (0.89, 2.61)     1.16 (0.51, 2.64) 
 Female Reference 
Insurance Type  
 Commercial Reference 
 VCC 2.53 (1.12, 5.72)     2.39 (1.00, 5.73) 
 Insurance, Not 
Specified 1.14 (0.50, 2.57) 
    
1.28 (0.53, 3.11) 
 Medicaid 1.55 (0.69, 3.50)     1.62 (0.65, 4.04) 
 Medicare 1.22 (0.67, 2.25)     1.25 (0.63, 2.48) 
 Military 0.81 (0.12, 5.47)     0.93 (0.12, 7.29) 
 Self-Pay 3.49 (1.19, 10.23)     2.89 (0.87, 9.62) 
Cancer Type  
 Breast Reference 
 Colorectal   2.59 (0.61, 10.97) 5.29 (1.24, 22.58) 4.67 (1.07, 20.49) 4.23 (0.83, 21.53) 
 Female Genital   0.81 (0.20, 3.26) 1.12 (0.25, 5.06) 1.33 (0.31, 5.71) 0.71 (0.15, 3.40) 
 Gastrointestinal   3.26 (0.93, 11.45) 6.77 (1.92, 23.85) 5.15 (1.47, 18.07) 4.03 (1.02, 15.98) 
 Head and Neck   2.32 (0.85, 6.33) 3.96 (1.59, 9.89) 2.34 (0.90, 6.03) 1.76 (0.53, 5.89) 
 
Leukemia, 
Lymphoma, other 
Hematopoietic 
  
0.59 (0.18, 1.93) 1.03 (0.37, 2.82) 1.06 (0.39, 2.84) 0.59 (0.14, 2.50) 
 Lung and 
Bronchus 
  
1.16 (0.34, 3.99) 1.12 (0.43, 2.96) 1.19 (0.46, 3.07) 0.99 (0.25, 3.98) 
 Other   2.76 (1.06, 7.19) 5.56 (2.26, 13.66) 5.19 (2.07, 13.00) 4.49 (1.53, 13.22) 
 Prostate   1.52 (0.47, 4.89) 2.95 (1.12, 7.72) 2.72 (1.02, 7.26) 1.54 (0.32, 7.44) 
Clinical Stage  
 0 Reference 
 1   0.52 (0.16, 1.75) 0.59 (0.17, 2.11) 0.47 (0.14, 1.64) 0.46 (0.12, 1.76) 
 2   0.77 (0.22, 2.65) 0.85 (0.24, 2.99) 0.67 (0.20, 2.30) 0.46 (0.16, 2.55) 
 3   0.97 (0.25, 3.76) 1.12 (0.29, 4.41) 0.89 (0.23, 3.40) 0.79 (0.17, 3.66) 
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Additional 
Chemotherapy 
  0.85 (0.49, 1.46) 
  
0.85 (0.46, 1.57) 
Additional Surgery   0.71 (0.33, 1.53)   0.70 (0.29, 1.66) 
Additional Hormonal 
Therapy 
  0.77 (0.46, 1.28) 
   
Additional 
Immunotherapy 
  0.58 (0.27, 1.25) 
   
Additional Other 
Therapy 
  2.52 (0.24, 26.63) 
   
Death After 5 or 
more years of 
Diagnosis 
   
1.37 (0.44, 4.25) 
  
Comorbid conditions  
 Anxiety    1.64 (0.91, 2.95) 1.91 (1.10, 3.31) 2.00 (1.11, 3.60) 
 Arthritis    1.37 (0.80, 2.33)    Back Pain    3.04 (1.80, 5.15) 3.17 (1.88, 5.35) 2.83 (1.65, 4.86) 
 Depression    1.57 (0.86, 2.87)   
 Diabetes    0.92 (0.51, 1.67)   
 Heart Disease    1.39 (0.84, 2.29)   
 Hypertension    1.35 (0.81, 2.24) 1.85 (1.16, 2.93) 1.77 (1.06, 2.96) 
 Lung Disease    1.93 (1.10, 3.37)   
Substance Use  
 Alcohol Use 1.11 (0.43, 2.85)      
 Nicotine Use 3.13 (1.83, 5.35)    3.27 (1.96, 5.47) 2.60 (1.46, 4.64) 
 Other Opioid Use 0.61 (0.10, 3.66)      
 Other Drug Use 1.22 (0.42, 3.50)      
Radiation Modality  
 Brachytherapy  0.69 (0.10, 4.77) 
    
 Conformal or 3-D  0.54 (0.26, 1.10) 
    
 External Beam  0.67 (0.30, 1.47) 
    
 IMRT Reference 
 Other   0.93 (0.08, 10.80) 
    
 Photons   0.48 (0.27, 0.87) 
    
 Photons and 
Electrons  
0.33 (0.10, 
1.17) 
    
 Stereotactic Radiosurgery  
0.72 (0.26, 
2.04)     
Bold denotes statistical significance; 5CS: 5-year Cancer Survivors; COU: Chronic Opioid User; 
POU: Previous Opioid User; OR: Odds Ratio; 95% CI: 95% Confidence Interval; UTOE: Unknown 
Timing of Opioid Exposure; IMRT: Intensity Modulated Radiation Therapy; VCC: Virginia Coordinated 
Care 
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Subgroup Analysis: Patients with VCC 
A major concern of the initial analysis was that there were potential opioid prescriptions 
missed because they were written outside of the institution and therefore not captured from the 
electronic health record. In order to assess the robustness of our initial results, a subgroup 
analysis of patients utilizing the institution-provided indigent care (VCC), which requires 
patients to get all of their care at the institution, was conducted. It is expected that these 
patients have complete records. Demographics for 5CS with VCC are described in Table 3.7. 
In comparison to the entire sample, patients with VCC had increased incidence of opioid 
prescription use after radiation. Of opioid naïve patients utilizing VCC (n = 175), 31.4% 
developed NPOU. For patients prescribed opioids prior to radiation therapy (n = 45), 75.6% 
continued opioid use after radiation. Compared to the entire sample, 5CS with VCC were 
slightly younger and generally had a higher number of opioid prescriptions written.  While the 
VCC cohort had a similar gender spread (mostly female, 74.9%) to the entire sample, the race 
distribution was quite different.  Instead of white patients (60.9%) as in the entire sample, the 
VCC patient subgroup was made up of mostly African American patients (57.9%).  
Additionally, the patients in the VCC subgroup may be sicker than the 5CS group, as the 
proportion of all types of comorbid diseases, advanced clinical stage of disease burden, and 
substance use in this subgroup were higher. However, differences in disease burden for these 
patients may be due to inherent health disparities between non-indigent and indigent 
populations. 
In the final logistic regression model for likelihood of developing NPOU for patients with 
VCC (Table 3.8), female genital cancers, arthritis, and nicotine use were associated with 
significantly greater odds of NPOU when controlling for other factors. In comparison to the 
entire sample, there were less significant factor associations with NPOU, but factors that were 
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significant in this group were also significant in the entire sample. Also, the factors of 
association in this subgroup of VCC patients had higher odds of NPOU. There were no 
significant associations to COU (data not shown) in this subgroup, although this may be due to 
insufficient power to detect differences from the smaller sample size (n =45).  
 
Table 3.7: Demographics of 5CS with VCC 
 Overall  
(n = 224) 
 COU 
(n = 34) 
NPOU 
(n = 55) 
POU 
(n = 11) 
NOU 
(n = 120) P-value 
Covariates Mean (Std) Median (IQR) 
 Mean (Std) Mean (Std) Mean (Std) Mean (Std)  
Age 53.5 (10.2) 55 (13)  55.1 (9.3) 50.5 (12.2) 51.3 (9.1) 54.6 (9.4) 0.0993 
Number of Opioid 
Prescriptions** 12.6 (18.4) 4 (15) 
 16.7 (18.4) 13.3 (19.9) 1.9 (1.6) 0 (0) <0.0001 
Died After 5 or more years 
of Diagnosis   
      
 Yes 8 3.6  3 (8.8) 2 (3.6) 0 (0) 3(2.5) 0.0180† 
 No 216 96.4  31 (91.2) 53 (96.4) 11 (100) 117 (97.5)  
Recurrence of Disease 
After 5 or more years of 
Diagnosis 
  
 
     
 Yes 1 0.5  0 (0) 0 (0) 0 (0) 1 (0.8) 0.5357† 
 No 223 99.6  34 (100) 55 (100) 11 (100) 119 (99.2)  
Gender         
 Female 167 74.9  25 (73.5) 39 (70.9) 9 (81.8) 91 (76.5) 0.0020† 
 Male 56 25.1  9 (26.5) 16 (29.1) 2 (18.2) 28 (23.5)  
Race         
 White 73 32.7  7 (20.6) 24 (43.6) 2 (18.2) 39 (32.8) <0.0001 
 Black or African 
American 129 57.9 
 22 (64.7) 28 (50.9) 8 (72.7) 71 (59.7)  
 Other 21 9.4  5 (14.7) 3 (5.5) 1 (9.1) 9 (7.6)  
Insurance         
 VCC 223 100.0  34 (100) 55 (100) 11 (100) 119 (100) N/A 
Cancer Type         
 Breast 112 50.2  22 (64.7) 17 (30.9) 7 (63.6) 65 (54.5) 0.0001y 
 Female Genital 43 19.3  1 (2.9) 15 (27.3) 2 (18.2) 23 (19.3)  
 Head and Neck 12 5.4  0 (0) 4 (7.3) 0 (0) 8 (6.7)  
 Other 33 14.7  5 (14.7) 18 (32.7) 2 (18.2) 8 (6.7)  
 Prostate 23 10.3  6 (17.7) 1 (1.8) 0 (0) 15 (12.6)  
Clinical Stage         
 0 17 7.6  1 (2.9) 2 (3.6) 0 (0) 14 (11.8) 0.1950y 
 1 49 22.0  8 (23.5) 13 (23.6) 2 (18.2) 26 (21.9)  
 2 74 33.2  14 (41.2) 13 (23.6) 3 (27.3) 42 (35.3)  
 3 30 13.5  7 (20.6) 11 (20.0) 1 (9.1) 10 (8.4)  
 Unknown 53 23.8  4 (11.8) 16 (29.1) 5 (45.5) 27 (22.7)  
Radiation Modality         
 Brachytherapy 33 14.8  4 (11.8) 5 (9.1) 4 (36.4) 19 (16.0) 0.3802y 
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 Conformal or 3-D 36 16.1  7 (20.6) 9 (16.4) 2 (18.2) 18 (15.1)  
 External beam 23 10.3  3 (8.8) 6 (10.9) 1 (9.1) 13 (10.9)  
 IMRT 25 11.2  3 (8.8) 10 (18.2) 1 (9.1) 11 (9.2)  
 Photons  103 50.0  16 (47.0) 24 (43.6) 3 (2.7) 57 (47.5)  
 Stereotactic radiosurgery 3 1.3  1 (2.9) 1 (1.8) 0 (0) 1 (0.8)  
Additional Chemotherapy         
 Yes 107 47.8  19 (55.9) 33 (60.0) 4 (36.4) 49 (40.8) <0.0001† 
 No 117 52.2  15 (44.1) 22 (40.0) 7 (63.6) 71 (59.2)  
Additional Surgery         
 Yes 163 72.8  27 (79.4) 36 (65.5) 9 (81.8) 88 (73.3) 0.0008† 
 No 61 27.2  7 (20.6) 19 (34.6) 2 (18.2) 32 (26.7)  
Additional Hormonal 
Therapy   
      
 Yes 93 41.5  15 (6.7) 14 (25.5) 6 (54.6) 58 (48.3) <0.0001† 
 No 131 58.5  19 (55.9) 41 (74.6) 5 (45.5) 62 (51.7)  
Additional Immunotherapy         
 Immune + 14 6.3  4 (11.8) 3 (5.5) 0 (0) 7 (3.1) 0.0119† 
 Immune - 210 93.8  30 (88.2) 52 (94.6) 11 (100) 113 (94.2)  
Additional Other Therapy         
 Yes 4 1.8  1 (2.9) 1 (1.8) 0 (0) 2 (1.7) 0.1308† 
 No 220 98.2  33 (97.1) 54 (98.2) 11 (100) 118 (98.3)  
Comorbid Conditions         
 Anxiety + 49 22.0  8 (23.5) 15 (27.3) 2 (18.2) 24 (20.2) 0.0016† 
 Anxiety - 174 78.0  26 (76.5) 40 (72.7) 9 (81.8) 95 (79.8)  
          
 Arthritis + 42 18.8  13 (38.2) 9 (16.4) 3 (27.3) 15 (12.6) <0.0001† 
 Arthritis - 181 81.2  21 (61.8) 46 (83.6) 8 (72.7) 104 (87.4)  
          
 Back Pain + 65 29.2  16 (47.1) 17 (30.9) 4 (36.4) 27 (22.7) <0.0001† 
 Back Pain - 158 70.9  18 (52.9) 38 (69.1) 7 (63.6) 92 (77.3)  
          
 Depression + 27 12.1  5 (14.7) 5 (9.1) 1 (9.1) 16 (13.5) 0.0063† 
 Depression - 196 87.9  29 (85.3) 50 (90.9) 10 (90.9) 103 (86.6)  
          
 Diabetes + 45 20.2  4 (11.8) 7 (12.7) 0 (0) 32 (26.9) <0.0001† 
 Diabetes - 178 79.8  30 (88.2) 48 (87.3) 11 (100) 87 (73.1)  
          
 Heart Disease + 65 29.2  13 (38.2) 16 (29.1) 3 (27.3) 33 (27.7) 0.0007† 
 Heart Disease - 158 70.9  21 (61.8) 39 (70.9) 8 (72.7) 86 (72.3)  
          
 Hypertension + 141 63.3  22 (64.7) 30 (54.6) 9 (81.8) 77 (64.7) 0.0004† 
 Hypertension - 82 36.8  12 (35.3) 25 (45.5) 2 (18.2) 42 (35.3)  
          
 Lung Disease + 47 21.1  11 (32.4) 15 (27.3) 3 (27.3) 18 (15.1) 0.0001† 
 Lung Disease - 176 78.9  23 (67.7) 40 (72.7) 8 (72.7) 101 (84.9)  
Substance Use         
 Alcohol + 12 5.4  3 (8.8) 1 (1.8) 3 (27.3) 5 (4.2) 0.0004† 
 Alcohol - 211 94.6  31 (91.2) 54 (98.2) 8 (72.7) 114 (95.8)  
          
 Nicotine + 80 35.9  18 (52.9) 26 (47.3) 6 (54.6) 29 (24.4) <0.0001† 
 Nicotine - 143 64.1  16 (47.1) 29 (52.7) 5 (45.5) 90 (75.6)  
          
 Other Opioid + 3 1.4  1 (2.9) 0 (0) 1 (9.1) 1 (0.8) 0.0244† 
 Other Opioid - 220 98.7  33 (97.1) 55 (100) 10 (90.9) 118 (99.2)  
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 Other Drug + 18 8.1  4 (11.8) 5 (9.1) 2 (18.2) 7 (5.9) 0.0035† 
 Other Drug - 205 91.9  30 (88.2) 50 (90.9) 9 (81.8) 112 (94.1)  
n = 223, missing clinical data for 1 patient; 4 patients had unknown opioid exposure timing (UTOE); Chi 
Squared test used unless stated; ** Number of prescriptions includes prescriptions written during 
radiation therapy that were not included in this analysis; †: Fisher’s Exact Test; y: Unable to Calculate 
Fishers Exact Test; 5CS: 5-year Cancer Survivors; Std: Standard Deviation; IQR: Interquartile Range 
COU: Chronic Opioid User; NPOU: New Persistent Opioid User; POU: Previous Opioid User; NOU: 
Never Opioid User; IMRT: Intensity Modulated Radiation Therapy 
 
 
Table 3.8: NPOU Binary Logistic Regressions of 5CS with VCC ON Prior to Radiation 
 
5 Year Cancer Survivors 
(n = 3,215) 
5 Year Cancer Survivors with VCC 
(n = 174) 
NPOU, NOU = reference Stepwise Theoretical Stepwise Theoretical 
Covariates     
Age 0.98 (0.97, 0.99) 0.98 (0.97, 0.99)  0.96 (0.91, 1.00) 
Race 
 African American 1.38 (1.11, 1.71) 1.38 (1.11, 1.71)  0.80 (0.34, 1.86) 
 White Reference 
 Other 0.75 (0.46, 1.23) 0.75 (0.46, 1.22)  2.39 (0.42, 13.70) 
Gender 
 Male  1.01 (0.76, 1.34)  0.65 (0.10, 4.08) 
 Female Reference 
Insurance Type 
 Commercial Reference 
 VCC 1.61 (1.07, 2.44) 1.60 (1.06, 2.42)   
 Insurance, Not Specified 1.47 (1.02, 2.12) 1.47 (1.02, 2.12)   
 Medicaid 2.08 (1.35, 3.23) 2.08 (1.34, 3.21)   
 Medicare 1.53 (1.14, 2.04) 1.52 (1.14, 2.03)   
 Military 0.92 (0.34, 2.49) 0.93 (0.34, 2.52)   
 Self-Pay 1.97 (1.30, 2.98) 1.96 (1.30, 2.97)   
Cancer Type 
 Breast Reference 
 Colorectal 3.26 (2.21, 4.81) 3.09 (2.03, 4.69)   
 Female Genital 2.72 (1.74, 4.26) 2.57 (1.62, 4.08) 2.60 (1.10, 6.15) 4.22 (1.19, 15.03) 
 Gastrointestinal 3.48 (1.90, 6.37) 3.24 (1.70, 6.19)   
 Head and Neck 4.27 (3.10, 5.89) 3.90 (2.59, 5.86) 1.52 (0.39, 5.89) 4.28 (0.42, 43.16) 
 Leukemia, Lymphoma, other Hematopoietic 1.69 (1.01, 2.84) 1.48 (0.82, 2.66)   
 Lung and Bronchus 2.91 (1.96, 4.31) 2.52 (1.55, 4.10)   
 Other 4.84 (3.33, 7.02) 4.48 (2.93, 6.85) 7.13 (2.59, 19.66) 20.06 (2.79, 144.22) 
 Prostate 0.85 (0.51, 1.40) 0.72 (0.38, 1.37) 0.22 (0.03, 1.79) 0.93 (0.04, 25.10) 
Clinical Stage 
 0 Reference 
 1 1.06 (0.65, 1.74) 1.07 (0.66, 1.75)  3.25 (0.47, 22.67) 
 2 1.16 (0.69, 1.96) 1.18 (0.70, 1.98)  2.16 (0.29, 16.08) 
 3 1.74 (1.00, 3.03) 1.75 (1.01, 3.05)  4.38 (0.46, 41.67) 
Additional Chemotherapy 1.58 (1.23, 2.02) 1.55 (1.21, 1.98)  1.43 (0.51, 4.04) 
Additional Surgery  0.86 (0.65, 1.14)  3.24 (0.91, 11.49) 
Comorbid conditions 
 Anxiety 1.52 (1.11, 2.08) 1.52 (1.11, 2.08)  0.98 (0.35, 2.71) 
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 Arthritis 1.56 (1.15, 2.13) 1.58 (1.16, 2.15)  4.70 (1.42, 15.51) 
 Back Pain 1.94 (1.46, 2.58) 1.94 (1.46, 2.58)  2.14 (0.84, 5.41) 
 Depression 1.55 (1.08, 2.23) 1.56 (1.08, 2.25)  0.40 (0.10, 1.59) 
 Lung Disease 1.84 (1.39, 2.43) 1.84 (1.39, 2.43)  1.00 (0.35, 2.84) 
Substance Use 
 Nicotine Use 1.59 (1.21, 2.08) 1.58 (1.21, 2.08) 2.55 (1.20, 5.42) 2.69 (1.13, 6.43) 
 Other Opioid Use 3.14 (1.05, 9.38) 3.05 (1.02, 9.13)   
Bold denotes statistical significance; 5CS: 5-year Cancer Survivors; ON: Opioid Naïve; NPOU: New 
Persistent Opioid User; NOU: Never Opioid User; OR: Odds Ratio; 95% CI: 95% Confidence Interval 
 
 
Sensitivity Analyses 
 To assess the robustness of our results, we conducted two sensitivity analyses with 
patients that lived at least 3 years (3-year cancer survivors [3CS]) and 1 year (1-year cancer 
survivors [1CS]) without recurrence, metastasis, or death. This increased patient sample size 
from the original sample by 7.5% and 28.9%, respectively.  
In comparison to 5CS, 3CS were only slightly older, had slightly more opioid 
prescriptions, but had more deaths and recurrence (Table 3.9 for ON prior to radiation; Table 
3.10 for OE prior to radiation). Proportions of other clinical and demographic covariates were 
similar to that of the entire sample including: gender, insurance spread, cancer type and stage, 
additional therapies, comorbid conditions, and substance use. In comparison to 5CS, 3CS had 
increased incidence of opioid prescription use after radiation. Of opioid naïve cancer survivors 
(n = 3,456), 20.9% developed NPOU (compared to 19.7% in 5CS) and for patients prescribed 
opioids prior to radiation therapy (n = 462), 56.9% continued opioid use after radiation 
(compared to 54.8% in 5CS). 
 In comparison to 5CS, 1CS were generally sicker with more deaths, more recurrence, 
more diabetes, and later stage disease (Table 3.9 for ON prior to radiation; Table 3.10 for OE 
prior to radiation). Additionally, 1CS were slightly older, were higher proportion of males, had 
more opioid prescriptions, had less breast cancers, more lung cancers, more chemotherapy 
and less surgery, and less commercial insurance, but more Medicare. In comparison to 5CS, 
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1CS had increased incidence of opioid prescription use after radiation (and increased 
incidence from the three-year sensitivity analysis). Of opioid naïve 1CS (n = 4,135), 25.0% 
developed NPOU (compared to 19.7% in 5CS) and for patients prescribed opioids prior to 
radiation therapy (n = 574), 61.0% continued opioid use after radiation (compared to 54.8% in 
5CS). 
In the logistic regression assessing factors for associations of development of NPOU, 
3CS and 1CS showed increased odds of developing NPOU with African American race, most 
insurance types compared to commercial insurance, certain cancer types, additional 
chemotherapy, and nicotine use, controlling for other factors.  As survival decreased, other 
opioid use was no longer significantly associated with increased odds of NPOU.  For 1CS, 
decreased odds of NPOU were found with surgery and most radiation modalities. While 
decreased odds of NPOU with surgery was only seen in 1CS, findings from Chapter 2 suggest 
that additional surgery, while acutely painful, may reduce opioid dose requirement and long-
term use due to pain source control. Increased odds of NPOU were demonstrated with death 
or recurrence after more than one year of diagnosis for 1CS.  
The logistic model assessing for patients with opioid assessing likelihood of continuing 
opioid use after radiation with opioid exposure prior to radiation for 5CS, 3CS, and 1CS (Table 
3.12), use of VCC insurance, comorbid back pain, comorbid hypertension, and nicotine use 
conferred increased odds of COU across groups. Data from patients only surviving less time 
than the 5CS resulted in similar odds of NPOU and COU. However, the 1CS group had 
statistically significant association of increased odds of NPOU and COU with death after more 
than one year from diagnosis. 
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Table 3.9: Demographics for 5CS, 3CS, and 1CS that were ON prior to Radiation  
  5-year Cancer Survivors 3-year Cancer Survivors 1-year Cancer Survivors 
  NOU 
(n = 2,624) 
NPOU 
(n = 645) 
 NOU 
(n = 2,732) 
NPOU 
(n = 724) 
 NOU 
(n = 3,100) 
NPOU 
(n = 1,035) 
Covariates Mean (Std) Mean (Std)  Mean (Std) Mean (Std)  Mean (Std) Mean (Std) 
Age 59.6 (11.9) 56.7 (12.4)  59.9 (11.9) 57.3 (12.8)  60.7 (12.2) 58.3 (12.7) 
Number of Opioid Prescriptions** 4.5 (13.5) 7.6 (12.8)  0.0 (<0.1) 7.8 (13.2)  0.0 (<0.1) 7.9 (12.7) 
  N (%) N (%)  N (%) N (%)  N (%) N (%) 
Died 5, 3,1 or more years After 
Diagnosis 
        
 Yes 97 (3.7) 27 (4.0)  224 (8.2) 96 (13.3)  557 (18.0) 384 (37.1) 
 No 2527 (96.3) 619 (96.0)  2,508 (91.8) 628 (86.7)  2,543 (82.0) 651 (62.9) 
Recurrence of Disease 5, 3, 1 or 
more years After Diagnosis 
        
 Yes 22 (0.8) 3 (0.5)  58 (2.1) 22 (3.0)  147 (4.7) 125 (12.1) 
 No 2,602 (99.2) 642 (99.5)  2,674 (97.9) 702 (97.0)  2,953 (95.3) 910 (87.9) 
Gender         
 Female 1,948 (74.3) 390 (60.5)  2,016 (73.8) 440 (60.8)  2,215 (71.5) 590 (57.0) 
 Male 675 (25.7) 255 (39.5)  716 (26.2) 284 (39.2)  885 (28.5) 445 (43.0) 
Race         
 White 1,675 (63.9) 354 (54.9)  1,743 (63.8) 392 (54.1)  1,989 (64.2) 576 (55.7) 
 Black or African American 817 (31.2) 267 (41.4)  852 (31.2) 302 (41.7)  964 (31.1) 421 (40.7) 
 Other 131 (5.0) 24 (3.7)  137 (5.0) 30 (4.1)  147 (4.7) 38 (3.7) 
Insurance         
 Commercial 1,186 (45.2) 201 (31.2)  1,205 (44.1) 220 (30.4)  1,299 (41.9) 301 (29.1) 
 VCC 119 (4.5) 55 (8.5)  123 (4.5) 59 (8.2)  137 (4.4) 78 (7.5) 
 Insurance, Not Specified 185 (7.1) 61 (9.5)  185 (6.8) 65 (9.0)  197 (6.4) 83 (8.0) 
 Medicaid 93 (3.6) 58 (9.0)  92 (3.4) 66 (9.1)  108 (3.5) 101 (9.8) 
 Medicare 892 (34.0) 193 (30.0)  981 (35.9) 234 (32.3)  1,190 (38.4) 363 (35.1) 
 Military 40 (1.5) 5 (0.8)  41 (1.5) 5 (0.7)  44 (1.4) 8 (0.8) 
 Self-Pay 99 (3.8) 65 (10.1)  97 (3.6) 67 (9.3)  108 (3.5) 93 (9.0) 
 Unknown 9 (0.3) 7 (1.1)  8 (0.3) 8 (1.1)  117 (0.8) 8 (0.8) 
Cancer Type         
 Breast 1,535 (59.4) 180 (27.9)  1,584 (58.0) 200 (27.6)  1,637 (52.8) 232 (22.4) 
 Colorectal 111 (4.3) 67 (10.4)  124 (4.5) 73 (10.1)  143 (4.6) 97 (9.4) 
 Female Genital 94 (3.6) 47 (7.3)  117 (4.3) 59 (8.1)  136 (4.4) 72 (7.0) 
 Gastrointestinal 45 (1.7) 22 (3.4)  52 (1.9) 30 (4.1)  88 (2.8) 79 (7.6) 
 Head and Neck 191 (7.4) 121 (18.8)  208 (7.6) 128 (17.7)  265 (8.5) 174 (16.8) 
 Leukemia, Lymphoma, Other 
Hematopoietic 98 (3.8) 24 (3.7) 
 100 (3.7) 27 (3.7)  109 (3.5) 38 (3.7) 
 Lung and Bronchus 127 (4.9) 78 (12.1)  159 (5.8) 97 (13.4)  294 (9.5) 195 (18.8) 
 Other 132 (5.1) 80 (12.4)  123 (.5) 82 (11.3)  153 (4.9) 117 (11.3) 
 Prostate 252 (9.7) 26 (4.0)  265 (9.7) 28 (3.9)  275 (8.9) 31 (3.0) 
Clinical Stage         
 0 265 (10.1) 24 (3.8)  270 (9.9) 24 (3.4)  276 (8.8) 27 (2.6) 
 1 772 (29.9) 137 (21.5)  803 (29.5) 154 (21.5)  877 (28.0) 182 (17.8) 
 2 642 (24.9) 142 (22.3)  675 (24.8) 161 (22.5)  755 (24.1) 227 (22.2) 
 3 239 (9.2) 160 (25.1)  274 (10.1) 181 (25.3)  389 (12.4) 317 (30.9) 
 Unknown 660 (25.6) 174 (27.3)  703 (25.8) 195 (27.3)  823 (26.6) 272 (26.5) 
Radiation Modality         
 Brachytherapy 367 (14.2) 42 (6.5)  377 (13.8) 49 (6.8)  395 (12.7) 59 (8.7) 
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 Conformal or 3-D 250 (9.7) 56 (8.7)  264 (9.7) 61 (8.4)  297 (9.6) 92 (8.9) 
 External Beam 399 (15.4) 93 (14.4)  433 (15.8) 108 (14.9)  564 (18.2) 166 (16.0) 
 IMRT 350 (13.5) 175 (47.1)  379 (13.9) 188 (26.0)  430 (13.9) 271 (26.2) 
 Photons  1,082 (41.9) 240 (37.2)  1,123 (41.1) 261 (36.0)  1,209 (39.0) 359 (34.7) 
 Stereotactic Radiosurgery 58 (2.2) 26 (4.0)  70 (2.6) 34 (4.7)  109 (3.5) 53 (5.1) 
 Other 79 (3.0) 13 (2.0)  86 (3.2) 23 (3.2)  101 (3.3) 35 (3.4) 
Additional Chemotherapy         
 Yes 1,010 (38.5) 390 (60.5)  1,064 (38.9) 440 (60.8)  1,277 (41.2) 654 (63.2) 
 No 1,614 (61.5) 255 (39.5)  1,668 (61.1) 284 (39.2)  1,823 (58.8) 381 (36.8) 
Additional Surgery         
 Yes 1,936 (73.8) 356 (55.2)  2,000 (73.2) 388 (53.6)  2,161 (79.7) 500 (48.3) 
 No 688 (26.2) 289 (44.8)  732 (26.8) 336 (46.4)  939 (30.3) 535 (51.7) 
Additional Hormonal Therapy         
 Yes 1,174 (44.7) 153 (23.7)  1,210 (44.3) 173 (23.9)  1,244 (40.1) 190 (18.4) 
 No 1,450 (55.3) 492 (76.3)  1,522 (55.7) 551 (76.1)  1,856 (59.9) 845 (81.6) 
Additional Immunotherapy         
 Yes 107 (4.1) 30 (4.7)  108 (3.9) 34 (4.7)  114 (3.7) 40 (3.9) 
 No 2,517 (95.9) 615 (95.4)  2,624 (96.0) 690 (95.3)  2,986 (96.3) 995 (96.1) 
Additional Other Therapy         
 Yes 21 (0.8) 5 (0.8)  21 (0.8) 5 (0.7)  23 (0.7) 8 (0.8) 
 No 2,603 (99.2) 640 (99.2)  2,711 (99.2) 719 (99.3)  3,077 (99.3) 1027 (99.2) 
Comorbid Conditions         
 Anxiety + 205 (7.8) 74 (32.6)  209 (7.7) 127 (17.5)  228 (7.4) 165 (15.9) 
 Anxiety - 2,418 (92.2) 153 (67.4)  2,523 (92.3) 597 (82.5)  2,872 (92.6) 870 (84.1) 
           Arthritis + 232 (8.8) 83 (36.6)  241 (8.8) 107 (14.8)  272 (8.8) 150 (14.5) 
 Arthritis - 2,391 (91.2) 144 (63.4)  2,491 (91.2) 617 (85.2)  2,828 (91.2) 885 (85.5) 
          
 Back Pain + 204 (7.8) 96 (42.3)  213 (7.8) 152 (21.0)  228 (7.4) 196 (18.9) 
 Back Pain - 2,419 (92.2) 131 (57.7)  2,519 (92.2) 572 (79.0)  2,872 (92.6) 839 (81.1) 
          
 Depression + 138 (5.3) 63 (27.8)  140 (5.1) 96 (13.3)  153 (4.9) 121 (11.7) 
 Depression - 2,485 (94.7) 164 (72.3)  2,592 (94.9) 628 (86.7)  2,947 (95.1) 914 (88.3) 
          
 Diabetes + 266 (10.1) 52 (22.9)  284 (10.4) 110 (15.2)  322 (10.4) 177 (17.1) 
 Diabetes - 2,357 (89.9) 175 (77.1)  2,448 (89.6) 614 (84.8)  2,778 (89.6) 858 (82.9) 
          
 Heart Disease + 427 (16.3) 94 (41.4)  53 (16.6) 200 (27.6)  522 (16.8) 277 (26.8) 
 Heart Disease - 2,196 (83.7) 133 (58.6)  2,279 (83.4) 524 (72.4)  2,578 (83.1) 758 (73.2) 
          
 Hypertension + 781 (29.8) 138 (60.8)  818 (30.0) 315 (43.5)  917 (29.6) 445 (43.0) 
 Hypertension - 1,842 (70.2) 89 (39.2)  1,914 (70.0) 409 (56.5)  2,183 (70.4) 590 (57.0) 
          
 Lung Disease + 227 (8.7) 76 (33.5)  243 (8.9) 187 (25.8)  290 (9.4) 273 (26.4) 
 Lung Disease - 23,96 (91.4) 151 (66.5)  2,489 (91.1) 537 (74.2)  2,810 (90.6) 762 (73.6) 
Substance Use         
 Alcohol + 44 (1.7) 33 (5.1)  45 (1.6) 37 (5.1)  52 (1.8) 60 (5.8) 
 Alcohol - 2,579 (98.3) 612 (94.9)  2,687 (98.4) 687 (94.9)  3,084 (98.3) 975 (94.2) 
          
 Nicotine + 249 (9.5) 186 (28.8)  254 (9.3) 202 (27.9)  288 (9.3) 283 (27.3) 
 Nicotine - 2,374 (90.5) 459 (71.2)  2,478 (90.7) 522 (72.1)  2,812 (90.7) 752 (72.7) 
          
 Other Opioid + 5 (0.2) 18 (2.8)  5 (0.2) 18 (2.5)  7 (0.2) 18 (1.7) 
 Other Opioid - 2,618 (99.8) 627 (97.2)  2,727 (99.8) 706 (97.5)  3,093 (99.8) 1017 (98.3) 
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 Other Drug + 31 (1.2) 38 (5.9)  35 (1.3) 40 (5.5)  44 (1.4) 56 (5.4) 
 Other Drug - 2,592 (98.8) 607 (94.1)  2,697 (98.7) 684 (94.5)  3,056 (98.6) 979 (94.6) 
** Number of prescriptions includes prescriptions written during radiation therapy that were not included 
in this analysis; Std: Standard Deviation; IQR: Interquartile Range; ON: Opioid Naïve; 5CS: 5-Year 
Cancer Survivors; 3CS: 3-Year Cancer Survivors; 1CS: 1-Year Cancer Survivors; NPOU: New 
Persistent Opioid User; NOU: Never Opioid User; IMRT: Intensity Modulated Radiation Therapy; VCC: 
Virginia Coordinated Care 
 
 
Table 3.10: Demographics for 5CS, 3CS, and 1CS that were OE Prior to Radiation 
  5-year Cancer Survivors  3-year Cancer Survivors 1-year Cancer Survivors 
  POU 
(n = 187) 
COU 
(n = 227)  
POU 
(n = 199) 
COU 
(n = 263)  
POU 
(n = 224) 
COU 
(n = 350) 
Covariates Mean (Std) Mean (Std)  Mean (Std) Mean (Std) 
 Mean (Std) Mean (Std) 
Age 57.7 (12.9) 55.5 (11.8)  57.5 (12.9) 55.8 (11.4)  57.9 (13.1) 56.8 (12.0) 
Number of Opioid Prescriptions** 1.4 (0.9) 18.6 (20.6)  1.5 (1.2) 20.1 (22.2)  1.6 (1.3) 19.1 (21.5) 
  N (%) N (%)  N (%) N (%)  N (%) N (%) 
Died 5, 3, 1 or more years After 
Diagnosis 
        
 Yes 6 (3.2) 11 (4.9)  16 (8.0) 44 (16.7)  36 (16.1) 128 (36.6) 
 No 181 (96.8) 216 (95.2)  183 (92.0) 219 (83.3)  188 (83.9) 222 (63.4) 
Recurrence of Disease 5, 3, 1 or 
more years After Diagnosis 
        
 Yes 0 (0) 0 (0)  4 (2.0) 10 (3.8)  12 (5.4) 39 (11.1) 
 No 187 (100) 227 (100)  195 (98.0) 253 (96.2)  212 (94.6) 311 (88.9) 
Gender         
 Female 154 (82.4) 156 (68.7)  165 (82.9) 180 (68.4)  184 (82.1) 229 (65.4) 
 Male 33 (17.7) 71 (31.3)  34 (17.1) 83 (31.6)  40 (17.9) 121 (34.6) 
Race         
 White 103 (55.1) 101 (44.5)  106 (53.3) 123 (46.8)  123 (54.9) 161 (46.0) 
 Black or African American 76 (40.6) 111 (48.9)  85 (42.7) 125 (47.5)  93 (47.5) 171 (48.9) 
 Other 8 (4.3) 15 (6.6)  8 (4.0) 15 (5.7)  8 (3.6) 18 (5.1) 
Insurance         
 Commercial 79 (42.3) 64 (28.2)  83 (41.7) 69 (26.2)  91 (40.6) 86 (24.6) 
 VCC 11 (5.9) 34 (15.0)  11 (5.5) 37 (14.1)  13 (5.8) 45 (12.9) 
 Insurance, Not Specified 15 (8.0) 18 (7.9)  16 (8.0) 18 (6.8)  18 (8.0) 26 (7.4) 
 Medicaid 12 (6.4) 28 (12.3)  13 (6.5) 34 (12.9)  14 (6.3) 44 (12.6) 
 Medicare 60 (32.1) 57 (25.1)  64 (32.2) 77 (29.3)  75 (33.5) 113 (32.3) 
 Military 3 (1.6) 2 (0.9)  3 (1.5) 2 (0.8)  3 (1.3) 3 (0.9) 
 Self-Pay 5 (2.7) 22 (9.7)  7 (3.5) 24 (9.1)  8 (3.6) 31 (8.9) 
 Unknown 2 (1.1) 2 (0.9)  2 (1.0) 2 (0.8)  2 (0.9) 2 (0.6) 
Cancer Type         
 Breast 122 (65.2) 103 (45.4)  132 (66.3) 117 (44.4)  141 (62.9) 140 (40.0) 
 Colorectal 3 (1.6) 11 (4.8)  3 (1.5) 14 (5.3)  3 (1.33) 19 (5.4) 
 Female Genital 6 (3.2) 4 (1.8)  7 (3.5) 6 (2.3)  8 (3.6) 10 (2.9) 
 Gastrointestinal 4 (2.1) 12 (5.3)  4 (0.2) 13 (4.9)  9 (4.0) 31 (8.9) 
 Head and Neck 9 (4.8) 25 (11.0)  9 (0.5) 32 (12.2)  9 (4.0) 44 (12.6) 
 Leukemia, Lymphoma, Other 
Hematopoietic 13 (7.0) 8 (3.5) 
 13 (6.5) 8 (3.0)  15 (6.7) 12 (3.4) 
 Lung and Bronchus 10 (5.4) 18 (7.9)  10 (5.0) 24 (9.1)  14 (6.3) 39 (11.1) 
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 Other 12 (6.4) 28 (12.3)  13 (6.5) 31 (11.8)  16 (4.1) 36 (10.3) 
 Prostate 8 (4.3) 18 (7.9)  8 (4.0) 18 (6.8)  9 (4.0) 19 (5.4) 
Clinical Stage         
 0 5 (2.7) 9 (4.0)  6 (3.0) 12 (4.6)  8 (3.6) 13 (3.7) 
 1 58 (31.0) 52 (23.0)  61 (30.7) 62 (23.7)  65 (29.0) 78 (22.4) 
 2 62 (33.2) 80 (35.4)  68 (34.2) 86 (32.8  74 (33.0) 109 (31.2) 
 3 18 (9.6) 38 (16.8)  20 (10.1) 44 (16.8)  25 (11.2) 74 (21.2) 
 Unknown 44 (23.9) 47 (20.8)  44 (22.1) 58 (22.1)    
Additional Chemotherapy         
 Yes 119 (63.6) 129 (56.8)  127 (63.8) 147 (55.9)  144 (64.3) 206 (58.9) 
 No 68 (36.4) 98 (43.2)  72 (36.2) 116 (44.1)  80 (35.7) 144 (41.1) 
Additional Surgery         
 Yes 147 (78.6) 149 (65.6)  159 (79.9) 173 (65.8)  174 (77.7) 220 (62.9) 
 No 40 (21.4) 78 (34.4)  40 (20.1) 90 (34.2)  50 (22.3) 130 (37.1) 
Additional Hormonal Therapy         
 Yes 89 (47.6) 70 (30.8)  94 (47.2) 78 (29.7)  99 (44.2) 90 (25.7) 
 No 98 (52.4) 157 (69.2)  105 (52.8) 185 (70.3)  125 (55.8) 260 (74.3) 
Additional Immunotherapy         
 Yes 23 (12.3) 13 (5.7)  24 (12.1) 14 (5.3)  27 (12.1) 20 (5.7) 
 No 164 (87.7) 214 (94.3)  175 (87.9) 249 (94.7)  197 (88.0) 330 (94.3) 
Additional Other Therapy         
 Yes 1 (0.5) 3 (1.3)  1 (0.5) 3 (1.1)  1 (0.5) 3 (0.9) 
 No 186 (99.5) 224 (98.7)  198 (99.5) 260 (98.9)  223 (99.6) 347 (99.1) 
Comorbid Conditions         
 Anxiety + 29 (15.5) 74 (32.6)  33 (16.6) 79 (30.0)  39 (17.4) 96 (27.4) 
 Anxiety - 158 (84.5) 153 (67.4)  166 (83.4) 184 (70.0)  185 (82.6) 254 (72.6) 
          
 Arthritis + 40 (21.4) 83 (36.6)  42 (21.1) 99 (37.6)  47 (21.0) 123 (35.1) 
 Arthritis - 147 (78.6) 144 (63.4)  157 (78.9) 164 (62.4)  177 (79.0) 227 (64.9) 
          
 Back Pain + 33 (17.7) 96 (42.3)  34 (17.1) 113 (43.0)  38 (17.0) 145 (41.4) 
 Back Pain - 154 (82.4) 131 (57.7)  165 (82.9) 150 (57.0)  186 (83.0) 205 (58.6) 
          
 Depression + 28 (15.0) 63 (27.8)  30 (15.1) 71 (27.0)  36 (16.1) 88 (25.1) 
 Depression - 159 (85.0) 164 (72.3)  169 (84.9) 192 (73)  188 (83.9) 262 (74.9) 
          
 Diabetes + 34 (18.2) 52 (22.9)  37 (18.6) 63 (24.0)  45 (20.1) 83 (23.7) 
 Diabetes - 153 (81.8) 175 (77.1)  162 (81.4) 200 (76.1)  179 (79.9) 267 (76.3) 
          
 Heart Disease + 48 (25.7) 94 (41.4)  53 (26.6) 114 (43.4)  62 (27.7) 147 (42.0) 
 Heart Disease - 139 (74.3) 133 (58.6)  146 (73.4) 149 (56.7)  162 (72.3) 203 (58.0) 
          
 Hypertension + 78 (41.7) 138 (60.8)  83 (41.7) 166 (63.1)  97 (43.3) 219 (62.6) 
 Hypertension - 109 (58.3) 89 (39.2)  116 (58.3) 97 (36.9)  127 (56.7) 131 (37.4) 
          
 Lung Disease + 30 (16.0) 76 (33.5)  31 (15.6) 93 (35.4)  41 (18.3) 122 (34.9) 
 Lung Disease - 157 (84.0) 151 (66.5)  168 (84.4) 170 (64.6)  183 (81.7) 228 (65.1) 
Substance Use         
 Alcohol + 9 (4.8) 31 (13.7)  9 (4.5) 35 (13.3)  11 (4.9) 42 (12.0) 
 Alcohol - 178 (95.2) 196 (86.3)  190 (95.5) 228 (86.7)  213 (95.1) 308 (88.0) 
          
 Nicotine + 35 (18.7) 109 (48.0)  38 (19.1) 124 (47.2)  42 (18.8) 154 (44.0) 
 Nicotine - 152 (81.3) 118 (52.0)  161 (80.9) 139 (52.9)  182 (81.3) 196 (56.0) 
          
 Other Opioid + 2 (1.1) 5 (2.2)  2 (1.0) 6 (2.3)  2 (0.9) 7 (2.0) 
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 Other Opioid - 185 (98.9) 222 (97.8)  197 (99.0) 257 (97.7)  222 (99.1) 343 (98.0) 
          
 Other Drug + 7 (3.7) 26 (11.5)  8 (4.0) 30 (11.4)  8 (3.6) 37 (10.6) 
 Other Drug - 180 (96.3) 201 (88.6)  191 (96.0) 233 (88.6)  216 (96.4) 313 (89.4) 
** Number of prescriptions includes prescriptions written during radiation therapy that were not included 
in this analysis; Std: Standard Deviation; IQR: Interquartile Range; OE: Opioid Exposed; 5CS: 5-Year 
Cancer Survivors; 3CS: 3-Year Cancer Survivors; 1CS: 1-Year Cancer Survivors; POU: Pervious 
Opioid User; COU: Continued Opioid User; IMRT: Intensity Modulated Radiation Therapy; VCC: 
Virginia Coordinated Care 
 
 
Table 3.11: NPOU Final Binary Logistic Regressions for ON 5CS, 3CS, and 1CS  
 
5-year Cancer survivors 
(n = 3,269) 
 3-year Cancer Survivors 
(n = 3,456) 
 1-year Cancer Survivors 
(n = 4,135) 
NPOU, NOU = 
reference Stepwise 
Stepwise + 
Theoretical 
 Stepwise Stepwise + Theoretical 
 Stepwise Stepwise + Theoretical 
Covariates         
Age 0.98 (0.97, 0.99) 0.98 (0.97, 0.99)  0.99 (0.98, 1.00) 0.99 (0.98, 1.00)  0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 
Race         
 African American 1.38 (1.11, 1.71) 1.38 (1.11, 1.71)  1.42 (1.16, 1.75) 1.42 (1.15, 1.74)  1.38 (1.15, 1.65) 1.37 (1.15, 1.64) 
 Other 0.75 (0.46, 1.23) 0.75 (0.46, 1.22)  0.88 (0.56, 1.38) 0.88 (0.56, 1.37)  0.85 (0.56, 1.29) 0.85 (0.56, 1.29) 
 White Reference 
Gender         
 Male  1.01 (0.76, 1.34)   0.95 (0.73, 1.24)   1.01 (0.81, 1.26) 
 Female Reference 
Insurance Type         
 Commercial Reference 
 VCC 1.61 (1.07, 2.44) 1.60 (1.06, 2.42)  1.64 (1.11, 2.44) 1.64 (1.10, 2.44)  1.58 (1.10, 2.26) 1.59 (1.11, 2.27) 
 Insurance, Not 
Specified 1.47 (1.02, 2.12) 1.47 (1.02, 2.12) 
 
1.47 (1.03, 2.10) 1.48 (1.04, 2.10) 
 
1.53 (1.11, 2.11) 1.52 (1.10, 2.10) 
 Medicaid 2.08 (1.35, 3.23) 2.08 (1.34, 3.21)  2.16 (1.43, 3.26) 2.14 (1.41, 3.23)  2.03 (1.42, 2.90) 2.01 (1.41, 2.88) 
 Medicare 1.53 (1.14, 2.04) 1.52 (1.14, 2.03)  1.47 (1.12, 1.93) 1.46 (1.11, 1.92)  1.35 (1.06, 1.72) 1.35 (1.06, 1.72) 
 Military 0.92 (0.34, 2.49) 0.93 (0.34, 2.52)  0.77 (0.29, 2.06) 0.78 (0.29, 2.09)  0.93 (0.40, 2.19) 0.93 (0.40, 2.19) 
 Self-Pay 1.97 (1.30, 2.98) 1.96 (1.30, 2.97)  1.88 (1.26, 2.80) 1.87 (1.26, 2.80)  1.94 (1.36, 2.78) 1.93 (1.34, 2.76) 
Cancer Type         
 Breast Reference 
 Colorectal 3.26 (2.21, 4.81) 3.09 (2.03, 4.69)  2.98 (2.06, 4.32) 2.84 (1.91, 4.22)  2.66 (1.86, 3.80) 2.63 (1.81, 3.81) 
 Female Genital 2.72 (1.74, 4.26) 2.57 (1.62, 4.08)  2.50 (1.67, 3.74) 2.31 (1.52, 3.51)  1.90 (1.28, 2.81) 1.88 (1.27, 2.79) 
 Gastrointestinal 3.48 (1.90, 6.37) 3.24 (1.70, 6.19)  3.70 (2.18, 6.25) 3.48 (1.97, 6.16)  3.65 (2.42, 5.49) 3.60 (2.33, 5.54) 
 Head and Neck 4.27 (3.10, 5.89) 3.90 (2.59, 5.86)  3.82 (2.81, 5.19) 3.50 (2.37, 5.15)  2.37 (1.69, 3.32) 2.35 (1.62, 3.39) 
 
Leukemia, 
Lymphoma, Other 
Hematopoietic 1.69 (1.01, 2.84) 1.48 (0.82, 2.66) 
 
1.77 (1.08, 2.89) 1.51 (0.86, 2.65) 
 
1.48 (0.91, 2.40) 1.45 (0.88, 2.40) 
 Lung and 
Bronchus 2.91 (1.96, 4.31) 2.52 (1.55, 4.10) 
 
3.02 (2.12, 4.31) 2.55 (1.64, 3.98) 
 
1.81 (1.23, 2.66) 1.79 (1.20, 2.67) 
 Other 4.84 (3.33, 7.02) 4.48 (2.93, 6.85)  5.26 (3.64, 7.60) 4.88 (3.19, 7.46)  4.00 (2.81, 5.69) 3.96 (2.72, 5.77) 
 Prostate 0.85 (0.51, 1.40) 0.72 (0.38, 1.37)  0.79 (0.49, 1.29) 0.68 (0.37, 1.24)  0.41 (0.24, 0.69) 0.40 (0.23, 0.71) 
Clinical Stage         
 0 Reference 
 1 1.06 (0.65, 1.74) 1.07 (0.66, 1.75)  1.18 (0.73, 1.91) 1.19 (0.74, 1.94)  1.25 (0.78, 1.99) 1.25 (0.78, 1.99) 
 2 1.16 (0.69, 1.96) 1.18 (0.70, 1.98)  1.32 (0.79, 2.20) 1.34 (0.80, 2.23)  1.50 (0.93, 2.43) 1.50 (0.93, 2.43) 
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 3 1.74 (1.00, 3.03) 1.75 (1.01, 3.05)  1.82 (1.06, 3.12) 1.84 (1.07, 3.15)  2.01 (1.22, 3.31) 2.01 (1.22, 3.32) 
Additional 
Chemotherapy 1.58 (1.23, 2.02) 1.55 (1.21, 1.98)  1.55 (1.23, 1.95) 1.51 (1.20, 1.91)  1.29 (1.05,1.60) 1.29 (1.05, 1.60) 
Additional Surgery  0.86 (0.65, 1.14)   0.80 (0.62, 1.05)  0.71 (0.56, 0.89) 0.71 (0.56, 0.90) 
Death After 5, 3, 1 
or more years of 
Diagnosis 
  
    
1.72 (1.40, 2.11) 1.72 (1.40, 2.11) 
Recurrence After  5, 
3, 1 or more years 
of Diagnosis 
  
    
1.83 (1.36, 2.45) 1.83 (1.36, 2.45) 
Comorbid conditions         
 Anxiety 1.52 (1.11, 2.08) 1.52 (1.11, 2.08)  1.54 (1.14, 2.08) 1.53 (1.13, 2.07)  1.52 (1.15, 2.00) 1.51 (1.15, 2.00) 
 Arthritis 1.56 (1.15, 2.13) 1.58 (1.16, 2.15)  1.51 (1.13, 2.03) 1.53 (1.14, 2.06)  1.53 (1.18, 2.00) 1.53 (1.18, 2.00) 
 Back Pain 1.94 (1.46, 2.58) 1.94 (1.46, 2.58)  1.79 (1.37, 2.35) 1.79 (1.36, 2.34)  1.88 (1.46, 2.42) 1.88 (1.46, 2.42) 
 Depression 1.55 (1.08, 2.23) 1.56 (1.08, 2.25)  1.61 (1.14, 2.28) 1.62 (1.15, 2.30)  1.57 (1.14, 2.15) 1.56 (1.13, 2.15) 
 Lung Disease 1.84 (1.39, 2.43) 1.84 (1.39, 2.43)  1.81 (1.39, 2.35) 1.81 (1.39, 2.35)  1.88 (1.49, 2.36) 1.87 (1.48, 2.35) 
Substance Use         
 Nicotine Use 1.59 (1.21, 2.08) 1.58 (1.21, 2.08)  1.57 (1.21, 2.03) 1.56 (1.20, 2.02)  1.63 (1.29, 2.05) 1.61 (1.28, 2.03) 
 Other Opioid Use 3.14 (1.05, 9.38) 3.05 (1.02, 9.13)  3.03 (1.02, 9.04) 2.95 (0.99, 8.82)   1.68 (0.63, 4.50) 
Radiation Modality         
 Brachytherapy       0.63 (0.42, 0.94) 0.63 (0.43, 0.94) 
 Conformal or 3-D       0.63 (0.45, 0.89) 0.63 (0.45, 0.89) 
 External Beam       0.57 (0.43, 0.76) 0.57 (0.43, 0.76) 
 IMRT Reference 
 Other        0.86 (0.52, 1.40) 0.86 (0.53, 1.41) 
 Photons        0.70 (0.54, 0.91) 0.70 (0.54, 0.91) 
 Stereotactic Radiosurgery   
    
0.66 (0.40, 1.07) 0.66 (0.40, 1.08) 
Bold denotes statistical significance; ON: Opioid Naïve; 5CS: 5-Year Cancer Survivors; 3CS: 3-Year 
Cancer Survivors; 1CS: 1-Year Cancer Survivors; NPOU: New Persistent Opioid User; NOU: Never 
Opioid User; VCC: Virginia Coordinated Care; OR: Odds Ratio; 95% CI: 95% Confidence Interval 
 
 
Table 3.12: COU Final Binary Logistic Regressions for OE 5CS, 3CS, and 1CS  
 
5-year Cancer survivors 
(n = 414) 
 3-year Cancer Survivors 
(n = 462) 
 1-year Cancer Survivors 
(n = 674) 
COU, POU = 
reference Stepwise 
Stepwise + 
Theoretical 
 Stepwise Stepwise + Theoretical 
 Stepwise Stepwise + Theoretical 
Covariates         
Age  0.98 (0.96, 1.01)   0.98 (0.96, 1.00)  0.98 (0.96, 0.99) 0.98 (0.96, 1.00) 
Race         
 African American  1.29 (0.76, 2.18)   0.93 (0.57, 1.54)   1.08 (0.69, 1.68) 
 Other  1.88 (0.64, 5.50)   1.47 (0.51, 4.25)   1.97 (0.72, 5.40) 
 White Reference 
Gender         
 Male  1.16 (0.51, 2.64)  1.69 (1.01, 2.81) 1.32 (0.62, 2.85)   1.81 (0.93, 3.54) 
 Female Reference 
Insurance Type         
 Commercial Reference 
 VCC  2.39 (1.00, 5.73)   3.02 (1.29, 7.06)   2.59 (1.18, 5.68) 
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 Insurance, Not 
Specified 
 
1.28 (0.53, 3.11) 
  
1.15 (0.48, 2.75) 
  
1.28 (0.59, 2.80) 
 Medicaid  1.62 (0.65, 4.04)   1.79 (0.77, 4.20)   1.49 (0.67, 3.31) 
 Medicare  1.25 (0.63, 2.48)   1.55 (0.83, 2.91)   1.51 (0.85, 2.71) 
 Military  0.93 (0.12, 7.29)   1.17 (0.15, 8.97)   1.21 (0.17, 8.69) 
 Self-Pay  2.89 (0.87, 9.62)   1.97 (0.69, 5.56)   1.70 (0.66, 4.37) 
Cancer Type         
 Breast Reference 
 Colorectal 4.67 (1.07, 20.49) 
4.23 (0.83, 
21.53) 
  
3.99 (0.82, 19.44) 
 
6.62 (1.79, 24.45) 4.89 (1.10, 21.67) 
 Female Genital 1.33 (0.31, 5.71) 0.71 (0.15, 3.40)   0.89 (0.23, 3.46)  1.45 (0.52, 4.06) 1.43 (0.45, 4.52) 
 Gastrointestinal 5.15 (1.47, 18.07) 
4.03 (1.02, 
15.98) 
  
3.80 (0.96, 15.08) 
 
3.33 (1.43, 7.80) 2.29 (0.84, 6.25) 
 Head and Neck 2.34 (0.90, 6.03) 1.76 (0.53, 5.89)   2.14 (0.66, 6.95)  3.84 (1.68, 8.78) 2.34 (0.80, 6.88) 
 
Leukemia, 
Lymphoma, Other 
Hematopoietic 1.06 (0.39, 2.84) 0.59 (0.14, 2.50) 
  
0.52 (0.13, 2.11) 
 
0.80 (0.32, 1.96) 0.46 (0.13, 1.64) 
 Lung and Bronchus 1.19 (0.46, 3.07) 0.99 (0.25, 3.98)   1.07 (0.27, 4.27)  1.85 (0.88, 3.92) 0.82 (0.25, 2.69) 
 Other 5.19 (2.07, 13.00) 
4.49 (1.53, 
13.22) 
  
2.77 (0.96, 8.01) 
 
2.33 (1.15, 4.73) 2.08 (0.82, 5.29) 
 Prostate 2.72 (1.02, 7.26) 1.54 (0.32, 7.44)   1.43 (0.31, 6.66)  2.52 (1.00, 6.37) 0.84 (0.21, 3.37) 
Clinical Stage         
 0 Reference 
 1 0.47 (0.14, 1.64) 0.46 (0.12, 1.76)   0.54 (0.16, 1.82)   0.95 (0.32, 2.86) 
 2 0.67 (0.20, 2.30) 0.46 (0.16, 2.55)   0.61 (0.17, 2.14)   1.01 (0.33, 3.14) 
 3 0.89 (0.23, 3.40) 0.79 (0.17, 3.66)   0.78 (0.2, 3.11)   1.33 (0.39, 4.50) 
Additional 
Chemotherapy 
 
0.85 (0.46, 1.57) 
  
0.92 (0.51, 1.65) 
  
0.92 (0.54, 1.56) 
Additional Surgery  0.70 (0.29, 1.66)   0.73 (0.32, 1.67)   0.69 (0.33, 1.44) 
Additional Hormonal 
Therapy 
   0.61 (0.39, 0.95) 0.83 (0.48, 1.44)   0.87 (0.52,1.45)  
Death After 5 years 
or more of Diagnosis 
      2.83 (1.76, 4.55) 2.48 (1.50, 4.10) 
Comorbid conditions         
 Anxiety 1.91 (1.10, 3.31) 2.00 (1.11, 3.60)   1.47 (0.84, 2.57)   1.31 (0.78, 2.19) 
 Arthritis       1.71 (1.06, 2.76) 1.63 (0.99, 2.67)  Back Pain 3.17 (1.88, 5.35) 2.83 (1.65, 4.86)  3.22 (1.99, 5.24) 3.09 (1.84, 5.17)  2.95 (1.87, 4.65) 2.98 (1.84, 4.81) 
 Hypertension 1.85 (1.16, 2.93) 1.77 (1.06, 2.96)  1.69 (1.10, 2.58) 1.78 (1.10, 2.89)  1.62 (1.07, 2.45) 1.47 (0.94, 2.29) 
 Lung Disease    1.84 (1.11, 3.05) 1.77 (1.02, 3.07)   1.36 (0.83, 2.24) 
Substance Use         
 Nicotine Use 3.27 (1.96, 5.47) 2.60 (1.46, 4.64)  2.71 (1.70, 4.34) 2.07 (1.20, 3.54)  2.23 (1.41, 3.53) 1.90 (1.15, 3.13) 
Bold denotes statistical significance; OE: Opioid Exposed; 5CS: 5-Year Cancer Survivors; 3CS: 3-
Year Cancer Survivors; 1CS: 1-Year Cancer Survivors; COU: Chronic Opioid User; POU: Previous 
Opioid User; VCC: Virginia Coordinated Care; OR: Odds Ratio; 95% CI: 95% Confidence Interval 
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Subgroup and Sensitivity Analysis Robustness 
The use of the VCC subgroup, as well as the 3CS and 1CS sensitivity analyses, 
generally supported our results for incidence and associated factors with NPOU and COU. 
From the VCC subgroup, we could see that patients VCC may have been sicker (with higher 
proportions of comorbid diseases). Therefore, NPOU and COU incidence was higher in 5CS 
with VCC.  Additionally, there were less significant factor associations with NPOU, but factors 
that were significant in this group were also significant in the entire sample. Due to insufficient 
power, we could not replicate COU results with the VCC subgroup.  However, 3CS and 1CS 
sensitivity analysis groups resulted in similar incidence estimates and odds of associated 
factors with NPOU and COU. 
 
Discussion 
 This is the first study to evaluate incidence and associated risks of NPOU and COU in 
patients that received radiation. While previous studies have investigated opioid use in curative 
intent surgery and chemotherapy in specific cancer types, to the best of our knowledge, no 
study has elucidated risks for patients specifically receiving radiation.16,34–37  In this study, we 
determined that 19.7% (VCC subgroup: 31.4%; 3CS and 1CS SA: 20.9-25.0%) of opioid naïve 
patients with cancer that receive radiation develop NPOU. Additionally, 54.8% (VCC subgroup: 
75.6%; 3CS and 1CS SA: 56.9-61.0%) of patients with cancer and opioid exposure prior to 
radiation continue opioid use after CIR. These results are similar to previously published 
results from a smaller study of comparable patient demographics. That study reported 19.7% 
(range: 6.6-31.6%) of patients at Grady Health System (GHS) in Atlanta, Georgia with any 
combination of cancer therapies continued opioid use after curative intent therapy.34 It should 
be noted that this study did not control for opioid exposure prior to curative intent therapy. Lee 
et al. reported from a nationally representative sample that “among previously opioid naïve 
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patients, 4,159 or 10% (95% CI, 10.1% to 10.7%) developed new persistent opioid use after 
curative-intent surgery.”16 Such wide prescribing of opioids after curative intent treatment calls 
for evidence-based recommendations and guidelines for opioid use that emphasize 
discontinuation in cancer survivors. 
Undergoing radiation therapy can subject patients to significant morbidity that can vary 
by treatment site, with patients treated for head and neck cancer tending to have a significant 
burden of radiation-related acute and late toxicity.4–6,38  There has been some attention to 
opioid use specifically in patients with head and neck cancers in the literature.4,17,39,40  In these 
studies, 15.4%-63% or 7%-33% of patients with head and neck cancers develop persistent 
opioid use following 3 or at least 6 months of radiation therapy, respectively.4,17,39,40 In our 
study, we observed that 5CS with head and neck cancers had higher odds of developing 
NPOU (3.90) compared to breast cancer, controlling for other factors. Supplemental 
multinomial logistic regression supported these results (Supplementary Tables 2-8). 
From the studies of patients with head and neck cancers in the literature, 
chemotherapy, alcohol use, and opioid use before and during treatment were significantly 
associated with persistent opioid use.4,17,39,40  In our patient sample, of all cancer types, 
additional chemotherapy, as well as comorbid conditions such as anxiety, arthritis, back pain, 
depression, lung disease and nicotine and other opioid use were significantly associated with 
NPOU.  
While head and neck cancers are notoriously caustic, from this study, we were able to 
show that patients with other cancers such as colorectal, female genital, gastrointestinal, and 
lung and bronchial also carry significant risk of NPOU when compared to breast cancer 
controlling for other factors.4,17,39,40 This may be because in comparison to other cancers, 
patients with breast cancer have been shown to have lower opioid use.41 
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This study highlighted socioeconomic and health disparity differences that exist in 
patients receiving radiation that developed NPOU and COU. Just as health disparities exist in 
cancer and opioid prescribing independently, we were able to show that significant health 
disparities exist in development of NPOU and COU across models in this study.42–44 African 
American patients were at 38% increased odds of developing NPOU. Those of lower 
socioeconomic status (requiring indigent, charity insurance - VCC) were at 60% and 2.39 times 
increased estimated odds of developing NPOU and COU, respectively. Additionally, those 
using Medicaid had 2.08 greater odds to develop NPOU. The results of higher opioid 
prescription use in low income insurance types following radiation therapy may be due to the 
fact that patients in disadvantaged sociodemographic positions have poorer outcomes, or due 
to inherent administrative forces from commercial insurers. A recent study published in JAMA 
Open comparing opioid prescribing patterns found that “a third of privately insured patients 
with cancer received an opioid prescription compared with more than half of patients with 
Medicaid. Patients with Medicaid received a higher days’ supply and dosage compared with 
privately insured patients.”45 Insurers may have exerted prescriptive control with utilization 
management strategies (prior authorizations, step-therapy, or day-supply quantity limits) to 
limit opioid prescribing for their beneficiaries. There is evidence to suggest that public insurers 
have been stronger in implementing utilization control measures.46 It is also possible that 
insurer preferred pharmacy coverage practices may have driven patients to obtain opioid 
prescriptions from outside of the academic institution studied, which were not included in our 
analyses. Our concerns for these scenarios reinforced the need for a subgroup analysis with 
full patient prescription data in the VCC subgroup. From our study, we observed that patients 
with lower presumed income (based on use of Medicaid or institution charity care VCC) carry 
greater odds of developing NPOU or COU. From the VCC subgroup analysis, higher disease 
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burden in indigent patients resulted in odds ratios of significant associations with NPOU of 
much higher magnitudes.  
Health disparities in cancer survivors were echoed in this study with chronic conditions 
and substance use, which are highly prevalent in lower socioeconomic patient populations and 
may confer poorer outcomes.47 In this study, cancer survivors with comorbid conditions such 
as anxiety, arthritis, back pain, depression, hypertension, and lung disease were at higher 
odds of developing NPOU or COU controlling for other factors. Additionally, patients with 
nicotine use were consistently at greater odds of developing NPOU and COU controlling for 
other factors across models.   
Lastly, across models, we observed a small decreased risk of NPOU with increasing 
age at diagnosis, controlling for other factors, suggesting that younger age at diagnosis results 
in slightly greater odds of developing NPOU. The mean patient age with cancer receiving 
radiation in this sample was between 55 and 60, whereas those with VCC (which may be a 
sicker subgroup) was between 50 and 56. It could be that patients of younger age have more 
aggressive disease, or are given a more aggressive treatment strategy to prolong life. Either 
scenario may ultimately result in a higher opioid requirement that increases risk of NPOU and 
COU. Additionally, physicians may be more cautious in opioid prescribing for older patients of 
due to concerns related to opioids including sedation, fall risk, and risk of side effects including 
opioid induced constipation.  
 
Limitations 
 This study had several limitations. First, this study only included patients at a single, 
urban hospital affiliated with an academic institution. Its providers may have different pain 
management practices or preferences that may not be nationally representative and thus, the 
results of this study may only be generalizable to other academic institutions of similar size 
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patient population, prescribing practices and geography. Second, this study utilized prescribing 
data rather than fill data. This raises the possibility of patients not filling prescriptions.  In 
addition, due to a lack of access to opioid prescriptions written by doctors outside of the 
institution, we may have missed opioid prescriptions prescribed outside our institution. This 
could have resulted in underestimation of opioid use overall or under- or overestimation of 
NPOU. In order to address this, we conducted the subgroup analysis with VCC patients for 
which we have all prescribing data. Third, we could not differentiate indication of opioid 
prescription to be due to cancer or non-cancer pain. Opioid prescriptions due to cancer pain 
would be, in theory, easier to discontinue than non-cancer pain after curative intent therapy 
that decreases or eliminates the source of the underlying cancer pain (i.e. tumor burden). 
Lastly, this study can only be generalized to patients with cancer that receive radiation. 
 
Conclusion 
 In conclusion, we determined that 19.7% of patients with no prior opioid exposure and 
with cancer that receive radiation develop NPOU.  Further, 54.8% patients with cancer and 
opioid exposure prior to radiation continue opioid use after CIR. Patients with head and neck 
cancers may be at highest risk of NPOU, but other cancers such as colorectal, female genital, 
gastrointestinal, and lung and bronchial also carry significant risk. Comorbidities such as 
anxiety, arthritis, back pain, depression, lung disease, and nicotine were significantly 
associated with NPOU. Anxiety, back pain, hypertension, and nicotine use were significantly 
associated with COU. This study highlighted socioeconomic and health disparity differences 
resulting in increased odds of NPOU and COU in those receiving radiation using low income-
based insurance. These findings warrant evidence-based recommendations and guidelines for 
opioid use and discontinuation in cancer survivors receiving radiation to prevent misuse and 
opioid related deaths. 
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Appendix 
 
Supplemental Table 3.1: Type 3 Analysis of Effects for Overall Significance of Variables 
Covariates 5CS 
NPOU 
5CS 
COU 
5CS VCC 
NPOU 
3CS 
NPOU 
3CS 
COU 
1CS 
NPOU 
1CS 
COU 
Age 0.0009 0.1816 0.0749 0.0023 0.0749 <0.0001 0.025 
Race 0.004 0.4121 0.7008 0.002 0.7008 0.0011 0.4193 
Gender 0.9512 0.7207 0.4738 0.7119 0.4738 0.9009 0.0804 
Insurance Type 0.0013 0.4353 0.257 0.0005 0.257 0.0002 0.3986 
Cancer Type <0.0001 0.0279 0.1158 <0.0001 0.1158 <0.0001 0.0455 
Clinical Stage 0.0109 0.0548 0.2763 0.0131 0.2763 0.0002 0.3577 
Additional Chemotherapy 0.0006 0.6025 0.7696 0.0005 0.7696 0.0168 0.7543 
Additional Surgery 0.2804 0.4157 0.4582 0.109 0.4582 0.0037 0.3189 
Additional Hormonal Therapy   0.4998  0.4998  0.5804 
Death After 5, 3, 1 or more years 
of Diagnosis 
     <0.0001 0.0004 
Recurrence After 5, 3, 1 or more 
years of Diagnosis 
     <0.0001  
Anxiety 0.0093 0.0207 0.1815 0.006 0.1815 0.0034 0.3096 
Arthritis 0.0039   0.0047  0.0016 0.0544 
Back Pain <0.0001 0.0002 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Depression 0.0175   0.0062  0.0064 0.0902 
Hypertension  0.0288 0.0189  0.0189   
Lung Disease <0.0001  0.044 <0.0001 0.044 <0.0001 0.2254 
Nicotine Use 0.001 0.0012 0.0084 0.0008 0.0084 <0.0001 0.0122 
Other Opioid Use 0.0463   0.0523  0.3039  
Radiation Modality .     0.0072  
5CS: 5-Year Cancer Survivor; 3CS: 3-Year Cancer Survivor; 1-CS: 1-Year Cancer Survivor; 
NPOU: New Persistent Opioid User; COU: Continued Opioid User 
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Supplemental Table 3.2: NPOU Radiation Specific Multinomial Logistic Regression 
NOU = reference COU   NPOU   POU   UTOE   
Radiation Modality OR 
95% 
CI Low 
95% CI 
High OR 
95% 
CI Low 
95% CI 
High OR 
95% 
CI Low 
95% CI 
High OR 
95% 
CI Low 
95% CI 
High 
 Brachytherapy 0.229 0.067 0.784 0.328 0.157 0.685 1.014 0.285 3.605 0.996 0.347 2.859 
 Conformal or 3-D 0.329 0.189 0.573 0.425 0.288 0.626 1.859 0.935 3.697 0.906 0.531 1.544 
 Electrons 0.085 0.009 0.772 0.318 0.098 1.034 N/A N/A N/A 0.755 0.163 3.494 
 External Beam 0.136 0.079 0.237 0.313 0.227 0.432 0.696 0.34 1.426 0.463 0.279 0.769 
 IMRT Reference 
 Other 0.351 0.038 3.232 0.62 0.141 2.725 2.386 0.25 22.761 1.135 0.125 10.266 
 
Photons (11-19 
MV) 0.221 0.099 0.493 0.427 0.263 0.692 1.735 0.712 4.228 0.537 0.236 1.225 
 Photons (2-5 MV) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
 
Photons (6-10 
MV) 0.233 0.142 0.383 0.409 0.299 0.561 1.282 0.677 2.429 0.488 0.297 0.803 
 Photons (>19 MV) 18.296 N/A N/A 46.436 N/A N/A N/A N/A N/A 55.731 N/A N/A 
 
Photons (Mixed 
energies) 0.228 0.129 0.402 0.524 0.368 0.746 1.57 0.798 3.091 0.674 0.392 1.159 
 
Photons and 
Electrons 0.214 0.076 0.605 0.235 0.095 0.584 1.943 0.718 5.256 0.955 0.397 2.299 
Radiation Site             
 Abdomen 4.95 2.415 10.147 2.637 1.371 5.07 1.698 0.637 4.529 3.676 1.799 7.512 
 Brain/Spinal cord  0.419 0.098 1.796 2.276 1.296 3.998 0.371 0.086 1.597 1.958 0.908 4.22 
 Breast Reference 
 Chest 2.769 1.818 4.217 3.144 2.302 4.295 1.736 1.120 2.691 2.298 1.521 3.472 
 Extremity bone 5.823 2.489 13.622 6.432 3.295 12.555 1.858 0.542 6.370 1.260 0.290 5.473 
 Head and neck 2.818 1.700 4.671 5.511 3.997 7.599 0.965 0.487 1.910 2.825 1.751 4.558 
 Lung 1.112 0.405 3.056 4.380 2.433 7.884 0.777 0.248 2.434 2.841 1.253 6.442 
 
Lymph node 
region N/A N/A N/A 1.489 0.433 5.116 3.263 1.065 9.996 1.560 0.354 6.871 
 Other 1.066 0.248 4.581 3.556 1.817 6.962 2.610 1.040 6.548 1.306 0.388 4.392 
 Pelvis 1.894 1.124 3.193 4.585 3.379 6.222 0.557 0.266 1.164 1.528 0.921 2.534 
 Prostate 0.951 0.476 1.901 0.727 0.439 1.203 0.507 0.216 1.189 0.347 0.142 0.845 
 Skin 1.669 0.181 15.367 0.661 0.079 5.561 1.893 0.222 16.112 N/A N/A N/A 
 Soft tissue 3.941 1.090 14.257 3.238 1.139 9.206 N/A N/A N/A 2.126 0.469 9.638 
 Spine 2.812 0.616 12.833 8.929 4.085 19.521 2.192 0.477 10.068 1.136 0.146 8.841 
 Uterus and cervix N/A N/A N/A 4.086 1.246 13.405 N/A N/A N/A N/A N/A N/A 
 Whole body 3.405 0.946 12.252 6.487 2.834 14.850 1.001 0.129 7.751 N/A N/A N/A 
 
 
Supplemental Table 3.3: NPOU Radiation Specific Clinical Multinomial Logistic Regression  
NOU = reference COU   NPOU   POU   UTOE   
Cancer Type OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% 
CI 
High 
 Anus 2.012 0.724 5.592 5.647 3.011 10.59 0.779 0.162 3.737 3.816 1.433 10.16 
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Brain and Nervous 
System 0.117 0.013 1.05 0.877 0.382 2.014 0.37 0.076 1.797 1.943 0.477 7.919 
 Breast Reference  
 Cervix 0.769 0.17 3.485 6.905 3.723 12.807 0.829 0.178 3.873 2.516 0.795 7.963 
 Colorectal 0.499 0.19 1.311 2.667 1.658 4.287 0.121 0.016 0.898 0.769 0.288 2.053 
 Corpus and Uterus 0.663 0.151 2.914 3.101 1.675 5.74 1.118 0.37 3.378 1.367 0.389 4.806 
 Esophagus 2.217 0.445 11.055 6.961 2.594 18.677 N/A N/A N/A 1.698 0.202 14.245 
 Hodgkin’s Disease 0.452 0.056 3.62 1.261 0.407 3.908 2.939 0.93 9.29 1.522 0.323 7.16 
 Larynx 2.308 0.885 6.017 6.094 3.393 10.945 0.444 0.055 3.569 5.475 2.393 12.526 
 
Leukemia, 
Lymphoma, Other 
Hematopoietic 
1.122 0.432 2.913 1.352 0.704 2.597 0.857 0.306 2.402 0.47 0.105 2.101 
 Liver 2.552 0.651 9.996 1.391 0.377 5.137 N/A N/A N/A 6.723 2.095 21.573 
 Lung and Bronchus 1.98 0.914 4.289 4.503 2.749 7.376 1.439 0.539 3.841 4.261 2.064 8.798 
 Multiple Myeloma 2.021 0.406 10.062 3.921 1.488 10.331 N/A N/A N/A 3.588 0.615 20.953 
 
Oral Cavity and 
Pharynx 2.5 1.273 4.912 5.826 3.712 9.143 0.96 0.349 2.638 4.401 2.28 8.495 
 Other 2.883 0.971 8.558 2.442 1.018 5.861 2.392 0.734 7.797 2.578 0.698 9.529 
 
Other Respiratory 
and Thoracic Organs 3.772 0.69 20.616 5.242 1.535 17.907 2.231 0.243 20.497 5.966 1.082 32.907 
 
Other Female 
Genital 0.774 0.099 6.062 3.731 1.524 9.133 N/A N/A N/A 3.427 0.941 12.473 
 Pancreas 2.81 0.555 14.22 0.904 0.108 7.54 6.106 1.664 22.405 6.565 1.591 27.094 
 Prostate 1.145 0.529 2.478 1.058 0.602 1.861 0.766 0.279 2.102 0.642 0.259 1.594 
 Skin 2.33 0.627 8.663 1.31 0.361 4.749 1.945 0.414 9.142 3.316 0.888 12.38 
 
Soft Tissue including 
Heart 2.493 0.954 6.516 5.693 3.051 10.623 1.12 0.254 4.94 1.637 0.464 5.774 
 Stomach 4.475 1.469 13.631 3.307 1.187 9.213 N/A N/A N/A 2.826 0.595 13.415 
 Unknown 3.736 1.026 13.611 1.523 0.547 4.242 1.293 0.24 6.973 3.262 0.583 18.257 
Clinical Stage             
 0 Reference 
 1 1.623 0.768 3.429 1.118 0.691 1.808 2.887 1.119 7.445 0.67 0.398 1.128 
 2 2.7 1.246 5.849 1.31 0.787 2.181 3.308 1.241 8.821 0.911 0.512 1.62 
 3 2.29 0.979 5.356 1.915 1.116 3.286 2.363 0.794 7.029 1.019 0.528 1.965 
 
Criteria Met but 
unknown 1.057 0.469 2.381 0.999 0.597 1.673 2.505 0.935 6.716 0.39 0.208 0.731 
 Not Applicable 2.956 0.935 9.345 3.498 1.623 7.538 5.36 1.317 21.82 0.8 0.23 2.782 
Additional 
Chemotherapy 1.625 1.123 2.351 1.655 1.299 2.107 2.367 1.604 3.495 1.352 0.947 1.931 
Additional Surgery 1.355 0.805 2.279 1.08 0.787 1.484 1.402 0.691 2.845 1.538 0.939 2.521 
Additional Hormonal 
Therapy 0.728 0.502 1.057 1.057 0.794 1.407 1.105 0.759 1.609 1.235 0.832 1.831 
Additional 
Immunotherapy 1.105 0.586 2.082 0.925 0.57 1.502 1.938 1.159 3.24 0.914 0.449 1.861 
Additional Other 
Therapy 2.019 0.579 7.037 1.116 0.399 3.117 0.552 0.072 4.208 2.396 0.779 7.371 
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Supplemental Table 3.4: NPOU Non-Radiation Specific Clinical Multinomial Logistic 
Regression 
NOU = reference COU   NPOU   POU   UTOE   
Cancer Type OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High 
 Anus 2.619 0.981 6.991 6.248 3.551 10.993 0.712 0.165 3.069 2.688 1.136 6.359 
 
Brain and 
Nervous System 0.18 0.019 1.712 1.02 0.437 2.383 0.42 0.085 2.072 1.757 0.431 7.169 
 Breast Reference 
 Cervix 0.562 0.119 2.648 5.76 3.252 10.203 0.676 0.158 2.900 1.716 0.583 5.052 
 Colorectal 0.906 0.339 2.421 3.271 2.086 5.128 0.131 0.018 0.959 0.627 0.244 1.613 
 
Corpus and 
Uterus 0.474 0.106 2.119 2.011 1.097 3.688 0.664 0.223 1.979 1.502 0.432 5.216 
 Esophagus 4.657 0.933 23.252 8.255 3.119 21.846 N/A N/A N/A 1.346 0.163 11.09 
 
Hodgkin's 
Disease 0.638 0.076 5.37 1.437 0.472 4.373 3.157 1.211 8.228 0.929 0.212 4.074 
 Larynx 2.775 1.117 6.896 5.944 3.598 9.822 0.281 0.038 2.076 3.173 1.608 6.261 
 
Leukemia, 
Lymphoma, 
Other 
Hematopoietic 
1.408 0.535 3.704 1.479 0.791 2.763 0.985 0.399 2.431 0.367 0.087 1.557 
 Liver 3.267 0.883 12.083 1.132 0.319 4.018 N/A N/A N/A 4.504 1.554 13.052 
 
Lung and 
Bronchus 1.144 0.606 2.158 3.124 2.158 4.523 0.79 0.384 1.626 2.537 1.511 4.257 
 Multiple Myeloma 2.559 0.481 13.615 4.744 1.833 12.279 N/A N/A N/A 2.758 0.497 15.3 
 
Oral Cavity and 
Pharynx 2.711 1.440 5.104 5.216 3.515 7.741 0.687 0.268 1.758 3.043 1.727 5.364 
 Other 2.975 0.931 9.505 1.995 0.824 4.83 1.831 0.559 5.999 2.24 0.61 8.222 
 
Other Respiratory 
and Thoracic 
Organs 
5.614 0.887 35.514 5.396 1.522 19.122 2.04 0.222 18.766 5.192 0.938 28.742 
 
Other Female 
Genital 0.446 0.049 4.105 2.827 1.13 7.071 N/A N/A N/A 3.026 0.852 10.744 
 Pancreas 2.863 0.495 16.563 0.937 0.111 7.929 4.605 1.231 17.227 5.918 1.456 24.045 
 Prostate 0.617 0.342 1.113 0.661 0.417 1.048 0.258 0.121 0.549 0.375 0.176 0.800 
 Skin 3.074 0.811 11.651 1.114 0.313 3.971 1.129 0.249 5.114 2.408 0.665 8.727 
 
Soft Tissue 
including Heart 3.825 1.466 9.978 5.103 2.816 9.248 0.732 0.171 3.141 1.212 0.359 4.089 
 Stomach 5.306 1.558 18.068 3.418 1.214 9.624 N/A N/A N/A 2.542 0.544 11.876 
 Unknown 4.391 1.121 17.201 1.794 0.654 4.927 1.318 0.266 6.536 2.102 0.398 11.096 
Clinical Stage             
 0 Reference 
 1 1.445 0.657 3.18 1.118 0.692 1.806 3.974 1.564 10.094 0.792 0.477 1.314 
 2 3.181 1.46 6.93 1.672 1.028 2.718 6.402 2.506 16.355 1.247 0.741 2.097 
 3 3.049 1.306 7.115 2.683 1.612 4.467 5.431 1.921 15.357 1.331 0.74 2.394 
 
Criteria Met but 
unknown 1.343 0.573 3.146 1.256 0.756 2.087 3.935 1.489 10.4 0.47 0.256 0.863 
 Not Applicable 1.683 0.494 5.738 2.96 1.369 6.401 5.994 1.494 24.049 0.854 0.246 2.959 
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Death After 5 years 
or more after 
Diagnosis 
1.539 0.743 3.187 1.107 0.683 1.794 0.971 0.398 2.368 0.567 0.222 1.444 
Recurrence 5 
years or more after 
Diagnosis 
N/A N/A N/A 0.459 0.118 1.782 N/A N/A N/A N/A N/A N/A 
Anxiety 2.277 1.548 3.351 1.573 1.165 2.124 1.249 0.778 2.005 1.362 0.805 2.304 
Arthritis 2.755 1.924 3.945 1.41 1.045 1.901 1.979 1.303 3.006 0.887 0.491 1.601 
Back Pain 4.099 2.895 5.803 2.142 1.626 2.823 1.689 1.09 2.617 1.207 0.709 2.055 
Depression 2.544 1.675 3.863 1.729 1.22 2.451 1.991 1.221 3.248 0.751 0.36 1.569 
Diabetes 1.049 0.699 1.573 0.915 0.675 1.24 1.445 0.922 2.264 1.083 0.623 1.883 
Heart Disease 1.32 0.936 1.861 1.225 0.958 1.567 1.061 0.718 1.569 0.546 0.333 0.894 
Hypertension 1.441 1.02 2.036 1.308 1.04 1.644 1.126 0.778 1.63 0.568 0.382 0.843 
Lung Disease 2.806 1.941 4.056 2.133 1.631 2.789 1.554 0.988 2.447 1.182 0.72 1.939 
Psychosis 0.726 0.194 2.719 0.612 0.219 1.708 0.932 0.198 4.38 N/A N/A N/A 
Stroke 1.565 0.772 3.174 0.859 0.498 1.482 0.627 0.213 1.852 1.179 0.466 2.982 
 
 
Supplemental Table 3.5: NPOU Sociodemographic Multinomial Logistic Regression 
NOU = reference COU   NPOU   POU   UTOE   
  OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High 
Age 0.973 0.959 0.988 0.976 0.967 0.985 0.984 0.968 1 0.998 0.984 1.013 
Race             
 
American Indian-
Alaskan 1.759 0.178 17.363 N/A N/A N/A 1.846 0.229 14.891 2.391 0.51 11.216 
 Asian 1.189 0.256 5.514 0.833 0.312 2.228 0.604 0.081 4.528 0.685 0.159 2.957 
 
Black of African 
American 1.601 1.182 2.168 1.255 1.035 1.522 1.379 1.005 1.893 0.807 0.594 1.096 
 Other 1.253 0.505 3.111 0.542 0.268 1.096 0.486 0.117 2.019 1.189 0.556 2.545 
 
Other of Hispanic 
or Latino or 
Spanish Origin  
10.336 3.565 29.97 2.005 0.674 5.959 6.974 2.123 22.913 0.79 0.099 6.297 
 White Reference 
 
White of Hispanic 
or Latino or 
Spanish Origin  
N/A N/A N/A 1.301 0.41 4.127 N/A N/A N/A 1.332 0.296 5.989 
Gender             
 Male 0.875 0.625 1.225 1.645 1.353 2.001 0.551 0.367 0.827 1.133 0.838 1.531 
 Female Reference 
Insurance Type  
 Commercial/HMO Reference 
 VCC 
2.61 1.583 4.303 2.028 1.392 2.954 1.038 0.526 2.049 0.483 0.173 1.348 
 Insurance, NOS  1.422 0.803 2.517 1.686 1.203 2.361 1.204 0.674 2.153 1.505 0.91 2.489 
 Medicaid 2.454 1.424 4.231 2.543 1.723 3.754 1.389 0.71 2.719 2.774 1.559 4.934 
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 Medicare 1.86 1.195 2.895 1.808 1.379 2.37 1.394 0.9 2.16 1.369 0.925 2.027 
 Military 0.976 0.222 4.286 0.678 0.259 1.775 1.471 0.438 4.943 0.658 0.155 2.803 
 Self-Pay 2.039 1.145 3.63 2.564 1.759 3.738 0.64 0.246 1.663 2.702 1.528 4.776 
 Unknown 1.968 0.362 10.689 3.5 1.184 10.345 3.392 0.662 17.363 3.464 0.709 16.93 
Alcohol Use 3.228 1.792 5.814 1.243 0.737 2.096 2.727 1.19 6.246 1.641 0.7 3.848 
Nicotine Use 5.679 4.056 7.951 2.616 2.051 3.336 1.934 1.247 3 0.981 0.615 1.566 
Other Opioid Use 1.901 0.494 7.316 4.69 1.642 13.395 2.54 0.431 14.95 N/A N/A N/A 
Other Drug Use 1.412 0.737 2.706 1.074 0.612 1.882 1.299 0.486 3.477 0.256 0.033 1.959 
 
Supplemental Table 3.6: NPOU Medications Multinomial Logistic Regression 
NOU = reference COU   NPOU   POU   UTOE   
Number of Opioid 
Prescriptions OR 
95% CI 
Low 
95% CI 
High OR 
95% CI 
Low 
95% CI 
High OR 
95% CI 
Low 
95% 
CI 
High OR 
95% CI 
Low 
95% CI 
High 
 Buprenorphine 
15.18 14.564 15.822 2.021 1.913 2.135 56.496 54.027 59.078 0.761 0.591 0.982 
 Codeine 
50.3 49.602 51.009 3.92 3.841 4 9.222 9.011 9.438 4.693 4.58 4.808 
 Dihydrocodeine N/A N/A N/A 0.523 N/A N/A 0.197 N/A N/A 0.056 N/A N/A 
 Fentanyl 3.425 3.39 3.46 7.223 7.163 7.284 0.288 0.274 0.302 0.904 0.885 0.923 
 Hydrocodone 13.134 13.045 13.225 6.093 6.054 6.132 12.662 12.554 12.77 43.05 42.812 43.29 
 Hydromorphone 7.784 7.7 7.868 4.753 4.706 4.801 2.711 2.646 2.778 2.902 2.84 2.965 
 Meperidine 6.871 5.004 9.434 21.97 19.988 24.149 19.96 17.166 23.21 516 481.031 553.512 
 Methadone 2.808 2.768 2.849 1.273 1.254 1.291 0.138 0.128 0.149 0.15 0.14 0.161 
 Morphine 
4.018 3.983 4.054 3.165 3.139 3.192 0.339 0.326 0.352 0.396 0.384 0.407 
 Oxycodone 
46.437 46.247 46.627 19.824 19.749 19.898 13.919 13.824 14.015 12.734 12.656 12.812 
 Oxymorphone 201.248 184.217 219.853 0.073 0.002 2.493 N/A N/A N/A 0.118 N/A 40.677 
 Tapentadol 
592.932 158.579 N/A N/A N/A N/A 26.005 0.001 N/A 0.032 N/A N/A 
 Tramadol 26.189 26.028 26.35 12.165 12.097 12.234 13.246 13.134 13.359 3.206 3.168 3.245 
 
Supplemental Table 3.7: NPOU Stepwise Multinomial Logistic Regression 
NOU = reference COU   NPOU   POU   UTOE   
Radiation Modality OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% CI 
High 
 Brachytherapy 0.298 0.142 0.623 0.224 0.149 0.337 1.407 0.659 3.005 0.285 0.161 0.505 
 Conformal or 3-D 0.895 0.508 1.576 0.268 0.183 0.392 3.75 2.044 6.879 0.477 0.292 0.778 
 Electrons 0.536 0.058 4.957 0.359 0.118 1.086 N/A N/A N/A 0.301 0.068 1.336 
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 External Beam 0.611 0.341 1.095 0.338 0.245 0.466 1.555 0.803 3.012 0.238 0.145 0.391 
 IMRT Reference 
 Other 1.964 0.193 20.011 0.596 0.124 2.87 6.815 0.744 62.464 0.611 0.07 5.333 
 Photons (11-19 MV) 0.646 0.28 1.494 0.338 0.207 0.552 2.659 1.148 6.156 0.3 0.134 0.669 
 Photons (2-5 MV) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
 Photons (6-10 MV) 0.545 0.333 0.892 0.241 0.178 0.327 2.449 1.412 4.249 0.23 0.144 0.368 
 Photons (>19 MV) 555.85 N/A N/A 67.606 N/A N/A N/A N/A N/A 46.611 N/A N/A 
 
Photons (Mixed 
energies) 0.567 0.321 1.001 0.316 0.226 0.441 2.754 1.527 4.969 0.35 0.214 0.574 
 Photons and Electrons 0.73 0.243 2.192 0.147 0.059 0.364 3.85 1.496 9.908 0.471 0.203 1.092 
Clinical Stage             
 0 Reference 
 1 1.445 0.647 3.227 1.326 0.819 2.148 2.719 1.049 7.05 0.695 0.414 1.165 
 2 2.158 0.969 4.806 1.242 0.758 2.034 2.617 0.994 6.89 0.762 0.44 1.318 
 3 1.984 0.825 4.773 2.816 1.67 4.748 1.674 0.574 4.887 1.119 0.604 2.077 
 
Criteria Met but 
unknown 1.185 0.502 2.796 1.373 0.834 2.262 2.33 0.87 6.238 0.445 0.245 0.808 
 Not Applicable 1.565 0.618 3.964 2.52 1.454 4.368 2.358 0.772 7.2 0.987 0.488 1.996 
Additional Chemotherapy 1.48 1.024 2.138 1.834 1.467 2.294 2.54 1.761 3.664 1.553 1.121 2.152 
Comorbid Conditions             
 Anxiety 1.964 1.318 2.925 1.483 1.099 2 1.166 0.72 1.889 1.473 0.869 2.498 
 Arthritis 3.265 2.243 4.753 1.357 1.006 1.829 2.24 1.458 3.441 0.89 0.491 1.614 
 Back Pain 3.29 2.313 4.68 1.884 1.433 2.477 1.544 0.993 2.402 1.199 0.701 2.053 
 Depression 2.302 1.506 3.518 1.397 0.989 1.971 1.913 1.168 3.135 0.697 0.334 1.456 
 Heart Disease 1.353 0.959 1.908 1.108 0.871 1.41 1.043 0.706 1.54 0.536 0.329 0.875 
 Hypertension 1.378 0.97 1.957 1.194 0.954 1.493 1.133 0.785 1.637 0.565 0.385 0.83 
 Lung Disease 1.775 1.215 2.593 2.019 1.546 2.638 1.299 0.819 2.061 1.233 0.744 2.042 
Age 0.971 0.955 0.987 0.984 0.974 0.994 0.99 0.974 1.007 1.007 0.992 1.023 
Race             
 
American Indian-
Alaskan 2.983 0.328 27.102 N/A N/A N/A 1.982 0.241 16.319 1.657 0.342 8.019 
 Asian 0.877 0.176 4.384 0.795 0.287 2.206 0.531 0.069 4.075 0.894 0.206 3.88 
 
Black of African 
American 1.426 1.016 2.003 1.216 0.986 1.5 1.287 0.917 1.805 0.866 0.628 1.192 
 Other 1.365 0.509 3.657 0.56 0.271 1.159 0.51 0.121 2.14 1.187 0.543 2.594 
 
Other of Hispanic or 
Latino or Spanish 
Origin  
12.038 3.769 38.452 2.074 0.672 6.397 7.599 2.203 26.213 0.82 0.1 6.703 
 White Reference 
 
White of Hispanic or 
Latino or Spanish 
Origin  
N/A N/A N/A 1.576 0.477 5.204 N/A N/A N/A 1.414 0.307 6.511 
Insurance             
 Commercial/HMO Reference 
 VCC 1.84 1.078 3.141 1.804 1.216 2.675 0.916 0.455 1.845 0.56 0.197 1.589 
 Insurance, NOS  1.672 0.921 3.035 1.645 1.154 2.345 1.352 0.747 2.447 1.372 0.815 2.309 
 Medicaid 1.872 1.032 3.396 2.305 1.527 3.478 1.29 0.647 2.571 2.831 1.573 5.095 
 Medicare 1.543 0.963 2.474 1.6 1.206 2.123 1.297 0.83 2.027 1.36 0.909 2.034 
 Military 1.343 0.297 6.065 0.817 0.305 2.191 1.502 0.436 5.175 0.608 0.14 2.652 
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 Self-Pay 1.845 0.995 3.422 2.4 1.616 3.562 0.64 0.245 1.671 2.52 1.389 4.572 
 Unknown 1.709 0.312 9.371 2.236 0.69 7.248 2.726 0.518 14.355 3.251 0.641 16.491 
Substance Use             
 Alcohol Use 2.711 1.495 4.918 1.091 0.633 1.881 2.249 1.002 5.046 1.891 0.792 4.515 
 Nicotine Use 3.55 2.48 5.083 1.814 1.397 2.356 1.525 0.977 2.38 0.863 0.518 1.439 
 
 
Supplemental Table 3.8: NPOU Final Multinomial Logistic Regression (Stepwise + Theoretical)  
NOU = reference COU   NPOU   POU   UTOE   
Radiation Modality OR 
95% 
CI 
Low 
95% 
CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High OR 
95% 
CI 
Low 
95% CI 
High 
 Brachytherapy 0.227 0.1 0.513 0.514 0.319 0.829 0.36 0.152 0.857 0.429 0.214 0.86 
 Conformal or 3-D 0.667 0.344 1.294 0.5 0.325 0.771 0.913 0.429 1.943 0.774 0.431 1.389 
 Electrons 0.185 0.017 2.021 0.691 0.209 2.291 N/A N/A N/A 0.475 0.093 2.412 
 External Beam 0.416 0.217 0.797 0.512 0.357 0.735 0.418 0.193 0.906 0.331 0.188 0.583 
 IMRT Reference 
 Other 1.371 0.134 14.064 0.792 0.162 3.882 2.225 0.219 22.58 1.268 0.133 12.1 
 
Photons (11-19 
MV) 0.469 0.187 1.181 0.467 0.27 0.808 0.792 0.306 2.05 0.476 0.196 1.156 
 Photons (2-5 MV) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
 
Photons (6-10 
MV) 0.37 0.207 0.658 0.514 0.359 0.736 0.56 0.277 1.132 0.391 0.223 0.686 
 
Photons (>19 
MV) N/A N/A N/A 256.476 N/A N/A N/A N/A N/A 116.776 N/A N/A 
 
Photons (Mixed 
energies) 0.403 0.206 0.79 0.699 0.468 1.042 0.631 0.299 1.336 0.589 0.322 1.077 
 
Photons and 
Electrons 0.538 0.166 1.741 0.466 0.182 1.192 0.81 0.28 2.345 0.855 0.336 2.173 
Clinical Stage  
 0 Reference 
 1 1.565 0.683 3.588 1.049 0.635 1.73 2.659 1.01 7.001 0.592 0.344 1.017 
 2 2.38 1.011 5.603 1.155 0.682 1.959 2.93 1.079 7.956 0.82 0.452 1.486 
 3 1.952 0.763 4.99 1.617 0.92 2.841 2.214 0.733 6.684 0.876 0.444 1.731 
 
Criteria Met but 
unknown 0.984 0.395 2.448 1.002 0.587 1.712 2.475 0.903 6.789 0.356 0.187 0.675 
 Not Applicable 1.003 0.279 3.614 2.29 1.009 5.198 4.024 0.957 16.929 0.792 0.219 2.864 
Additional 
Chemotherapy 1.382 0.896 2.132 1.539 1.179 2.009 2.742 1.81 4.154 1.476 1.014 2.148 
Comorbid 
Conditions             
 Anxiety 2.123 1.404 3.21 1.496 1.095 2.044 1.219 0.746 1.992 1.48 0.864 2.538 
 Arthritis 3.342 2.27 4.921 1.516 1.113 2.066 2.198 1.421 3.4 0.935 0.512 1.71 
 Back Pain 3.405 2.365 4.902 1.924 1.449 2.554 1.526 0.974 2.39 1.239 0.718 2.138 
 Depression 2.271 1.464 3.522 1.557 1.09 2.225 1.784 1.08 2.949 0.742 0.353 1.559 
 Heart Disease 1.313 0.92 1.873 1.175 0.914 1.511 0.958 0.643 1.427 0.523 0.318 0.862 
 Hypertension 1.299 0.905 1.863 1.183 0.937 1.494 1.166 0.802 1.695 0.55 0.371 0.816 
 Lung Disease 1.891 1.273 2.809 1.811 1.37 2.395 1.289 0.801 2.074 1.171 0.701 1.956 
Age 0.966 0.949 0.984 0.981 0.97 0.991 0.997 0.979 1.015 1.007 0.99 1.023 
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Race             
 
American Indian-
Alaskan 4.949 0.562 43.623 N/A N/A N/A 2.045 0.244 17.15 1.657 0.328 8.363 
 Asian 0.883 0.177 4.415 0.715 0.258 1.983 0.567 0.071 4.542 0.805 0.18 3.596 
 
Black of African 
American 1.564 1.093 2.238 1.37 1.097 1.709 1.27 0.895 1.801 0.948 0.683 1.317 
 Other 1.406 0.522 3.791 0.532 0.252 1.126 0.502 0.118 2.141 1.151 0.517 2.561 
 
Other of Hispanic 
or Latino or 
Spanish Origin  
13.022 3.939 43.048 2.083 0.655 6.618 8.857 2.419 32.435 0.841 0.098 7.21 
 White Reference 
 
White of Hispanic 
or Latino or 
Spanish Origin  
N/A N/A N/A 1.358 0.389 4.742 N/A N/A N/A 0.921 0.189 4.497 
Insurance             
 Commercial/HMO Reference 
 VCC 2.171 1.246 3.784 1.735 1.15 2.618 0.929 0.452 1.91 0.524 0.183 1.505 
 Insurance, NOS  1.699 0.928 3.111 1.538 1.069 2.213 1.44 0.788 2.629 1.345 0.793 2.28 
 Medicaid 1.936 1.046 3.584 2.175 1.418 3.336 1.37 0.676 2.778 2.894 1.593 5.258 
 Medicare 1.634 1.005 2.658 1.538 1.149 2.06 1.341 0.847 2.123 1.362 0.907 2.045 
 Military 1.194 0.237 6.027 0.922 0.337 2.523 1.924 0.55 6.727 0.79 0.178 3.506 
 Self-Pay 2.076 1.089 3.957 2.191 1.449 3.313 0.891 0.333 2.385 2.567 1.383 4.767 
 Unknown 1.704 0.3 9.677 2.204 0.679 7.153 4.182 0.753 23.216 3.505 0.66 18.622 
Substance Use             
 Alcohol Use 2.478 1.31 4.686 0.851 0.482 1.502 2.956 1.243 7.031 1.506 0.611 3.71 
 Nicotine Use 3.729 2.559 5.434 1.625 1.235 2.138 1.665 1.048 2.643 0.719 0.426 1.213 
Sex             
 Male 0.609 0.36 1.029 0.978 0.727 1.314 0.637 0.344 1.18 0.841 0.538 1.315 
 Female Reference 
Additional Surgery 1.136 0.615 2.098 0.978 0.694 1.376 1.562 0.731 3.336 1.962 1.162 3.311 
Additional 
Hormonal Therapy 0.734 0.48 1.124 1.109 0.823 1.495 1.185 0.804 1.745 1.217 0.815 1.817 
Cancer Type             
 Anus 1.761 0.522 5.942 4.583 2.266 9.268 0.801 0.151 4.248 4.334 1.499 12.529 
 
Brain and 
Nervous System 0.189 0.018 1.972 0.772 0.3 1.984 0.351 0.062 2.002 1.913 0.42 8.705 
 Breast Reference 
 Cervix 0.185 0.035 0.977 3.422 1.696 6.904 0.528 0.103 2.709 3.086 0.891 10.692 
 Colorectal 0.705 0.237 2.101 3.161 1.836 5.442 0.129 0.017 1.001 0.716 0.254 2.022 
 
Corpus and 
Uterus 0.647 0.131 3.202 2.509 1.264 4.977 1.159 0.354 3.793 2.06 0.554 7.651 
 Esophagus 6.45 1.091 38.125 8.563 2.961 24.766 N/A N/A N/A 1.949 0.22 17.233 
 
Hodgkin's 
Disease 0.41 0.043 3.913 1.113 0.335 3.698 5.102 1.423 18.294 2.441 0.486 12.252 
 Larynx 2.459 0.724 8.349 6.236 3.09 12.585 0.69 0.077 6.18 8.366 3.125 22.393 
 
Leukemia, 
Lymphoma, 
Other 
Hematopoietic 
2.259 0.71 7.192 1.396 0.67 2.911 1.531 0.484 4.847 0.622 0.135 2.872 
 Liver 6.645 1.075 41.073 1.906 0.478 7.61 N/A N/A N/A 11.737 3.087 44.625 
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Lung and 
Bronchus 0.691 0.236 2.027 3.106 1.699 5.679 0.597 0.169 2.114 4.181 1.804 9.687 
 Multiple Myeloma 6.342 1.015 39.648 5.369 1.866 15.453 N/A N/A N/A 4.297 0.695 26.583 
 
Oral Cavity and 
Pharynx 2.342 0.936 5.857 5.184 2.956 9.092 0.881 0.26 2.991 4.85 2.13 11.041 
 Other 2.547 0.683 9.506 1.929 0.733 5.075 2.857 0.794 10.279 3.12 0.8 12.167 
 
Other Respiratory 
and Thoracic 
Organs 
6.473 0.918 45.634 5.328 1.417 20.04 2.947 0.288 30.116 6.832 1.114 41.891 
 
Other Female 
Genital 0.299 0.026 3.483 2.245 0.836 6.025 N/A N/A N/A 3.713 0.95 14.51 
 Pancreas 3.137 0.454 21.671 0.998 0.115 8.636 4.852 1.102 21.37 8.5 1.834 39.401 
 Prostate 1.109 0.37 3.32 0.774 0.387 1.548 0.976 0.266 3.585 0.967 0.324 2.886 
 Skin 7.256 1.657 31.784 1.576 0.404 6.146 3.6 0.708 18.321 3.863 0.942 15.834 
 
Soft Tissue 
including Heart 4.855 1.593 14.79 6.575 3.297 13.111 1.458 0.31 6.861 1.826 0.492 6.776 
 Stomach 5.796 1.441 23.314 3.483 1.144 10.61 N/A N/A N/A 3.217 0.623 16.599 
 Unknown 5.004 0.937 26.716 1.701 0.542 5.342 1.674 0.257 10.907 3.473 0.55 21.932 
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CHAPTER 4: PRESCRIBED OPIOID DOSES IN CANCER SURVIVORS PRE- AND POST-
CURATIVE INTENT RADIATION 
Abstract 
Background: Improvements in cancer therapy have led to an increase in the aggregate number 
of cancer survivors and the duration of time spent in the survivorship period. There is growing 
awareness of opioid use in cancer survivors as the population increases. Pain management is 
an important consideration for patients with cancer, as malignancies, invasive surgery, 
chemotherapy, and radiation can all lead to significant pain. Approximately 50% of cancer 
patients will receive radiation therapy as a component of their treatment, for which opioid 
utilization is of increasing concern. Neither opioid dose utilization pre- and post-curative intent 
radiation (CIR) or the factors associated with opioid doses is known. Objective: Determine 
opioid oral morphine equivalent (OME) doses for cancer survivors after CIR and factors 
associated with higher opioid dose burden. Methods: Electronic medical record clinical and 
pharmacy data from cancer survivors receiving radiotherapy for any indication from a single 
academic cancer center from January 1, 2008 to December 31, 2018 was utilized to calculate 
OME doses before and after CIR. A panel data model was used to estimate factors associated 
with high opioid doses and a mixed linear model was used to predict average opioid dose used 
one year after CIR. Subgroup and sensitivity analyses were then conducted. Results: Cancer 
survivors that lived at least 5 years after diagnosis and had an opioid prescription prior to 
radiation were estimated to have, on average, 68.2 (95% CI: 62.8-73.6, panel data model) - 
68.3 (95% CI: 62.9-73.7, mixed linear model) OMEs higher that those without an opioid 
prescription prior to radiation over the course of time, controlling for other factors.  Across 
models and subgroups, patients with public insurance and comorbid conditions of anxiety, 
depression, and other drug use are associated with higher average OMEs over time, while 
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patients with diabetes and hypertension are associated with lower average OMEs over time. 
Controlling for other factors, we predict that patients that undergo radiation for their cancer will 
use, on average, 4.1 (95% CI: 3.1-5.1) OMEs one year after end of radiation. Discussion: From 
this study, we can see that many cancer survivors do not utilize opioids long-term before or 
after radiation. However, for those using opioids to manage cancer and treatment related pain, 
sustained high doses of opioids are used. Conclusion: Substantial opioid dosages in cancer 
survivors who received radiation therapy warrants evidence-based recommendations and 
guidelines for opioid use and discontinuation to prevent misuse and opioid related deaths. 
 
Background 
Five-year survival from cancer diagnosis has increased from less than 50% to a mean 
of 67% (with a large range based on cancer site) over the last several decades.1,2 Increased 
survival, in part due to improvements in antineoplastic therapy, has led to an increase in both 
the aggregate number of cancer survivors and the duration of time patients spend in the 
survivorship period.  Pain management is an important consideration for patients that receive 
cancer treatment.  Opioids are a cornerstone of pain management in patients with cancer, as 
malignancies themselves can lead to significant pain, in addition to pain resulting from invasive 
surgery, chemotherapy, and radiation.3–5 Approximately 50% of cancer patients will receive 
radiation therapy as a component of their treatment.6  Undergoing radiation therapy can 
subject patients to significant morbidity that can vary by treatment site, with patients treated for 
head and neck cancer tending to have a significant burden of radiation-related acute and late 
toxicity.4,7,8 
Thus, cancer survivors who have received radiation are an important demographic to 
consider, as opioid use and abuse have reached epidemic proportions in the United States.  
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There is emerging evidence of high rates of opioid misuse (use of opioids contrary to the 
directed or prescribed pattern of use, regardless of presence or absence of harm) in patients 
with cancer.9–14 One study found that more than half (58%) of patients with cancer were 
noncompliant with their prescribed opioid therapy.10  Ultimately, an estimated 29% of patients 
with cancer are at high-risk for misuse.3,15  Additionally, recent evidence suggests that cancer-
directed therapies (especially surgery and radiation directed to the head and neck) may 
promote opioid use long after the cancer therapy is concluded.8,16–18  
While there are evidence based recommendations for opioid formulations to use for 
patients with cancer undergoing therapy, there are no daily oral morphine equivalent (OME) 
dose recommendations for patients with cancer.19  The 2016 chronic opioid prescribing 
guidelines for non-cancer pain (cancer pain explicitly excluded) recommended avoiding daily 
OME doses greater than 90 and for prescribers to use caution with daily OME doses greater 
than 50.20  Subsequently Guy Jr et al. noted that decreases in opioid prescriptions followed the 
“publication of two national guidelines defining high-dose opioid prescribing as >200 MME/day.  
[…, These guidelines] coincided with studies demonstrating progressively increasing overdose 
risk at prescribed opioid dosages exceeding 20, 50, and 100 [OME] per day and publications 
highlighting associations of prescribed opioids with overdose deaths.”21 
It has been suggested that opioid utilization patterns (chronic opioid use by total daily 
dose, dose escalations, and dose reductions) are similar between patients with cancer pain 
and patients with non-cancer pain, although patients were not matched.22,23 However, this has 
not been studied well in cancer survivors.  Cancer survivors with chronic opioid use have been 
found to have a higher daily dose of opioids than controls in some cancers.24  Patients with 
active cancer that were non-compliant with their prescribed opioid therapy have also been 
found to have higher morphine equivalent daily doses.10 A review of 22 articles on opioid 
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analgesic dose and adverse health outcomes in non-cancer patients determined that “risk of 
misuse, overdose, and death increases with increasing opioid analgesic dose [but, there] is no 
clear dose inflection point beyond which the risk of these adverse health outcomes increases 
[and no] analgesic dose is without risk.”25  Presumably, increased doses of opioids confer 
similar risk for patients with cancer and cancer survivors long after curative intent therapy. 
However, opioid dose utilization in cancer survivors after curative intent radiation (CIR) has not 
been studied.   
As more patients are surviving cancer, understanding opioid use, and specifically opioid 
dose, is of greater concern, especially as there is little to no consensus on the therapeutic 
framework of treating pain for these patients.26 Understanding levels of opioid utilization and 
factors that may put patients at risk for higher opioid requirements may help identify patients 
that may have difficulty weaning off opioid regimens. 
 
Methods 
Data Source, Patient Identification, and Patient Covariates 
In order to conduct this project, we utilized electronic medical record data from 
individuals receiving radiotherapy for any indication at Virginia Commonwealth University’s 
Massey Cancer Center between January 1, 2008 to December 31, 2018. Patients 18 years of 
age or older with any cancer type and stage receiving radiation with or without any additional 
treatment modalities (surgery, chemotherapy) were included. Patients receiving radioisotopes 
or radium as their primary radiation therapy were excluded. We only included patients that 
classify as cancer survivors, defined as the absence of metastatic disease or recurrence within 
5 years of diagnosis (5CS). Prisoners were excluded. Covariate information on the date of 
cancer diagnosis, cancer type, stage, treatment type, treatment details, comorbid conditions, 
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germane social history (including alcohol, tobacco, or illicit drug use), and demographic 
information (e.g., age, race, ethnicity and insurance status and type - including Virginia 
Coordinated Care [VCC], the institution sponsored health insurance for which all medical 
records should be available for these patients) was used. Prescribed opioid medications were 
included if written for the outpatient setting for at least a 14-day supply. Due to the differing 
approach to pain treatment acutely, inpatient opioids and prescriptions written during radiation 
treatment were excluded. Further, only patients with sufficient prescription information to 
calculate OMEs were included in this study. 
Opioid Prescription Equivalencies 
Medication prescribing data was coded to create a monthly longitudinal record of the 
average daily oral morphine equivalent (OME) dose for each patient as described in Chapter 2. 
Methods included utilizing outpatient prescriptions of at least 14 days supply coded with 
established OME conversion factors. Prescription OMEs were averaged for each patient at 
each of 5 time points as described in Figure 4.1. Univariate analysis of average OME at each 
time point per patient over time was then conducted.  
 
Figure 4.1: Timeline of Opioid Dose Assessment 
Dx: Diagnosis date; OME: Oral morphine equivalent dose 
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Patient Grouping and Categorization 
Patients were grouped based on variations in treatment and by cancer type.  Patients 
that receive surgery versus those that do not may have different pain levels and thus a 
different average OME.   Patients were classified by use criteria by methods described in 
Chapter 3, generally following Lee et al. and Silver et al (Table 4.1).17,27  These groupings were 
used to inform accuracy of calculated OME doses based on opioid classification.  OME doses 
from Figure 4.1 were verified to be correct based on Chapter 3’s opioid use determined 
category.  An accurate example being a patient classified as NPOU with zero calculated OME 
dose at time 1 and at time 2-5 calculated OME doses greater than zero. There were patients 
that could be categorized by opioid exposure based on date of prescription (and day supply) in 
Chapter 3, but were missing some information required to calculate OME. Patients that OME 
calculated doses did not fit their opioid exposure categorization were not included in this study. 
An excluded case example being a patient classified as COU based on date of prescription 
(and day supply), with calculated OME at time 1 as greater than zero, but at time OME 2-5, 
calculated OME was zero. The patient in this case was missing necessary information to 
calculate OME at times OME 2-5, and would appear in this study to be a POU when that was 
not the case.   
Table 4.1: Summary of Patient Groups by Opioid Exposure 
Group  Abbreviation Definition  
Chronic Opioid User COU Prescribed at least one opioid prescription 30 days before treatment 
(OE) and at least one opioid prescription 30 days after treatment 
Never Opioid User NOU Had no known opioid prescription history before (ON) or after 
treatment 
New Persistent Opioid 
User 
NPOU Previously ON who was prescribed at least one opioid prescription 
30 after treatment 
Previous Opioid User POU Prescribed at least one opioid prescription 30 days before treatment 
(OE) and no known opioid prescription history after treatment 
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Statistical Analysis: Panel Data Model and Mixed Linear Model 
To estimate factors associated with average daily OME dose after CIR therapy, two 
model types were utilized.  Dummy variables were created for all categorical covariates. For 
both models, a dummy variable of presence of OME dose at baseline, “Baseline Opioid 
Prescription” (yes = 1, no =0) was used. A dynamic panel data model (PDM) was built as, 
OMEt = f(OMEt-1, covariates), where t = 90 days before radiation start and 90, 180, 270, 360 
days after radiation end (Figure 4.1; Specific Aim 3b, Tables 4.2 and 4.3).  Two PDMs were 
built: (1) a significant model with only covariates included with p-values <0.05 and (2) a 
theoretical model with significant covariates from model 1 and important covariates to adjust 
for age, race, sex, treatment modality, comorbidities, and insurance. The second model, a 
mixed linear model (MLM), allowed for assessment of OME per day and was used to predict 
average daily OME after CIR.  As with the PDMs, significant and theoretical models were 
created with covariates of age, race, sex, treatment modality, comorbidities, insurance 
(Specific Aim 3c, Tables 4.2 and 4.3). Results of the average OME per day variable from the 
MLM were then utilized to predict average OME dosages controlling for other factors at each 
time point following radiation. Resulting average OME dose per day was multiplied by the time 
point day to estimate total average OME dose predicted at each time point. 
 For the panel data model, the Breusch and Pagan Lagrangian Multiplier (LM) test for 
random effects resulted in a p-value < 0.0001. Therefore, a random effects model was used 
instead of the ordinary least squares (OLS) model. Additionally, the Hausman test for fixed 
versus random effects estimators supported use of random effects model.  The random effect 
utilized in the MLM was the de-identified patient ID number. P-values of <0.05 were considered 
statistically significant. Statistical analyses were conducted using Stata v15.1 and SAS v9.4 
(SAS Institute, Cary, NC). 
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Table 4.2: Methods for Specific Aim 3 
 
Table 4.3: Panel Data Model and Mixed Linear Models  
Regression Model Type Model 
Panel Data 
Model 1 
Significant 𝑂𝑀𝐸!=β0 + β1…n(Clinical Significant Factors)+ βn+1…n+2 
(Sociodemographic Significant Factors ) +	εa 
Panel Data 
Model 2 
Theoretical 𝑂𝑀𝐸!	=β0 + β1…n(Clinical Significant Factors)+ βn+1…n+2 
(Sociodemographic Significant Factors ) +	εa 
Mixed Linear 
Model 1 
Significant 𝑂𝑀𝐸	=β0 + β1(OME&'()*+,))+ β2(Day)	+ β3…n (Clinical Significant Factors)+ 
βn+1…n+2 (Sociodemographic Significant Factors ) +	ε
a 
Mixed Linear 
Model 2 
Theoretical 𝑂𝑀𝐸	=β0 + β1(OME&'()*+,))+ β2(Day)	+ β3…n (Clinical Significant Factors)+ 
βn+1…n+2 (Sociodemographic Significant Factors ) +	ε
a 
Significant model includes significant covariates only; Theoretical model includes significant 
covariates and important non-significant covariates 
 
 
Subgroup and Sensitivity Analyses 
In order to assess the robustness of our results, we conducted four subgroup analyses. 
First, a subgroup analysis for patients with VCC was conducted to compare to patients without 
VCC to determine if differences existed due to potentially missed pre-radiation opioid 
prescriptions in patients without VCC. To further assess impact of missing prescriptions and 
assess the difference due to “0” OME doses for NOU, we conducted a subgroup analysis with 
patients with at least one calculated OME prescription (removed patients classified as NOU, 
i.e. those with OME doses of “0” before and after radiation). Lastly, we conducted sensitivity 
analyses of patients with cancer that received radiation and lived without recurrence, 
metastatic disease, or death for at least 1 (1-Year Cancer Survivors; 1CS) and 3 years (3-Year 
Cancer Survivors; 3CS) after diagnosis. 
Specific Aim 3 
In cancer survivors who received curative intent radiation therapy for their 
malignancy, examine new persistent and continued chronic opioid use and 30-day 
average daily OME dose after curative intent radiation therapy 
Method 
3b Examine average daily OME dose for opioid use overall over time before and after 
curative intent radiation 
Panel data 
models 
3c Predict average daily OME dose between new persistent and continued chronic 
opioid use in the year following radiation therapy 
Mixed linear 
models 
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Results 
Between January 1, 2008 and December 31, 2018, 7,767 patients over the age of 18 
underwent radiation therapy for their malignancies at a single institution (Chapter 2).  Of these 
patients, 1,059 had known opioid exposure status and survived without metastasis or 
recurrence of their disease beyond 5 years (5-Year Cancer Survivors; 5CS), but only 414 
patients had sufficient prescription information to be able to calculate OME or be classified as 
never opioid users (Figure 4.2). In other words, 38.7% (414 / 1,059) of patients with opioid 
prescriptions had sufficient information to calculate OME corresponding to their assigned 
opioid use category. Patients with opioid prescriptions had an average of 6.2 prescriptions 
(Standard Deviation [SD]: 10.8, Median: 2, Interquartile Range [IQR]: 4, Range: 1-79) over the 
course of the study, with average days supply of 29.5 days (Standard Deviation [SD]: 10.7, 
Median: 30, Interquartile Range [IQR]: 0, Range: 14-90) per prescription. 
Table 4.4 describes patient demographics, clinical characteristics, and opioid use 
categories for patients included in this study as well as those in subgroup analyses.  Across 
samples, patients were majority female, white (except VCC being majority African American), 
did not have comorbid conditions (except VCC, with the majority of patients having 
hypertension), had additional surgery and the largest number carried commercial insurance. 
Breast cancer was the most common cancer type (54.2% in the base case). Most patients fell 
in the NOU (85.9%)  category, except when NOU patients were removed for the “No NOU” 
group for which most patients were NPOUs. The VCC and No NOU groups were more likely to 
have comorbidities. Opioid use was much higher in VCC and No NOU groups. Table 4.5 
describes summary statistics of daily OME for prescriptions at each time point. Average OME 
doses were higher following radiation therapy and decreased slightly over time. 
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Figure 4.2: CONSORT Diagram 
 
Table 4.4: Patient Demographics 
  Base Case 
(n = 2,928) 
VCC 
(n = 167) 
No NOU 
(n = 414) 
1 Year 
(n = 3,654) 
3 Year 
(n = 3,115) 
Age      
 Mean (SD) 58.9 (12.1) 53.1 (10.4) 54.8 (12.7) 59.9 (12.4) 59.2 (12.2) 
Median (IQR) 59 (16) 55 (14) 56 (16) 60 (16) 60 (15) 
  N (%) 
Gender      
 Female 2,097 (71.6) 122 (73.1) 230 (55.6) 2,492 (68.2) 2,212 (71.0) 
 Male 831 (28.4) 45 (17.0) 184 (44.4) 1,162 (31.8) 903 (29.0) 
Race      
 Black or African American 955 (32.6) 99 (59.3) 166 (40.1) 1,200 (32.84) 1,201 (32.8) 
 White 1,828 (62.4) 55 (32.9) 229 (55.3) 2,280 (62.4) 1,936 (62.2) 
 Other 145 (5.0) 13 (7.8) 19 (4.6) 174 (4.8) 158 (5.1) 
Insurance Type      
 Commercial 1,268 (43.3) 0 (0) 128 (30.9) 1,445 (39.6) 1,313 (42.2) 
 VCC 167 (5.7) 167 (100) 50 (12.1) 201 (5.5) 173 (5.6) 
 Insurance, Not Specified 212 (7.2) 0 (0) 35 (8.5) 247 (6.8) 218 (7.0) 
 Medicaid 131 (4.5) 0 (0) 45 (10.9) 176 (4.8) 139 (4.5) 
 Medicare 960 (32.8) 0 (0) 101 (24.4) 1,342 (36.7) 1,072 (34.4) 
 Military 40 (1.4) 0 (0) 2 (0.5) 47 (1.3) 42 (1.3) 
 Self-Pay 138 (4.7) 0 (0) 49 (11.8) 175 (4.8) 146 (4.7) 
 Unknown 12 (0.4) 0 (0) 4 (1.0) 21 (0.6) 12 (0.4) 
Cancer Type      
Patients >18 years old with cancer undergoing radiation therapy from 
January 2008 to December 2018 (N = 7,767) 
Base Case 
(n = 2,928) No NOU (n = 414) 
Included in Analysis 
(n = 3,887) 
Clinical Exclusions (n = 3,880): 
- Died within 5 years (n = 2,793) 
- Had disease recurrence within 5 years (n = 233) 
- Metastatic Disease (n = 470) 
- Patient receiving radioisotopes and radium (n = 384) 
Prescription Exclusions: 
- Unknown time of opioid use in relation to radiation (n = 204) 
- Missing necessary prescription information to accurately fit 
opioid exposure group (n = 755) 
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 Breast 1,586 (54.2) 82 (49.1) 100 (24.2) 1,716 (47.0) 1,647 (53.9) 
 Colorectal 164 (5.6) 9 (5.4) 55 (13.3) 219 (6.0) 181 (5.8) 
 Female Genital 113 (3.9) 33 (19.8) 22 (5.3) 142 (3.9) 120 (3.9) 
 Gastrointestinal 71 (2.4) 1 (0.6) 26 (6.3) 151 (4.1) 81 (2.6) 
 Head and Neck 196 (6.7) 8 (4.8) 69 (16.7) 252 (6.9) 212 (6.8) 
 Lung 158 (5.4) 3 (1.8) 42 (10.1) 376 (10.3) 195 (6.3) 
 Prostate 263 (9.0) 18 (10.8) 12 (2.9) 288 (7.9) 278 (8.9) 
 Other 377 (12.9) 13 (7.8) 88 (21.3) 510 (14.0) 401 (12.9) 
Clinical Stage      
 0 261 (9.0) 15 (9.0) 9 (2.2) 275 (76) 269 (8.7) 
 1 818 (28) 37 (22.2) 75 (18.4) 941 (25.8) 861 (27.8) 
 2 734 (25.2) 59 (35.3) 102 (25) 885 (24.3) 776 (25.0) 
 3 345 (11.8) 18 (10.8) 108 (26.5) 580 (15.9) 388 (12.5) 
 Unknown 757 (26.0 38 (22.8) 114 (27.9) 960 (26.4) 808 (26.1) 
Additional Chemotherapy      
 Chemotherapy + 1,254 (42.8) 80 (47.6) 289 (69.8) 1,699 (46.5) 1,354 (43.5) 
 Chemotherapy - 1,674 (57.2) 88 (52.4) 125 (30.2) 1,956 (53.5) 1,762 (56.6) 
Additional Surgery      
 Surgery + 2,093 (71.5) 121 (72.0) 231 (55.8) 2,416 (66.1) 2,195 (70.4) 
 Surgery - 836 (28.5) 47 (28.0) 183 (44.2) 1,239 (33.9) 921 (29.6) 
Comorbid Conditions      
 Anxiety + 302 (10.3) 38 (22.8) 105 (25.4) 370 (10.1) 321 (10.3) 
 Anxiety - 3,626 (89.7) 129 (77.3) 309 (74.6) 3,284 (89.9) 2,794 (89.7) 
       
 Back Pain + 309 (10.6) 45 (27.0) 118 (28.5) 395 (10.8) 337 (10.8) 
 Back Pain -  2,619 (89.5) 122 (73.05) 296 (71.5) 3,295 (89.2) 2,778 (89.2) 
       
 Depression + 208 (7.1) 23 (13.8) 77 (18.6) 258 (7.1) 223 (7.2) 
 Depression - 2,720 (92.9) 144 (86.2) 337 (81.4) 3,396 (92.9) 2,892 (92.8) 
       
 Hypertension + 949 (32.4) 104 (62.3) 204 (49.3) 1,210 (33.1) 1,018 (32.7) 
 Hypertension - 1,979 (67.6) 63 (37.7) 210 (50.7) 2,444 (66.9) 2,097 (67.3) 
       
 Lung Disease + 337 (11.5) 33 (19.8) 127 (30.7) 486 (13.3) 373 (12.0) 
 Lung Disease - 2,591 (88.5) 134 (80.2) 287 (69.3) 3,168 (86.7) 2,742 (88.0) 
Substance Use      
 Alcohol Use + 76 (2.6) 9 (5.4) 36 (8.7) 108 (3.0) 86 (2.8) 
 Alcohol Use - 2,852 (97.4) 158 (94.6) 378 (91.3) 3,546 (97.0) 3,029 (97.2) 
       
 Nicotine Use + 388 (13.3) 58 (34.7) 153 (37.0) 517 (14.2) 418 (13.4) 
 Nicotine Use - 2,540 (86.8) 109 (65.3) 261 (63.0) 3,137 (85.9) 2,697 (86.6) 
       
 Other Drug Use + 65 (2.2) 13 (7.8) 34 (8.2) 99 (2.7) 74 (2.4) 
 Other Drug Use - 2,863 (97.8) 154 (92.2) 380 (91.8) 3,555 (97.3) 3,041 (97.6) 
Opioid Use Status      
 COU 179 (6.1) 26 (15.5) 179 (43.2) 266 (7.3) 196 (6.3) 
 NPOU 220 (7.5) 22 (13.1) 220 (53.1) 352 (9.6) 242 (7.8) 
 POU 15 (0.5) 2 (1.2) 15 (3.6) 17 (0.5) 16 (0.5) 
 NOU 2514 (85.9) 118 (70.2) 0 (0) 3,020 (82.6) 2,662 (85.4) 
COU: Chronic Opioid User; NPOU: New Persistent Opioid User; POU: Previous Opioid 
User; NOU: Never Opioid User; VCC: Virginia Coordinated Care 
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Table 4.5: Summary of Prescriptions by Time Point without NOU 
Day Number of Averaged Prescriptions 
Average OME Dose 
(Std) 
Median OME Dose 
(IQR) Range 
OME 1: -90 194 20.6 (65.7) <0.1 (15.7) <0.1 – 896.0 
OME 2: 90 319 54.9 (132.4) 15.5 (50.4) <0.1 – 1,480.9 
OME 3: 180 362 53.4 (121.6) 17.1 (48.2) <0.1 – 1,511.3 
OME 4: 270 386 51.8 (108.2) 16.2 (46.2) <0.1 – 1,104.6 
OME 5: 360 406 51.9 (105.1) 16.2 (45.6) <0.1 – 962.7 
Total 1667 46.5 (109.6) 12.4 (42.5) <0.1 – 1,511.3 
OME: Oral Morphine Equivalent; Std: Standard Deviation; IQR: Interquartile Range; 
NOU: Never Opioid User 
 
 
Panel Data and Mixed Linear Models 
 Estimation of both model methods resulted in similar estimates of average daily OME 
(Table 4.6). 5CS who had an opioid prescription with a calculated OME 90 days before 
radiation start had substantially higher average daily OME doses than those without an opioid 
before radiation.  On average, the difference was 68.2 (95% CI: 62.8-73.6) from the PDM and 
68.3 (95% CI: 62.9-73.7) from the MLM OMEs, controlling for other factors.  Other 
characteristics that were associated with higher average OMEs over time, controlling for other 
factors, included public insurance compared to private or other types of insurance, comorbid 
conditions of anxiety and depression, and other drug use.  Comorbid diabetes and 
hypertension consistently resulted in significantly lower OMEs across models, controlling for 
other factors. For 5CS, no cancer type was significantly associated with OME dose in the 
panel data model, whereas colorectal, female genital, and head and neck cancers were 
associated with increased OME in the mixed linear model. 
 
Table 4.6: Panel Data and Mixed Linear Models of OME Over Time in 5CS (Base Case) 
 
Panel Data Model Mixed Linear Model 
Significant Theoretical Significant Theoretical 
Characteristic Coefficient (95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Intercept -0.43 (-2.17, 1.31) 0.6290 
3.30 
(-5.67, 12.26) 0.4710 
-1.90 
(-3.68, -0.12) 0.036 
-3.20 
(-12.74, 6.33) 0.5099 
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Average OME 
Per Day -- -- -- -- 
0.01 
(0.01, 0.01) <0.0001 
0.01 
(0.01, 0.01) <0.0001 
Baseline Opioid 
Prescription 
69.86 
(64.55, 75.17) <0.0001 
68.19 
(62.79, 73.60) <0.0001 
69.86 
(64.54, 75.17) <0.0001 
68.33 
(62.93, 73.74) <0.0001 
Age at 
Diagnosis   
-0.11 
(-0.24, 0.02) 0.0850   
-0.11 
(-0.24, 0.02) 0.0925 
Gender (Male) 2.97 (0.13, 5.81) 0.0400 
3.16 
(-1.38, 7.70) 0.1730 
2.97 
(0.13, 5.81) 0.0405 
3.62 
(-0.93, 8.17) 0.1185 
Race (African 
American)   
-2.25 
(-5.08, 0.57) 0.1180   
-2.29 
(-5.12, 0.54) 0.1121 
Insurance 
(Public)   
3.86 
(0.85, 6.87) 0.0120   
3.71 
(0.71, 6.72) 0.0155 
Cancer Type         
 Breast   1.35 (-4.42, 7.11) 0.6470   
6.30 
(-0.32, 12.92) 0.0619 
 Colorectal   0.85 (-5.92, 7.63) 0.8060   
8.94 
(1.15, 16.72) 0.0244 
 Female Genital 
  4.17 
(-3.98, 12.31) 0.3160   
12.55 
(3.47, 21.63) 0.0068 
 Head and Neck 
  4.75 
(-2.15, 11.65) 0.1770   
9.26 
(1.83, 16.70) 0.0146 
 Lung   2.09 (-5.27, 9.44) 0.5780   
6.80 
(-1.16, 14.75) 0.094 
 Prostate   -1.96 (-8.76, 4.83) 0.5720   
2.51 
(-4.80, 9.82) 0.5009 
 Other   3.39 (-2.90, 9.68) 0.2900   
9.78 
(2.90, 16.66) 0.0054 
Comorbid 
Condition         
 Anxiety 12.76 (8.28, 17.24) <0.0001 
11.48 
(6.93, 16.03) <0.0001 
12.76 
(8.28, 17.25) <0.0001 
11.35 
(6.81, 15.89) <0.0001 
 Back Pain   3.23 (-1.13, 7.59) 0.1460   
2.99 
(-1.37, 7.35) 0.1784 
 Depression 7.46 (2.18, 12.75) 0.0060 
6.90 
(1.59, 12.21) 0.0110 
7.46 
(2.17, 12.75) 0.0057 
7.12 
(1.81, 12.42) 0.0086 
 Diabetes -4.63 (-8.93, -0.34) 0.0340 
-4.73 
(-9.06, -0.40) 0.0320 
-4.63 
(-8.93, -0.34) 0.0345 
-4.70 
(-9.03, -0.38) 0.0332 
 Hypertension -3.58 (-6.55, -0.62) 0.0180 
-3.62 
(-6.72, -0.53) 0.0220 
-3.58 
(-6.55, -0.62) 0.0180 
-3.53 
(-6.63, -0.44) 0.0254 
Substance Use         
 Alcohol Use   6.40 (-2.18, 14.97) 0.1440   
7.35 
(-1.25, 15.95) 0.0937 
 Nicotine Use 5.36 (1.31, 9.40) 0.0090 
4.29 
(0.06, 8.52) 0.0470 
5.36 
(1.31, 9.40) 0.0095 
4.16 
(-0.05, 8.36) 0.0529 
 Other Drug Use 
29.82 
(20.80, 38.83) <0.0001 
27.48 
(18.15, 36.81) <0.0001 
29.82 
(20.80, 38.83) <0.0001 
27.12 
(17.79, 36.45) <0.0001 
95% CI: 95% Confidence Interval; Bold indicates statistical significance, p-value <0.05; 
5CS: 5-Year Cancer Survivors 
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Subgroup and Sensitivity Analyses 
VCC Patients 
 In order to assess the robustness of our results, the first subgroup analysis conducted 
involved only patients receiving indigent charity VCC care for which patients receive all care at 
the institution.  This group was identified to specifically address potential for and effects of 
missing prescriptions from outside institutions not captured in this study. In comparison to the 
base case model demographics, patients with VCC were slightly younger, and had a higher 
proportion of African Americans, female genital cancers, comorbid conditions, and substance 
use (Table 4.4). Additionally, there were higher proportions of opioid use including COU and 
NPOU. As in the base case, the PDM and MLM for the VCC group produced similar estimates 
across models (Table 4.7). Comparing the models, average OME over time with presence of 
OME at baseline and OME per day were slightly higher for patients with VCC than the base 
case.  Unlike the base case, being of African American race resulted in statistically significant 
lower OME doses across models over time and controlling for other factors. Additionally, unlike 
the base case, there were no statistically significant clinical factors, such as cancer type, 
comorbid conditions, or substance use across VCC subgroup models, although a significant 
association with nicotine use was seen in the panel data model. 
 
Table 4.7: Panel Data and Mixed Linear Models of OME Over Time in 5CS with VCC 
 
Panel Data Model Mixed Linear Model 
Significant Theoretical Significant Theoretical 
Characteristic Coefficient (95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Intercept 55.35 (16.37, 94.33) 0.0050 
42.13 
(-20.84, 105.10) 0.1900 
52.20 
(12.88, 91.51) 0.0096 
31.66 
(-41.60, 104.93) 0.3945 
Average OME 
Per Day -- -- -- -- 
0.02 
(0.01, 0.03) 0.0006 
0.02 
(0.01, 0.03) 0.0006 
Baseline 
Opioid 
Prescription 
71.56 
(52.64, 90.47) <0.0001 
71.79 
(51.66, 91.93) <0.0001 
71.56 
(52.50, 90.61) <0.0001 
71.82 
(51.51, 92.12) 
<0.000
1 
Age at 
Diagnosis 
-0.83 
(-1.51, -0.15) 0.0170 
-0.69 
(-1.49, 0.11) 0.0900 
-0.83 
(-1.52, -0.14) 0.0183 
-0.68 
(-1.49, 0.12) 0.0958 
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Gender (Male)   -12.85 (-57.12, 31.42) 0.5690   
-8.83 
(-52.61, 34.95) 0.6908 
Race (African 
American) 
-14.96 
(-29.20, -0.73) 0.0390 
-15.82 
(-31.56, -0.09) 0.0490 
-14.96 
(-29.30, -0.62) 0.041 
-16.07 
(-32.00, -0.14) 0.048 
Insurance 
(Public) -- -- -- -- -- -- -- -- 
Cancer Type         
 Breast   8.04 (-38.32, 54.39) 0.7340   
15.39 
(-46.14, 76.93) 0.6218 
 Colorectal   -10.60 (-69.28, 48.08) 0.7230   
6.99 
(-46.17, 60.16) 0.7953 
 Female Genital 
  3.24 
(-63.23, 69.72) 0.9240   
23.92 
(-39.05, 86.89) 0.4541 
 Head and Neck 
  13.46 
(-33.62, 60.55) 0.5750   
17.26 
(-38.24, 72.76) 0.5397 
 Lung   -8.07 (-72.60, 56.45) 0.8060   
-2.49 
(-76.31, 71.33) 0.947 
 Prostate   19.07 (-22.74, 60.88) 0.3710   
22.52 
(-27.88, 72.92) 0.3786 
 Other   13.40 (-44.49, 71.29) 0.6500   
12.87 
(-40.87, 66.61) 0.6367 
Comorbid 
Condition         
 Anxiety   11.67 (-7.86, 31.21) 0.2420   
11.48 
(-8.26, 31.22) 0.2522 
 Back Pain   -7.39 (-25.15, 10.37) 0.4150   
-7.66 
(-7.66, -25.66) 0.4018 
 Depression   -3.63 (-26.21, 18.95) 0.7530   
-3.44 
(-26.21, 19.34) 0.7659 
 Diabetes   -0.63 (-19.75, 18.49) 0.9490   
-0.17 
(-19.46, 19.13) 0.9865 
 Hypertension   -6.18 (-24.04, 11.69) 0.4980   
-6.62 
(-24.67, 11.44) 0.4703 
Substance Use         
 Alcohol Use   -21.62 (-57.99, 14.76) 0.2440   
-22.75 
(-58.43, 12.94) 0.2098 
 Nicotine Use   17.86 (0.56, 35.16) 0.0430   
17.27 
(-0.24, 34.78) 0.0532 
 Other Drug Use 
  -21.33 
(-51.37, 8.72) 0.1640   
-21.17 
(-51.54, 9.19) 0.1702 
N = 414; 95% CI: 95% Confidence Interval; Bold indicates statistical significance, p-
value <0.05 
 
No NOU 
 To further assess the effect of a large proportion of patients with no known opioid 
prescriptions, a second subgroup analysis was conducted excluding patients that fell in the 
NOU group (i.e. those that never had a known prescription, but who could have had outside 
prescriptions that were not captured). Compared to the base case group, the gender split was 
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much more even (far fewer females and breast cancers), suggesting that many females do not 
get opioid prescriptions or that they are not captured (Table 4.4).  A lower proportion of 
patients received surgery, but higher proportions received chemotherapy, had comorbid 
diseases, and reported substance use. Comparing the models to the base case, average OME 
per day over time controlling for other factors was higher, while those with baseline opioid 
prescriptions were more than 10 OMEs lower overall across models (Table 4.8). Anxiety and 
other drug use remained statistically significant with OMEs more than double that of the base 
case overall, controlling for other factors and across models. 
 
Table 4.8: Panel Data and Mixed Linear Models of OME Over Time in 5CS (No Unknown 
OME) 
 
Panel Data Model Mixed Linear Model 
Significant Theoretical Significant Theoretical 
Characteristic Coefficient (95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Intercept 4.89 (-7.97, 17.76) 0.4560 
5.76 
(-47.64, 59.16) 0.8330 
-5.53 
(-18.65, 7.60) 0.4082 
-24.32 
(-79.64, 31.01) 0.3880 
Average OME 
Per Day -- -- -- -- 
0.06 
(0.05, 0.08) <0.0001 
0.06 
(0.05, 0.08) <0.0001 
Baseline 
Opioid 
Prescription 
54.85 
(37.31, 72.39) <0.0001 
55.75 
(37.79, 73.70) <0.0001 
54.85 
(37.26, 72.44) <0.0001 
56.53 
(38.61, 74.44) <0.0001 
Age at 
Diagnosis   
-0.20 
(-1.00, 0.59) 0.6160   
-0.18 
(-0.97, 0.62) 0.6657 
Gender (Male)   15.60 (-7.58, 38.77) 0.1870   
18.51 
(-4.78, 41.80) 0.1190 
Race (African 
American)   
-11.81 
(-30.94, 7.33) 0.2270   
-13.71 
(-32.85, 5.42) 0.1597 
Insurance 
(Public)   
16.09 
(-2.44, 34.62) 0.0890   
14.14 
(-4.42, 32.70) 0.1350 
Cancer Type         
 Breast   0.97 (-32.20, 34.13) 0.9540   
21.55 
(-15.96, 59.07) 0.2594 
 Colorectal   -9.18 (-42.28, 23.91) 0.5870   
23.27 
(-13.68, 60.22) 0.2165 
 Female Genital 
  9.50 
(-37.38, 56.38) 0.6910   
45.42 
(-5.73, 96.57) 0.0816 
 Head and Neck 
  5.27 
(-27.49, 38.04) 0.7520   
22.34 
(-13.01, 57.70) 0.2149 
 Lung   5.23 (-31.67, 42.13) 0.7810   
23.75 
(-16.26, 63.76) 0.2440 
 Prostate   -27.72 0.3460   -10.09 0.7382 
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(-85.42, 29.98) (-69.38, 49.21) 
 Other   14.50 (-18.82, 47.81) 0.3940   
39.85 
(4.44, 75.26) 0.0275 
Comorbid 
Condition         
 Anxiety 41.22 (21.26, 61.18) <0.0001 
37.56 
(14.97, 60.15) 0.0010 
41.22 
(21.21, 61.24) <0.0001 
36.13 
(13.63, 58.63) 0.0017 
 Back Pain   6.72 (-13.92, 27.37) 0.5230   
4.37 
(-16.35, 25.09) 0.6784 
 Depression   16.91 (-8.29, 42.12) 0.1880   
18.12 
(-7.05, 43.29) 0.1577 
 Diabetes   -18.73 (-43.10, 5.63) 0.1320   
-18.49 
(-42.79, 5.81) 0.1354 
 Hypertension   -16.70 (-36.42, 3.03) 0.0970   
-16.85 
(-36.53, 2.83) 0.0932 
Substance Use         
 Alcohol Use   3.08 (-31.60, 37.76) 0.8620   
5.34 
(-29.33, 40.02) 0.7621 
 Nicotine Use   10.54 (-9.95, 31.04) 0.3130   
10.11 
(-10.19, 30.41) 0.3282 
 Other Drug Use 
66.44 
(34.61, 98.28) <0.0001 
47.52 
(12.31, 82.73) 0.0080 
66.44 
(34.52, 98.37) <0.0001 
48.43 
(13.33, 83.53) 0.0070 
95% CI: 95% Confidence Interval; Bold indicates statistical significance, p-value <0.05 
 
Sensitivity Analysis 3: Lived Without Recurrence, Metastatic Disease, or Death for at Least 3 
Years 
 The next sensitivity analysis allowed for patients who only survived a minimum of 3 
years beyond cancer diagnosis without recurrence or death (3CS) to be included.  The 
additional two years of data resulted in an additional 187 patients compared to the base case. 
The demographics of patients in this group were very similar to that of the base case (Table 
4.4).  Comparing the estimates of the models to the base case, average OME per day was 
very similar, while those with a baseline prescription, public insurance, certain cancers, 
depression, alcohol use, and other drug use had higher OMEs across models (Table 4.9).   
 
Table 4.9: Panel Data and Mixed Linear Models of OME Over Time in Cancer (3CS) 
 
Panel Data Model Mixed Linear Model 
Significant Theoretical Significant Theoretical 
Characteristic Coefficient (95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
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Intercept -0.07 (-1.92, 1.79) 0.9430 
10.01 
(-0.50, 20.52) 0.0620 
-1.72 
(-3.61, 0.17) 0.0750 
-2.13 
(-13.29, 9.02) 0.7076 
Average OME 
Per Day -- -- -- -- 
0.01 
(0.01, 0.01) <0.0001 
0.01 
(0.01, 0.01) <0.0001 
Baseline 
Opioid 
Prescription 
72.59 
(66.43, 78.75) <0.0001 
70.54 
(64.23, 76.84) <0.0001 
72.59 
(66.43, 78.76) <0.0001 
70.64 
(64.34, 76.93) <0.0001 
Age at 
Diagnosis   
-0.15 
(-0.30, 00-.00) 0.0430   
-0.15 
(-0.30, 0.00) 0.0530 
Gender (Male)   -0.43 (-5.62, 4.76) 0.8710   
0.31 
(-4.89, 5.51) 0.9058 
Race (African 
American)   
-1.84 
(-5.15, 1.48) 0.2780   
-1.85 
(-5.16, 1.46) 0.2726 
Insurance 
(Public)   
5.64 
(2.11, 9.18) 0.0020   
5.39 
(1.86, 8.92) 0.0028 
Cancer Type         
 Breast   -4.03 (-10.74, 2.68) 0.2390   
6.09 
(-1.56, 13.75) 0.1185 
 Colorectal   0.56 (-7.26, 8.38) 0.8890   
9.81 
(0.84, 18.77) 0.0321 
 Female Genital 
  4.15 
(-5.35, 13.65) 0.3920   
13.78 
(3.23, 24.34) 0.0105 
 Head and Neck 
  0.02 
(-8.04, 8.07) 0.9970   
9.43 
(0.82, 18.04) 0.0319 
 Lung   -1.88 (-10.16, 6.39) 0.6560   
7.80 
(-1.14, 16.73) 0.0871 
 Prostate   -4.35 (-12.33, 3.63) 0.2850   
4.99 
(-3.48, 13.46) 0.2484 
 Other   -0.48 (-7.84, 6.88) 0.8980   
14.00 
(6.02, 21.99) 0.0006 
Comorbid 
Condition         
 Anxiety 9.70 (4.42, 14.98) <0.0001 
8.48 
(3.14, 13.83) 0.0020 
9.70 
(4.42, 14.99) 0.0003 
8.50 
(3.17, 13.84) 0.0018 
 Back Pain 6.94 (1.89, 11.99) 0.0070 
6.78 
(1.70, 11.86) 0.0090 
6.94 
(1.89, 11.99) 0.0071 
6.50 
(1.43, 11.57) 0.0120 
 Depression 13.45 (7.24, 19.67) <0.0001 
13.49 
(7.26, 19.71) <0.0001 
13.45 
(7.23, 19.67) <0.0001 
13.72 
(7.50, 19.94) <0.0001 
 Diabetes   -7.18 (-12.22, -2.14) 0.0050   
-7.02 
(-12.05, -1.99) 0.0062 
 Hypertension -4.79 (-8.07, -1.52) 0.0040 
-3.20 
(-6.84, 0.43) 0.0840 
-4.79 
(-8.07, -1.51) 0.0042 
-3.03 
(-6.66, 0.61) 0.1025 
Substance Use         
 Alcohol Use 15.40 (5.91, 24.89) 0.0010 
12.90 
(3.12, 22.67) 0.0100 
15.40 
(5.90, 24.89) 0.0015 
14.12 
(4.34, 23.90) 0.0047 
 Nicotine Use   3.58 (-1.34, 8.50) 0.1530   
3.66 
(-1.23, 8.55) 0.1424 
 Other Drug Use 
41.67 
(31.43, 51.91) <0.0001 
38.10 
(27.54, 48.67) <0.0001 
41.67 
(31.43, 51.92) <0.0001 
37.66 
(27.10, 48.22) <0.0001 
95% CI: 95% Confidence Interval; Bold indicates statistical significance, p-value <0.05; 
3CS: 3-year Cancer Survivors 
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Sensitivity Analysis 4: Lived Without Recurrence, Metastatic Disease, or Death for at Least 1 
Year (1CS) 
 The fourth sensitivity analysis allowed for an additional two years of data that included 
patients surviving at least one year following diagnosis (1CS). 1CS had similar demographics 
to those in the base case and in the 3CS group (Table 4.4). Estimates in the 1CS models 
followed similar trends to as the 3CS models, with some characteristics having estimates 
slightly larger in magnitude (Table 4.10). Notably, this was the first group to have statistically 
significant estimates of higher OMEs for males compared to females. 
 
Table 4.10: Panel Data and Mixed Linear Models of OME Over Time in Cancer (1yr) 
 
Panel Data Model Mixed Linear Model 
Significant Theoretical Significant Theoretical 
Characteristic Coefficient (95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Coefficient 
(95% CI) P-value 
Intercept 7.63 (-0.05, 15.32) 0.0520 
16.22 
(5.85, 26.59) 0.0020 
5.22 
(-2.48, 12.92) 0.1837 
3.82 
(-6.79, 14.42) 0.4806 
Average OME 
Per Day -- -- -- -- 
0.01 
(0.01, 0.02) <0.0001 
0.01 
(0.01, 0.02) <0.0001 
Baseline 
Opioid 
Prescription 
72.21 
(66.21, 78.21) <0.0001 
71.66 
(65.63, 77.70) <0.0001 
72.21 
(66.21, 78.21) <0.0001 
71.88 
(65.85, 77.90) <0.0001 
Age at 
Diagnosis 
-0.14 
(-0.26, -0.01) 0.0300 
-0.25 
(-0.40, -0.11) 0.0010 
-0.14 
(-0.26, -0.01) 0.0297 
-0.24 
(-0.39, -0.09) 0.0017 
Gender (Male) 4.34 (1.04, 7.65) 0.0100 
4.97 
(0.16, 9.77) 0.0430 
4.34 
(1.04, 7.65) 0.0100 
5.39 
(0.59, 10.19) 0.0279 
Race (African 
American)   
-1.95 
(-5.31, 1.41) 0.2560   
-1.94 
(-5.30, 1.41) 0.2560 
Insurance 
(Public)   
6.20 
(2.64, 9.77) 0.0010   
5.89 
(2.32, 9.45) 0.0012 
Cancer Type         
 Breast   -4.48 (-10.81, 1.86) 0.1660   
4.69 
(-1.91, 11.28) 0.1635 
 Colorectal   -2.33 (-10.01, 5.34) 0.5510   
4.88 
(-3.32, 13.08) 0.2434 
 Female Genital 
  7.11 
(-2.25, 16.47) 0.1370   
14.59 
(4.75, 24.44) 0.0037 
 Head and Neck 
  -2.75 
(-10.58, 5.09) 0.4920   
5.93 
(-1.99, 13.85) 0.1422 
 Lung   -3.77 (-10.91, 3.37) 0.3010   
5.07 
(-2.23, 12.37) 0.1736 
 Prostate   -9.55 (-17.41, -1.68) 0.0170   
-0.88 
(-8.81, 7.05) 0.8287 
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 Other   -1.68 (-8.61, 5.25) 0.6340   
13.53 
(6.39, 20.67) 0.0002 
Comorbid 
Condition         
 Anxiety 7.03 (1.60, 12.45) 0.0110 
5.94 
(0.50, 11.39) 0.0320 
7.03 
(1.60, 12.45) 0.0111 
6.01 
(0.58, 11.45) 0.0301 
 Back Pain 11.70 (6.57, 16.83) <0.0001 
11.44 
(6.30, 16.58) <0.0001 
11.70 
(6.57, 16.83) <0.0001 
10.95 
(5.81, 16.09) <0.0001 
 Depression 9.62 (3.27, 15.96) 0.0030 
9.87 
(3.51, 16.22) 0.0020 
9.62 
(3.27, 15.97) 0.0030 
9.86 
(3.52, 16.20) 0.0023 
 Diabetes   -5.69 (-10.68, -0.69) 0.0260   
-5.52 
(-10.51, -0.53) 0.0303 
 Hypertension -5.69 (-9.06, -2.31) 0.0010 
-4.25 
(-7.93, -0.57) 0.0240 
-5.69 
(-9.06, -2.31) 0.0010 
-4.08 
(-7.76, -0.41) 0.0296 
Substance 
Use         
 Alcohol Use 14.83 (5.31, 24.36) 0.0020 
14.16 
(4.59, 23.73) 0.0040 
14.83 
(5.30, 24.37) 0.0023 
15.17 
(5.60, 24.74) 0.0019 
 Nicotine Use 5.83 (1.04, 10.63) 0.0170 
5.08 
(0.19, 9.97) 0.0420 
5.83 
(1.04, 10.63) 0.0171 
5.18 
(0.32, 10.05) 0.0369 
 Other Drug Use 
29.42 
(19.36, 39.36) <0.0001 
28.52 
(18.44, 38.61) <0.0001 
29.42 
(19.35, 39.48) <0.0001 
28.66 
(18.59, 38.73) <0.0001 
95% CI: 95% Confidence Interval; Bold indicates statistical significance, p-value <0.05 
 
 
Predictions of estimated average daily OME following radiation from the mixed linear 
models of each subgroup were calculated and presented in Table 4.11. 
 
Table 4.11: Prediction of Average Daily OME in Cancer Survivors Following Radiation 
OME (95% CI) 
Group Estimate 90 days 180 days 270 days 360days 
5CS 0.0091 (0.0069, 0.0113) 
1.64 
(1.25, 2.03) 
2.46 
(1.88, 3.04) 
3.27 
(2.50, 4.05) 
4.09 
(3.13, 5.06) 
Subgroups 
5CS VCC 0.0195 (0.0084, 0.0305) 
3.50 
(1.51, 5.50) 
5.25 
(2.27, 8.24) 
7.01 
(3.03, 10.99) 
8.76 
(3.78, 13.74) 
5CS No NOU 0.0643 (0.0494, 0.0793) 
11.58 
(8.89, 14.27) 
17.37 
(13.33, 21.41) 
23.16 
(17.78, 28.54) 
28.95 
(22.22, 35.68) 
3CS 0.0102 (0.0079, 0.0125) 
1.83 
(1.42, 2.24) 
2.75 
(2.14, 3.36) 
3.67 
(2.85, 4.49) 
4.59 
(3.56, 5.61) 
1CS 0.0149 (0.0123, 0.0175) 
2.68 
(2.21, 3.15) 
4.02 
(3.32, 4.72) 
5.36 
(4.42, 6.30) 
6.70 
(5.53, 7.87) 
OME: Oral Morphine Equivalent; 95% CI: 95% Confidence Interval; 5CS: 5-Year Cancer 
Survivors; 3CS: 3-Year Cancer Survivors; 1CS: 1-Year Cancer Survivors 
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Discussion 
 This is the first study to evaluate opioid doses utilized following radiation in cancer 
survivors. From this study, we can see that many cancer survivors do not utilize opioids long 
term before or after radiation. However, sustained doses of opioids are used for those that took 
opioids to manage cancer and treatment related pain, particularly for patients with baseline 
(pre-radiation) opioid prescriptions with measurable OMEs. This study determined that for 
patients with baseline opioid prescriptions, average OME dose was 62.8-73.3 higher over the 
course of the study than patients without baseline opioid prescriptions from both models used.  
While there are no opioid prescribing guidelines specifically for patients with cancer or 
those that have undergone cancer treatment, there are guidelines for opioid dosing in non-
cancer pain. The 2016 chronic opioid prescribing guidelines for non-cancer pain (where cancer 
pain is explicitly excluded) recommend avoiding daily OME doses greater than 90 and for 
prescribers to use caution with daily OME doses greater than 50.20  In this study, we saw 
prescribed OME on average around the recommendation of non-cancer pain, but with large 
variations far above the recommended limit. For those with baseline opioid prescriptions 
across all models, average OME doses over time fell within non-cancer pain 
recommendations. This suggests that while pain guidelines explicitly exclude cancer pain, 
prescribers may have followed non-cancer prescribing recommendations when prescribing for 
cancer patients. 
 In this study, we found that factors contributing to higher average OMEs over time were 
dependent on demographics rather than cancer related clinical characteristics. Our results 
have shown that public insurance, comorbid conditions, and substance use resulted in higher 
OMEs over time, controlling for other factors. We did not find that cancer related clinical 
factors, especially additional treatments such as chemotherapy or surgery, were associated 
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with opioid dose. We only observed OME dose associations with cancer type in some models 
(5CS MLM [increased dose with colorectal, female genital, and head and neck cancers]; 3CS 
MLM[increased dose with colorectal, female genital, head and neck cancers]; 1CS PDM 
[decreased dose with prostate cancer] and MLM [increased dose with colorectal, female 
genital, head and neck cancers]) This is in contrast to what we showed in Chapter 3 where 
initiation of long-term opioid use was associated with cancer type and treatment. This suggests 
that opioid dose, but not use, is patient specific regardless of their cancer diagnosis or 
treatment regimen. This may be the reason why diabetes and hypertension were not shown to 
be associated with NPOU in Chapter 3, but shown in this study to be associated with lower 
average OMEs over time. Patients with these chronic conditions may be receiving closer and 
more regular primary care management, resulting in high provider attention and management 
of prescription medications including opioids. 
 While age at diagnosis was not a factor that was statistically significant across all cases 
and models, the direction of the association was consistent with prior chapters of increasing 
age being associated with lower opioid use. As suggested in Chapter 3, patients of younger 
age may have more aggressive disease or are given a more aggressive treatment strategy to 
prolong life resulting in a higher opioid requirement. Additionally, physicians may be more 
cautious in opioid dose prescribing for patients of increasing age due to concerns related to 
opioids including sedation, fall risk, and risk of side effects including opioid induced 
constipation. 
From the subgroup analyses of this study, removing no known opioid prescriptions 
resulted in higher doses across characteristics and models, suggesting that our base case 
estimates are conservative estimates of opioid dose use in cancer survivors. Notably anxiety 
and other drug use estimates double when potentially unknown OMEs are removed. The 
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effects of these two characteristics may be underestimated in the base case model and 
therefore should be screened for in cancer survivors using opioids long-term for risk of high 
dose use. Subgroup analysis including patients that survived less than one and three years 
after cancer diagnosis resulted in similar estimates across characteristics and models 
supporting the robustness of our results. However, as patients had lower survival, there were 
slight increases in opioid doses which may be related to the severity of disease.  Notably in 
patients that only survived one year following cancer diagnosis, males were significantly 
associated with higher opioid doses over time controlling for other factors. This finding echoes 
what was seen in Chapter 2 and could be a real effect that is undetected due to insufficient 
power in the base case model.  
Subgroup analysis of patients with VCC resulted in statistically significant associations 
with race.  Patients with VCC of African American race had lower estimates of OME doses 
over time, controlling for other factors. This corresponds with the results from Chapter 2. While 
not statistically significant, the direction of the race estimate is also seen in the base case. This 
could be due to the capture of all prescriptions in patients with VCC or inherent differences 
between patients in the base case and patients that utilize VCC. Inherent differences between 
the VCC group and the base case are underscored by the lack of significant associations 
related to comorbid conditions and substance use in patients with VCC. While differences exist 
between the 5CS and VCC groups, the findings of the VCC subgroup reinforce the baseline 
opioid prescription finding.  Additionally, the differences between the groups were all in the 
same direction: VCC patients being sicker, and therefore, may serve as a high end extreme. 
Predicting average OME dose following radiation from the MLM of various groups 
suggests that undergoing cancer radiation therapy results in at least some long-term opioid 
dose use. When patients not suspected of using opioid prescriptions are included in the model, 
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predicted opioid dose use is relatively small overall. However, when patients with no known 
OMEs are removed, predicted OME doses following radiation therapy are about three times 
higher. Therefore, predicted doses of the base case are likely conservative estimates of long-
term opioid dose.  
 
Limitations 
This study had several limitations. First, this study only included patients at a single, 
urban, academic institution. Providers here may have different pain management practices or 
preferences that may not be nationally representative.  Thus, the results of this study may only 
be generalizable to other academic institutions of similar size, patient population, and 
geography.  
Our analyses utilized prescription data rather than fill data. This raises the possibility of 
patients not filling prescriptions.  Also, our analysis does not include opioid prescriptions 
written by doctors outside of the institution. This could have resulted in underestimation of 
opioid use overall and opioid dose.  Additionally, 38.7% of patients had prescriptions that were 
missing variables necessary to calculate OME to fall within their pre-determined opioid use 
classification (NPOU, COU, NOU, POU). To the best of our ability, we verified prescription use 
over time and did not include patients with missing OME prescriptions that resulted in OME 
use contrary to opioid use classification. In order to address missing prescriptions that would 
have resulted in different opioid utilization classifications, we conducted two subgroup 
analyses: first, with VCC patients for which we have all prescription data and second, removing 
patients with no known opioid prescriptions. Second, the NOU group is the group with the 
highest likelihood of having missed prescriptions (written outside the institution) since we could 
not capture any prescriptions for those patients, in other categories we have at least some 
prescription information and some confidence in the accuracy of their prescriptions. Average 
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OME over time with presence of OME at baseline and OME per day were higher for both 
subgroups (patients with VCC and excluding NOU patients) than the base case. From the VCC 
subgroup, being of African American race resulted in statistically significant lower OME doses.  
We could not differentiate the indication of opioid prescription to be due to cancer or 
non-cancer pain. Opioid prescriptions due to cancer pain would be, in theory, easier to 
discontinue than those for non-cancer pain because curative intent therapy would remove or 
reduce the underlying inciting malignancy. Lastly, this study can only be generalized to 
patients with cancer that receive radiation, as all of the patients in the study received radiation. 
 
Conclusion 
In conclusion, we determined that on average, cancer survivors that undergo radiation 
and have a baseline opioid prescription use about 68 OMEs more per day than those that do 
not, controlling for other factors.  Patients with public insurance, anxiety and depression, and 
substance use are associated with higher average OMEs over time. Conversely, patients with 
diabetes and hypertension are associated with lower average OMEs over time. Controlling for 
other factors, we predict that patients that undergo radiation for their cancer will use, on 
average, 4.1 OMEs (2.7mg of oxycodone 5CS) per day including NOU, or 29.0 OMEs (19.3mg 
of oxycodone) per day for No NOU one year after the end of radiation. These findings warrant 
evidence-based recommendations and guidelines for opioid use and discontinuation in cancer 
survivors receiving radiation to prevent misuse and opioid related deaths. 
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 CHAPTER 5: TIME TO DISCONTINUATION OF OPIOIDS IN PATIENTS WITH CANCER 
AFTER CURATIVE INTENT RADIATION 
Abstract 
Background: There is growing awareness of long-term opioid use after curative intent 
radiotherapy in cancer survivors as the number of patients surviving cancer increases. Patients 
receiving curative intent radiotherapy should be able to discontinue opioids soon after 
treatment, although this has not been studied. Objective: Examine the time patients with 
cancer receiving curative intent radiation (CIR) remain on opioids after curative intent 
treatment and examine associated factors to help identify patients that may have difficulty 
weaning off opioid regimens. Methods: Electronic medical record clinical and opioid 
prescription data of cancer survivors from a single academic institution between January 1, 
2008 and December 31, 2018 was utilized. Kaplan Meier survival models were used to 
estimate time to discontinuation (TTD) of opioids after end of radiation therapy. Stepwise Cox 
proportional hazards models were employed to identify factors associated with time until opioid 
discontinuation. Results: For cancer survivors receiving opioid prescriptions following radiation, 
median TTD of opioids was 16.8 months (95% CI: 13.1-19.1 months) following the end of 
radiation. Median TTD of opioids was shorter for patients without opioid exposure prior to 
therapy (NPOU; 13.0 months, 95% CI: 10.0-17.3 months) compared to patients with opioid 
exposure prior to therapy (COU; 21.4 months, 95% CI: 17.5-28.8 months) (p-value = 0.0004). 
Factors associated with shorter TTD included: new persistent opioid use (NPOU; no opioid 
exposure prior to radiation) compared to chronic opioid use (COU; opioid exposure prior to 
radiation) (HR: 1.35, 95% CI: 1.07-1.71) and head and neck cancers (HR: 1.60, 95% CI: 1.01-
2.53) in comparison to breast cancer. Conversely, additional surgery (HR: 0.68, 95% CI: 0.50-
0.91), death after more than five years of diagnosis (HR: 0.55, 95% CI: 0.34-0.91), as well as 
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alcohol (HR: 0.63, 95% CI: 0.42-0.95) and nicotine (HR: 0.78, 95% CI: 0.62-0.98) use were 
associated with longer TTD of opioids. Discussion: Cancer survivors continue receiving opioid 
prescriptions for almost a year and a half after completion of CIR. Patients receiving additional 
surgery and those with alcohol and nicotine use are at higher risk. Patients with NPOU and 
head and neck cancers have shorter TTD. Conclusion: Evidence based guidelines for clinical 
management of opioid use in cancer survivors after CIR are warranted due to high numbers of 
patients that continue to use opioids long after CIR. 
 
Background 
Five-year survival from cancer has increased from less than 50% in the 1970s to a 
mean of 69.6% in 2011 (with a large range based on cancer site).1,2 This increase in survival 
has led to an increase in both the aggregate number of cancer survivors and also the duration 
of time patients spend in the survivorship period. Pain management is an important 
consideration for patients with cancer, as malignancies can lead to significant pain in addition 
to pain resulting from invasive surgery, chemotherapy, and radiation. Opioids are a 
cornerstone of pain management for cancer patients.3–5 Curative intent therapy (treatment to 
cure) with surgery and/or radiation subjects patients to burdensome acute and delayed 
treatment-related pain, but in theory, removes underlying painful malignancies and associated 
morbidity long-term. Pain in cancer survivors that have undergone curative intent therapy is 
poorly characterized and there is little to no consensus on the therapeutic framework of 
treating pain for these patients.6  As more patients are surviving cancer, continued opioid use 
after curative intent therapy is of greater concern.  
 A goal of curative intent therapy is to remove the underlying cause of pain so that pain 
management with opioids is no longer needed.  However, discontinuing opioids in patients with 
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chronic pain can be quite difficult. A study of non-cancer chronic pain patients found that 65-
67% of patients receiving chronic opioids remained on treatment after five years.7 Another 
study utilizing a national representative database (Truven Health Marketscan) of non-cancer 
patients found that 43-87% of patients continue opioids beyond two years, and more troubling, 
“drug abuse and overdose rates increased with longer use.”8  Additionally, from a combined 
cohort study and meta-analysis published in 2020, cancer-related pain and opioid 
requirements (including high-dose opioids) are associated with poor survival in patients with 
cancer.9 Therefore, decreasing cancer pain burden and ultimately, discontinuation of opioids, 
while potentially difficult, should be an essential part of cancer survivor care. 
Discontinuation of opioids following curative intent treatment has not been studied well. 
A study of non-cancer patients using chronic opioids receiving non-orthopedic surgery 
matched to non-surgical chronic opioid users found that surgery was associated with a 34% 
likelihood of discontinuation of opioids after one year.10 Oxycodone use, higher opioid dose, 
COPD, and dementia were associated with reduced odds of discontinuation. One study 
investigating opioid discontinuation in patients with oropharyngeal cancer from the 
Surveillance, Epidemiology and End Results (SEER)–Medicare database reported median 
time on opioids of 3 weeks (95% confidence interval, 3.00-4.00) and mean of 7.37 (SE: 0.31) 
weeks censoring at 6 months after treatment.11  
Radiotherapy has a role in pain mitigation and is used in the palliative setting as a non-
invasive adjunctive treatment to complement opioid therapy and minimize opioid 
dependence.12 Approximately 50% of cancer patients will receive radiation therapy as a 
component of their treatment.13 Patients receiving curative intent radiotherapy should be able 
to discontinue opioids after treatment, although this has not been studied. Understanding the 
duration that patients with cancer remain on opioids after curative intent radiation (CIR) and 
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the patient factors associated with time to discontinuation (TTD) may assist in identifying 
patients that have difficulty weaning off opioid regimens.  The objective of this study is to 
describe opioid use by TTD in the months following radiation and factors associated with 
length of TTD (Table 5.1 – Specific Aim 3d). 
 
Table 5.1: Methods for Specific Aim 3 
 
Methods 
Data Source, Patient Identification, and Patient Covariates 
We utilized electronic medical record data from cancer survivors who received 
radiotherapy for any indication at Virginia Commonwealth University Massey Cancer Center 
between January 1, 2008 and December 31, 2018. Patients 18 years of age or older with any 
cancer type and stage receiving radiation with or without any additional treatment modalities 
(i.e. surgery, chemotherapy) were included. We only included patients that classified as cancer 
survivors, defined as the absence of metastatic disease or recurrence within 5 years of 
diagnosis. Prisoners were excluded. Relevant covariates potentially associated with continued 
opioid use after radiation included cancer type, stage, treatment type, comorbid conditions, 
germane social history (nicotine use), and demographic information (age, race, and insurance 
status and type – including Virginia Coordinated Care [VCC], the institution sponsored health 
insurance for indigent patients for which all medical records should be). Patients with 
prescribed opioid medications were included if prescriptions were written for the outpatient 
setting, written after the radiation therapy end date, and written for at least a 14-day supply. 
Specific Aim 3 
In cancer survivors who received curative intent radiation therapy for 
their malignancy, examine new persistent and continued chronic 
opioid use and 30-day average daily OME dose after radiation therapy 
Method 
3d Describe opioid use by time to discontinuation in the months 
following radiation 
Kaplan-Meier Survival & Cox 
Proportional Hazard Models 
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Patients receiving opioid prescriptions were followed for 36 months following end of radiation. 
There were 872 patients that met these criteria. 
 
Opioid Discontinuation 
 Patients were followed from the end date of radiation to the last day of available 
prescribed opioids (last day-supply prescribed based on date prescribed and calculated total 
day-supply). Patients were censored if (1) the maximum encounter date documented from the 
electronic medical record fell before the last day of the last prescribed opioid, (2) the date of 
death fell before the last day of the last prescribed opioid, or (3) the study period ended before 
the last day of the last prescribed opioid. 
 
Statistical Analysis 
Descriptive statistics including means, medians, standard deviations, and interquartile 
ranges were calculated for patient clinical and sociodemographic characteristics. One-way 
ANOVA was conducted for continuous variables against opioid exposure status. Chi-squared 
tests were used on categorical variables with Fisher’s exact test used when expected cell 
counts were less than 5.  P-values of <0.05 were considered statistically significant. Table 5.1 
describes the methods associated with Specific Aim 3. Kaplan Meier survival models were 
used to estimate TTD of opioids after the end of radiation therapy. Subsequently, Cox 
proportional hazards models were conducted with the SAS stepwise selection process using 
criterion of p<=0.05 to select and retain significant variables. Categorical variables for 
comorbid conditions and substance used were coded as “1”= yes, presence of comorbid 
condition or substance use or “0”=no, with “0” being the reference group.  Reference groups 
for other categorical variables were as noted in the results table. A final model was built with 
relevant clinical factors and significant factors from the stepwise model to determine 
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associations with time until opioid discontinuation. Statistical analyses were conducted using 
Stata v15.1 and SAS v9.4 (SAS Institute, Cary, NC). 
 
Subgroup Analyses 
To determine if prior use of chronic opioid medications was associated with 
discontinuation, patients were grouped by opioid exposure prior to radiation therapy by 
previously described methods (Chapter 3).14,15 Patients were initially stratified by opioid 
exposure as opioid naïve (ON) or opioid exposed (OE). They were then categorized as: New 
Persistent Opioid User (NPOU: ON prior to radiation, but continued use after radiation) or 
Chronic Opioid User (COU: OE prior to radiation and continued use after radiation) (Table 
5.2).14,16  Lastly, in order to determine if differences existed due to potentially missed opioid 
prescriptions written outside of the institution and thus not captured, we conducted a subgroup 
analysis for patients with VCC for which we had full prescription data.  
 
Table 5.2: Summary of Patient Groups by Opioid Exposure 
 Group  Abbreviation Definition  
Pre-Radiation Treatment 
 Opioid Naïve ON No known prescribed opioids greater than or equal to 30 days 
before treatment 
 Opioid Exposed OE Known opioids prescribed greater than or equal to 30 days before 
treatment 
Pre- and Post-Radiation Treatment 
 Chronic Opioid User COU Prescribed at least one opioid prescription 30 days before treatment 
(OE) and at least one opioid prescription 30 days after treatment 
 New Persistent Opioid 
User 
NPOU Previously ON who was prescribed at least one opioid prescription 
30 after treatment 
 
Results 
 The majority of patients in this study were white (52.2%) and female (62.6%).  The high 
proportion of females may be due to the high proportion of breast cancers (32.5%) in the 
sample. The majority of patients had additional chemotherapy (59.5%) or surgery (57.9%). 
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However, the majority of patients did not have comorbid conditions or use alcohol or nicotine 
(Table 5.3). 
Overall, median TTD of opioids for all patients was 16.8 months/1.4 years (95% CI: 
13.6-19.1 months, Figure 5.1). Factors associated with shorter TTD of opioids included: NPOU 
compared to COU (HR: 1.35, 95% CI: 1.07-1.71) and head and neck cancer (HR: 1.60, 
95%CI: 1.01-2.53) when compared to breast cancer (Table 5.4). Conversely, additional 
surgery (HR: 0.68, 95% CI: 0.50-0.91), death more than five years after diagnosis (HR: 0.55, 
95% CI: 0.34-0.91), as well as alcohol (HR: 0.63, 95% CI: 0.42-0.95) and nicotine (HR: 0.78, 
95% CI: 0.62-0.98) use were associated with longer TTD. 
 
Table 5.3: Demographics of 5CS Overall and by Opioid Exposure 
Characteristic 
Overall 
(n = 872) 
 COU 
(n = 227, 26%) 
NPOU 
(n = 645, 74%) P-value 
  Mean (Std) Median (IQR)  Mean (Std) Mean (Std)  
Age 56.4 (12.2) 57 (15)  55.5 (11.8) 56.7 (12.4) 0.2076 
  N %  N (%) N (%)  
Gender      0.0270* 
 Female 546 62.6  156 (68.7) 390 (60.5)  
 Male 326 37.4  71 (31.3) 255 (39.5)  
Race      0.0124* 
 African American 378 43.4  111 (48.9) 267 (41.4)  
 Other 39 4.5  15 (6.6) 24 (3.7)  
 White 455 52.2  101 (44.5) 354 (54.9)  
Insurance Type      0.1326 
 Commercial 265 30.4  64 (28.2) 201 (31.2)  
 VCC 89 10.2  34 (15.0) 55 (8.5)  
 Insurance, Not Specified 79 9.1  18 (7.9) 61 (9.5)  
 Medicaid 86 9.9  28 (12.3) 58 (9.0)  
 Medicare 250 28.7  57 (25.1) 193 (30.0)  
 Military 7 0.8  2 (0.9) 5 (0.8)  
 Self-Pay 87 10.0  22 (9.7) 65 (10.1)  
 Unknown 9 1.0  2 (0.9) 7 (1.1)  
Cancer Type      <0.0001* 
 Breast 283 32.5  103 (45.4) 180 (27.9)  
 Colorectal 78 8.9  11 (4.8) 67 (10.4)  
 Female Genital 60 6.9  5 (2.2) 55 (8.5)  
 Gastrointestinal 34 3.9  12 (5.8) 22 (3.4)  
 Head and Neck 126 14.4  24 (10.6) 102 (11.7)  
 Lung and Bronchus 96 11.0  18 (7.9) 78 (12.1)  
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 Other 151 17.3  36 (15.9) 115 (13.2)  
 Prostate 44 5.0  18 (7.9) 26 (4.0)  
Clinical Stage      0.0018* 
 0 33 3.82  9 (4.0) 24 (3.8)  
 1 189 21.9  52 (23.0) 137 (21.5)  
 2 222 25.7  80 (35.4) 142 (22.3)  
 3 198 22.9  38 (16.8) 160 (25.1)  
 Unknown 230 26.4  48 (21.1) 182 (28.2)  
Death 5 Years or More After 
Diagnosis   
 
   
 Yes 37 4.2  11 (4.8) 26 (4.3) 0.6000 
 No 835 95.8  216 (95.2) 619 (95.7)  
Recurrence 5 Years or More After 
Diagnosis   
 
   
 Yes 3 0.3  0 (0) 3 (0.5) 0.3030 
 No 869 99.7  227 (100.0) 642 (99.5)  
Additional Chemotherapy      0.3370 
 Chemotherapy + 519 59.5  129 (56.8) 390 (60.5)  
 Chemotherapy - 353 40.5  98 (43.2) 255 (39.5)  
Additional Surgery      0.0061* 
 Surgery + 505 57.9  149 (65.6) 356 (55.2)  
 Surgery - 367 42.1  78 (34.4) 289 (44.8)  
Additional Immunotherapy      0.5200 
 Immunotherapy + 43 4.9  13 (5.7) 30 (4.7)  
 Immunotherapy - 829 95.1  214 (9.4) 615 (95.3)  
Comorbid Conditions       
 Anxiety + 192 22.0  74 (32.6) 118 (18.3) <0.0001* 
 Anxiety - 680 78.0  153 (67.4) 527 (81.7)  
        
 Arthritis + 180 20.6  83 (36.6) 97 (15.0) <0.0001* 
 Arthritis - 692 79.4  144 (63.4) 548 (85.0)  
        
 Back Pain + 236 27.1  96 (42.3) 140 (21.7) <0.0001* 
 Back Pain -  636 72.9  131 (57.7) 505 (78.3)  
    
 
   
 Depression + 147 16.8  63 (27.8) 84 (13.0) <0.0001* 
 Depression - 725 83.1  164 (72.3) 561 (87.0)  
        
 Hypertension + 423 48.5  138 (60.8) 285 (44.2) <0.0001* 
 Hypertension - 449 51.5  89 (39.2) 360 (55.8)  
    
 
   
 Lung Disease + 241 27.6  76 (33.5) 165 (25.6) 0.0222* 
 Lung Disease - 631 72.4  151 (66.5) 480 (74.4)  
Substance Use       
 Alcohol Use + 64 7.3  31 (13.7) 33 (5.1) <0.0001* 
 Alcohol Use - 808 92.7  196 (86.3) 612 (95.9)  
        
 Nicotine Use + 295 33.8  109 (48.0) 186 (28.8) <0.0001* 
 Nicotine Use - 577 66.2  118 (52.0) 459 (71.2)  
n = 872. Chi Squared test used unless stated; * denotes statistical significance with p-value < 
0.05; Std: Standard Deviation; IQR: Interquartile Range; 5CS: 5-Year Cancer Survivors; COU: 
Chronic Opioid User; NPOU: New Persistent Opioid User; VCC: Virginia Coordinated Care 
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Figure 5.1: TTD of Opioid Prescriptions in 5CS Following Radiation 
 
Table 5.4: Cox Proportional Hazard Model Results of TTD of Opioids in 5CS 
 Stepwise Stepwise + Theoretical 
Covariates (n=872) HR (95% CI) 
Age 1.01 (1.01, 1.02) 1.02 (1.00, 1.03) 
Race  
 African American 1.01 (0.82, 1.24) 0.95 (0.76, 1.18) 
 Other 1.76 (1.15, 2.70) 1.58 (1.01, 2.48) 
 White Reference 
Gender   
 Male  0.81 (0.60, 1.09) 
 Female  Reference 
Insurance Type   
 Commercial Reference 
 VCC  1.10 (0.79, 1.53)  Insurance, Not Specified  1.71 (1.18, 2.47)  Medicaid  0.94 (0.63, 1.41)  Medicare  0.97 (0.71, 1.33)  Military  2.11 (0.64, 6.93)  Self-Pay  1.15 (0.82, 1.62) 
Opioid Exposure   
 NPOU (ON prior to radiation) 1.38 (1.11 ,1.72) 1.35 (1.07, 1.71) 
 COU (OE prior to radiation) Reference 
Cancer Type   
 Breast Reference 
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 Colorectal 1.22 (0.87, 1.73) 1.08 (0.71, 1.64) 
 Female Genital 0.77 (0.48, 1.24) 0.68 (0.40, 1.14) 
 GI 1.03 (0.62, 1.70) 0.99 (0.55, 1.76) 
 Head and Neck 1.44 (1.01, 2.06) 1.60 (1.01, 2.53) 
 Lung and Bronchus 0.52 (0.35, 0.77) 0.53 (0.33, 0.87) 
 Other 0.90 (0.59, 1.39) 0.91 (0.55, 1.50) 
 Prostate 0.80 (0.46, 1.38) 1.47 (0.69, 3.13) 
Clinical Stage  
 0 Reference 
 1  0.94 (0.58, 1.53)  2  0.77 (0.45, 1.32) 
 3  1.04 (0.59, 1.84) 
Additional Chemotherapy  1.24 (0.92, 1.66) 
Additional Surgery  0.68 (0.50, 0.91) 
Additional Immunotherapy  1.39 (0.82, 2.36) 
Death 5 Years or More After Diagnosis 0.57 (0.36, 0.91) 0.55 (0.34, 0.91) 
Recurrence 5 Years or More After Diagnosis  0.55 (0.13, 2.32) 
Comorbid conditions   
 Anxiety  0.93 (0.73, 1.19) 
 Arthritis  0.89 (0.68, 1.17)  Back Pain  0.91 (0.73, 1.14) 
 Lung Disease  0.97 (0.77, 1.23) 
Substance Use   
 Alcohol Use 0.55 (0.37, 0.81) 0.63 (0.42, 0.95) 
 Nicotine Use  0.78 (0.62, 0.98) 
Bold denotes statistical significance ; NPOU: New Persistent Opioid User; ON: 
Opioid Naïve; OE: Opioid Exposed; COU: Chronic Opioid User; HR: Hazard Ratio; 95% 
CI: 95% Confidence Interval; VCC: Virginia Coordinated Care 
 
Subgroup Analyses 
Opioid Exposure Status 
The majority of patients continuing opioid use after radiation were classified as NPOU 
(74%).  Bivariate analysis with opioid exposure status revealed significantly more females (and 
breast cancers) and patients of African American race in the COU group than in the NPOU 
group (Table 5.3). In the NPOU group, there were more patients with head and neck (laryngeal 
and oropharyngeal) cancers and patients using Medicare. Conversely, in the COU group, there 
were more comorbid diseases and patients using VCC or Medicaid. There was a statistically 
significant difference in median TTD of opioids when patients were grouped by opioid 
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exposure status. Patients’ median TTD was 13.0 months/1.1 years (95% CI: 10.0-17.3 
months) for patients with NPOU compared to 21.4 months/1.8 years (95% CI: 17.5-28.8 
months) for patients with COU (p-value = 0.0004, Figure 5.2). 
 
 
Figure 5.2: TTD of Opioid Prescriptions in 5CS Following Radiation by Opioid Exposure Group 
(TTD: Time to Discontinuation; 5CS: 5-Year Cancer Survivors; COU: Chronic Opioid User, 
NPOU: New Persistent Opioid User) 
 
Patients with VCC Only 
 Similar to the results obtained on the entire sample, the majority of VCC patients were 
classified as NPOU (61.8%), female (71.9%) (with high proportion of patients with breast 
cancer: 43.8%), and having additional chemotherapy (55.9%) or surgery (70.8%) (Table 5.5). 
In contrast to the entire sample, patients with VCC were slightly younger, most patients with 
VCC were Black or African American (56.2%), had comorbid hypertension (58.4%), and less 
than half of the patients used nicotine (49.4%). There was a higher proportion of breast 
cancers in the COU group and higher proportion of colorectal cancers in the NPOU compared 
to the full sample. Additionally, there were higher proportions of anxiety and nicotine use in the 
NPOU group for patients with VCC. 
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Patients with VCC had a median TTD of opioids of 27.2 months (2.3 years; 95% CI: 
12.8-31.3 months, Figure 5.3). No variables were found to be associated with discontinuation 
of opioids from the Cox proportional hazard model stepwise building (Table 5.6).  However, 
from the theoretical model, female genital cancers (HR: 8.54, 95% CI: 2.09-34.92) when 
compared to breast cancer and comorbid back pain (HR: 2.03, 95% CI: 1.12-3.69) were 
associated with shorter TTD of opioids.  
Like the entire sample, bivariate analysis with opioid exposure status showed that there 
were more patients with breast cancer and patients of African American race in the COU group 
than in the NPOU group. There were less male and white patients, and more head and neck 
cancers in the NPOU group than the COU group. There were more comorbid diseases in the 
COU group, except for anxiety (Table 5.5). Unlike the entire sample, there was no statistically 
significant difference in discontinuation of opioids for patients based on opioid exposure status 
(NPOU: 28.5 months/2.4 years, 95% CI: 12.5-32.4 months; COU: 27.2 months/2.3 years, 95% 
CI: 7.5-31.8 months; p-value 0. 6651; Figure 5.4). 
 
Table 5.5: Demographics for 5CS with VCC: Overall and by Opioid Exposure  
 
Overall 
(n = 89) 
 COU 
(n = 34, 38.2%) 
NPOU 
(n = 55, 61.8%) P-value 
  Mean (Std) Median (IQR)  Mean (Std) Mean (Std)  
Age 52.2 (11.4) 52 (14)  55.1 (9.3) 50.5 (12.2) 0.0652 
  N %  N (%) N (%)  
Gender      0.7893 
 Female 64 71.9  25 (73.5) 39 (70.9)  
 Male 25 28.1  9 (26.5) 16 (29.1)  
Race      0.0519† 
 African American 50 56.2  22 (64.7) 28 (50.9)  
 Other 8 9.0  5 (14.7) 3 (5.5)  
 White 31 34.8  7 (20.6) 24 (43.6)  
Cancer Type      <0.0001*† 
 Breast 39 43.8  22 (64.7) 17 (30.9)  
 Female Genital 19 21.4  1 (2.9) 18 (32.7)  
 Gastrointestinal 6 6.7  1 (2.9) 5 (9.1)  
 Head and Neck 5 5.6  1 (2.9) 4 (7.3)  
 Lung and Bronchus 5 5.6  1 (2.9) 4 (7.3)  
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 Other 8 9.0  2 (5.6) 6 (10.9)  
 Prostate 7 7.9  6 (17.7) 1 (7.9)  
Clinical Stage      0.2902 
 0 3 3.4  1 (2.9) 2 (3.6)  
 1 21 23.6  8 (23.5) 13 (23.6)  
 2 27 30.3  14 (41.2) 13 (23.6)  
 3 18 20.2  7 (20.6) 11 (20.0)  
 Unknown 20 22.5  4 (11.8) 16 (29.1)  
Death 5 Years or More After Diagnosis       
 Yes 5 5.6  3 (8.8) 2 (3.6) 0.3660† 
 No 84 94.4  31 (91.2) 53 (96.4)  
Recurrence 5 Years or More After 
Diagnosis   
 
   
 Yes 0 0  0 (0) 0 (0) -- 
 No 34 100  34 (100) 55 (100)  
Additional Chemotherapy      0.7017 
 Chemotherapy + 52 58.4  19 (55.9) 33 (60.0)  
 Chemotherapy - 37 41.6  15 (44.1) 22 (40.0)  
Additional Surgery      0.1595 
 Surgery + 63 70.8  27 (79.4) 36 (65.5)  
 Surgery - 26 29.2  7 (20.6) 19 (34.6)  
Additional Immunotherapy      0.4210† 
 Immunotherapy + 7 7.9  4 (11.8) 3 (5.5)  
 Immunotherapy - 82 92.1  30 (88.2) 52 (94.5)  
Comorbid Conditions       
 Anxiety + 23 25.8  8 (23.5) 15 (27.3) 0.6951 
 Anxiety - 66 74.2  26 (76.5) 40 (72.7)  
        
 Arthritis + 22 24.7  13 (38.3) 9 (16.4) 0.0201* 
 Arthritis - 67 75.3  21 (61.8) 46 (83.6)  
        
 Back Pain + 33 37.1  16 (47.1) 17 (30.9) 0.1254 
 Back Pain -  56 62.9  18 (52.9) 38 (69.1)  
        
 Depression + 10 11.2  5 (14.7) 5 (9.1) 0.4151 
 Depression - 79 88.8  29 (85.3) 50 (90.9)  
    
    
 Hypertension + 52 58.4  22 (64.7) 30 (54.6) 0.3447 
 Hypertension - 37 41.6  12 (35.3) 25 (45.5)  
        
 Lung Disease + 26 29.2  11 (32.4) 15 (27.3) 0.6086 
 Lung Disease - 63 70.8  23 (67.7) 40 (72.7)  
Substance Use       
 Alcohol Use + 4 4.5  3 (8.8) 1 (1.8) 0.1540† 
 Alcohol Use - 85 95.5  31 (91.2) 54 (98.2)  
    
 
   
 Nicotine Use + 44 49.4  18 (52.9) 26 (47.3) 0.6033 
 Nicotine Use - 45 50.6  16 (47.1) 29 (52.7)  
n = 89. Chi Squared test used unless stated; †: Fisher’s Exact Test; * denotes statistical 
significance p < 0.05; 5CS: 5-Year Cancer Survivors; VCC: Virginia Coordinated Care; Std: 
Standard Deviation; IQR: Interquartile Range; COU: Chronic Opioid User; NPOU: New 
Persistent Opioid User 
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Figure 5.3: TTD of Opioid Prescriptions in 5CS with VCC by Opioid Exposure Group  
(TTD: Time to Discontinuation; 5CS: 5-Year Cancer Survivors; VCC: Virginia Coordinated 
Care) 
 
Table 5.6: Cox Proportional Hazard Model Results of TTD of Opioids in 5CS with VCC 
Following Radiation 
 Theoretical 
Covariates HR (95% CI) 
Age 1.04 (1.01, 1.08) 
Race  
 African American 0.94 (0.44, 2.00) 
 Other 0.82 (0.25, 2.64) 
 White Reference 
Gender  
 Male 0.43 (0.13, 1.41) 
 Female Reference 
Opioid Exposure  
 NPOU 0.86 (0.39, 1.89) 
 COU Reference 
Cancer Type  
 Breast Reference 
 Female Genital 8.54 (2.09, 34.92) 
 Gastrointestinal 2.17 (0.48, 9.78) 
 Head and Neck 7.88 (0.97, 63.88) 
 Lung and Bronchus 1.16 (0.16, 8.66) 
 Other 38.50 (3.80, 390.48) 
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 Prostate 5.27 (0.52, 53.22) 
Clinical Stage  
 0 Reference 
 1 0.52 (0.11, 2.54) 
 2 1.46 (0.23, 9.30) 
 3 1.98 (0.27, 14.50) 
 Unknown 0.12 (0.02, 0.92) 
Additional Chemotherapy 1.17 (0.40, 3.48)  
Additional Surgery 2.01 (0.66, 6.07) 
Additional Immunotherapy 2.09 (0.66, 6.64) 
Death 5 Years or More After Diagnosis 0.58 (0.15, 2.30)  
Comorbid conditions  
 Anxiety 0.73 (0.32, 1.66) 
 Arthritis 1.08 (0.51, 2.30) 
 Back Pain 2.03 (1.12, 3.69) 
 Depression 1.44 (0.48, 4.34) 
Substance Use  
 Alcohol Use 2.52 (0.64, 9.94) 
 Nicotine Use 0.78 (0.38, 1.59) 
n = 89; Bold denotes statistical significance; 5CS: TTD: Time to Discontinuation; 5-Year 
Cancer Survivor; NPOU: New Persistent Opioid User; COU: Chronic Opioid User; VCC: 
Virginia Coordinated Care; HR: Hazard Ratio; 95% CI: 95% Confidence Interval 
 
 
Figure 5.4: TTD of Opioid Prescriptions in 5CS with VCC Following Radiation by Opioid 
Exposure Group (TTD: Time to Discontinuation; 5CS: 5-Year Cancer Survivors; COU: Chronic 
Opioid User, NPOU: New Persistent Opioid User, VCC: Virginia Coordinated Care) 
 
 146 
Discussion 
 This is the first study to show that cancer survivors receiving opioid prescriptions after 
completion of CIR continue opioid use for months-to-years after the end of treatment. 
Discontinuation of opioids in these patients should be an essential part of cancer survivor care 
in order to prevent poor outcomes associated with continued opioid use.9 Continued use of 
opioids in non-cancer patients has resulted in “drug abuse and overdose rates [which] 
increased with longer use” and may be the case for patients with cancer.8 Therefore, 
decreasing opioid utilization in patients with cancer that received curative intent radiotherapy 
should be prioritized soon after completion of treatment. 
Our study identifies potentially modifiable patient factors (alcohol and nicotine use) that 
are associated with increased TTD of opioid therapy following CIR. Knowledge of patient use 
of alcohol and nicotine should alert prescribers to the need for substance use management. 
Such knowledge is also helpful for future public health initiatives in order to target interventions 
towards patient populations at-risk for prolonged opioid use after radiation therapy.  
It was not surprising to observe that patients with alcohol and nicotine use had longer 
times to discontinuation of opioids. Current smoking has been shown to be associated with 
increased odds of opioid use disorder and higher daily opioid doses among males.17 
Additionally, studies have shown that almost one third of patients on chronic opioid therapy 
concurrently use alcohol and sedatives.18 Therefore, substance use management should be 
considered for these patients at high risk for continued use, abuse, and misuse.19 
A notable finding was that patients with head and neck experienced earlier 
discontinuation of opioids following curative intent radiotherapy. Head and neck cancers are 
notoriously caustic. As a result, as discussed in Chapter 3, we found an increased risk of 
developing NPOU for patients with these cancers. While patients with head and neck cancers 
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may have increased opioid utilization following radiotherapy (due to caustic disease and 
treatment symptoms such as dysphagia and odynophagia), they may have an easier time 
discontinuing opioids. This could be because they are more likely to have no prior use of 
opioids before treatment which was also highly associated with shorter TTD.  Associated early 
discontinuation with NPOU also suggests that those with longer term opioid exposure may 
have more difficulty in discontinuing. Supporting this, we found that prior opioid exposure 
before initiation of radiotherapy leads to approximately a 2/3 additional year of opioid 
prescription utilization following radiotherapy treatment completion. This could be due to 
increased dependence on opioids or the presence of painful comorbid conditions that persist 
during and after cancer treatment. 
 It was not surprising to find that surgery was associated with longer time to opioid 
discontinuation.  A previous study found that patients with cancer continued filling prescriptions 
with daily doses similar to chronic opioid users one year after curative intent surgery.14  
As suggested from Chapter 2, invasive surgery may be able to limit opioid dose requirement 
due to physical removal of the tumor pain source, but not opioid treatment duration time. 
Additionally, the finding that older patients have shorter times to discontinuation is somewhat 
expected. As patients age, concerns with opioid side effects, such as sedation, risk of falls, 
constipation, respiratory depression, and overdose, increase. This finding is consistent with the 
result from Chapter 3 that there is a decrease in risk of developing NPOU as patients age. 
 The purpose of the VCC subgroup analysis was to assess the robustness of our results.  
Unfortunately, we were unable to replicate overall TTD or difference in discontinuation of 
opioids by opioid exposure group for patients with VCC. This may have been due to low VCC 
sample size, incomplete capture of prescriptions in the full sample, or because the VCC 
subgroup was inherently different from the full sample. We suspect the latter to be true from 
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comparing patient demographics. There were 12.2 percentage points less patients with NPOU 
and 15.6 percentage points more patients with nicotine use in the VCC subgroup than in the 
entire sample. Both of these characteristics were associated with discontinuation time.  NPOU 
was associated with shorter TTD while nicotine use was associated with longer TTD. 
Therefore, patients in the VCC subgroup, may be at higher risk for long-term opioid use 
following CIR because all VCC patients were indigent and because the VCC group included a 
higher proportion of COU and nicotine use, both of which are associated with longer TTD. This 
suggests that the TTD determined in patients with VCC may be on the long end of the range of 
opioid treatment duration following CIR. 
 
Limitations 
There are several limitations to this study.  First, due to its cross-sectional nature, we 
pooled data over ten years. We have shown that the mean opioid dose prescribed decreased 
over time (Chapter 2; especially in later parts of this study) and it could be that those that had 
exposure to higher opioid doses from the first half of the study may have had a more difficult 
time discontinuing opioids or were transitioned to methadone. Additionally, we did not assess 
the type of medication used. Patients that were on methadone may not be eligible to 
discontinue due to maintenance therapy for opioid dependence.  We also did not investigate 
differences between long- and short-acting opioid formulations.  
Second, we utilized prescriptions ordered. These may not have necessarily been filled.  
If prescriptions were not filled, TTD was overestimated.  Conversely, if patients were not 
adherent to medications as prescribed and had gaps between fills, TTD would be 
underestimated.  It is also possible that opioid prescriptions written outside of the institution 
after CIR were missed and we potentially underestimated TTD. We attempted to assess this 
with a subgroup analysis of VCC patients with known prescriptions However, patients in this 
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group were different from the entire sample and, as a result, may be at higher risk for slower 
discontinuation of opioids. 
 Lastly, it would have been ideal to conduct a sensitivity analysis with patients that 
survived only 1 or 3 years beyond diagnosis (1-year cancer survivors [1CS]; 3-year cancer 
survivors [3CS]). However, the median TTD of opioids for the patients in this study was 1.4 
and 2.3 years following end of radiation for the total sample and VCC sample, respectively. 
Including a sensitivity analysis of patients with survival less than the median TTD (1CS) could 
artificially shorten TTD. Including a sensitivity analysis of 3CS could artificially shorten TTD as 
with 1CS, or lengthen TTD, if 3CS continue opioids until end of life (beyond end of study period 
36 months). 
 
Conclusion 
 Cancer survivors receiving opioid prescriptions after completion of CIR continue opioid 
use for a median of almost one and a half years after the end of treatment. Therefore, 
decreasing opioid utilization in patients with cancer after curative intent radiotherapy should be 
prioritized. Evidence-based guidelines for clinical management of opioid use in cancer 
survivors after CIR is warranted to prevent poor outcomes associated with long-term opioid 
use.  Our results indicate that patients that receive surgery or use alcohol or nicotine are more 
likely to have longer times to discontinuation of opioids and should be prioritized for opioid 
management after CIR. 
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CHAPTER 6: DISCUSSION 
Summary of Findings 
This dissertation focused on four specific issues related to opioid utilization in cancer 
survivors that received curative intent radiation (CIR). The first study examined longitudinal 30-
day average daily oral morphine equivalent (OME) doses at a single institution in cancer 
survivors who received CIR that survived at least 5 years without death or recurrence of 
disease (5CS) over the course of a decade.  It also described differences in 30-day average 
daily OME dose by various groups.  The second study examined opioid use patterns (new 
persistent opioid use [NPOU] or chronic opioid use [COU]) in 5CS over the same time period 
and assessed factors associated with opioid use. The third study examined opioid doses in 
5CS before and after CIR as well as factors associated with opioid dose. The final study 
examined time to discontinuation (TTD) of opioids following CIR in 5CS. Major findings are 
summarized in Table 6.1. 
Based on our analysis, there was an increase in 30-day average daily OME dose 
prescribing from late 2009 to 2012, which decreased after 2012. We saw that men, those of 
white compared to black race, those with public insurance, and patients with additional 
chemotherapy or no additional surgery appeared to be prescribed higher 30-day average daily 
OME doses between 2008 and 2018.  Additionally, 5CS at this institution were generally 
prescribed higher rates of opioid prescriptions per patient and 30-day average daily OME 
doses than in the general American, non-cancer public.  Trends of opioid prescribing in the last 
decade for 5CS receiving CIR were similar to previously reported trends in patients without 
cancer and outside of the United States, but with higher per patient prescriptions and 30-day 
average daily OME dose quantities. 
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From our analysis of 5CS receiving CIR, roughly one in five opioid naïve (ON) 5CS 
developed new persistent opioid use (NPOU) and more than half of patients with opioid 
exposure prior to radiation continued opioid use (COU). Certain cancer types (including head 
and neck cancer), stage 3 disease, and additional chemotherapy conferred increased odds of 
NPOU. Sociodemographic factors that conferred increased risk of NPOU included African 
American race, certain insurance types, and comorbid conditions including: arthritis, back pain, 
depression, lung disease, other opioid use, and nicotine use.  Indigent provided health 
insurance, anxiety, back pain, hypertension, and nicotine use were significantly associated 
with increased odds of COU after radiation.  
Our findings suggest that 5CS with opioid prescriptions prior to radiation have, on 
average, prescriptions with sustained doses of 68.2 - 68.3 OMEs per day higher that those that 
do not have opioid prescriptions prior to radiation. We found that most 5CS do not utilize 
opioids long-term before or after CIR.  However, those with public insurance and comorbid 
conditions of anxiety, depression, and other drug use are associated with higher average 
OMEs.  Conversely, 5CS with diabetes and hypertension are associated with lower average 
OMEs.  From our results, we predict that 5CS that undergo CIR for their cancer will use at 
least some level of opioids, on average 4.1 OMEs per day, one year after end of radiation 
regardless of opioid use before CIR. 
Our analysis revealed that 5CS with opioid prescriptions following CIR continue 
receiving opioid prescriptions for almost a year and a half (16.8 months) after completion of 
CIR. Median TTD of opioids was shorter for patients without opioid exposure prior to therapy 
(NPOU; 13.0 months) compared to patients with opioid exposure prior to therapy (COU; 21.4 
months). Factors associated with shorter TTD included NPOU and head and neck cancers. 
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Conversely, additional surgery, death more than five years after diagnosis, as well as alcohol 
and nicotine use were associated with longer TTD of opioids.  
Overall, presence of comorbidities, substance use, and indigent or public insurance 
were associated with greater opioid burden, use, dose and length of time of opioid use. 
Specific Aim 4 of this dissertation was to explicitly describe health disparities including gender, 
race, and insurance status associated with opioid utilization in 5CS (Table 6.2). This study 
identified socioeconomic and health differences in patients receiving CIR that result in 
increased opioid use, odds of NPOU and COU, opioid dose, and longer TTD of opioids (Table 
6.3).  
Just as health disparities exist in cancer and opioid prescribing independently, we were 
able to show that significant health disparities exist in opioid use and development of NPOU 
and COU across models in this study. African American patients were at 38% increased 
estimated odds of developing NPOU. Those of lower socioeconomic status (requiring indigent, 
charity insurance - VCC) were at 60% and 2.39 increased estimated odds of developing NPOU 
and COU, respectively. Additionally, those using Medicaid had 2.08 greater odds of developing 
NPOU.  The results of higher opioid prescription use in low income insurance types following 
radiation therapy may be due to the fact that patients in disadvantaged sociodemographic 
positions have poorer outcomes. Our observations were reinforced with a subgroup analysis of 
5CS with VCC. From our studies, we observed that patients with lower presumed income 
(based on use of Medicaid or institution charity care VCC) carry greater odds of developing 
NPOU or COU. Additionally, higher disease burden in indigent patients resulted in odds ratios 
showing significant associations with NPOU of much higher magnitudes. 5CS with VCC of 
African American race had lower estimates of OME doses over time, controlling for other 
factors. This corresponds with the descriptive results from Chapter 2 showing that those of 
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white race were prescribed higher doses of opioids.  It has been well established that white 
patients receive greater access to opioid analgesics than African Americans, despite similar 
pain levels in non-cancer pain.1–8  While these practices have protected African American 
patients from increased hospitalizations, African Americans have not had pain adequately 
treated.9,10 Even in patients with cancer, African American patients are more likely not to 
receive adequate guideline recommended pain treatment, and more likely to receive 
analgesics with toxic metabolites.11,12 This study adds to the collection of work on racial 
disparities in analgesic treatment, specifically in cancer survivors. 
Health disparities in cancer survivors were echoed in this study with chronic conditions 
and substance use, which are highly prevalent in lower socioeconomic patient populations and 
may confer poorer outcomes. In this study, 5CS with comorbid conditions including anxiety, 
arthritis, back pain, depression, hypertension, and lung disease were at higher risk for higher 
average OME, longer TTD of discontinuation of opioids, and at greater odds of developing 
NPOU or COU.  
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Table 6.1: Summary of Findings  
Chapter 2 3 4 5 
Study 1 2 3 4 
Title Longitudinal Opioid 
Prescription Use in 
Patients with Cancer 
Receiving Radiotherapy 
from 2008 to 2018 at a 
Single Cancer Center 
Incidence and Associated 
Risks of New Persistent 
and Continued Opioid Use 
in Cancer Survivors After 
Curative Intent Radiation 
Prescribed Opioid 
Doses in Cancer 
Survivors Pre and Post 
Curative Intent 
Radiation 
Time to Discontinuation 
of Chronic Opioids in 
Cancer Survivors After 
Curative Intent Radiation 
Objective Describe longitudinal 
trends in 5CS who 
received CIR 
Calculate incidence of and 
examine factors 
associated with NPOU and 
COU in 5CS who received 
CIR 
Determine OME doses 
in 5CS who received 
CIR and factors 
associated with opioid 
dose burden 
Determine TTD of 
opioids in months and 
factors associated with 
length of TTD in 5CS 
following CIR 
Method Descriptive time series Incidence and binomial 
logistic regression 
Panel data model and 
mixed linear model 
Kaplan-Meier survival 
and Cox proportional 
hazard models 
Outcomes Descriptive 30-day 
average daily OME dose 
longitudinal trends 
NPOU and COU incidence 
 
OR of factors associated 
with NPOU and COU 
Average OME dose 
after end of radiation 
 
Predicted OME dose 1 
year following CIR 
TTD of opioids following 
CIR 
 
HR of factors associated 
with TTD 
Major 
Findings 
30-day average daily 
OME dose prescribing 
increased from late 2009 
to 2012, and decreased 
after 2012 
 
Factors with apparent 
higher 30-day average 
daily OME doses:  
• Men 
• White race 
• Chemotherapy 
• No surgery 
19.7% ON 5CS developed 
NPOU 
 
54.8% OE 5CS COU 
 
Factors associated with 
increased risk of NPOU: 
• Head & neck cancers 
• Stage 3 disease 
• Chemotherapy 
• African American race 
• Anxiety 
• Arthritis 
• Back Pain 
• Depression 
• Lung disease 
• Other Opioid use 
• Nicotine use 
 
Factors associated with 
increased risk of COU: 
• VCC 
• Anxiety 
• Back pain 
• Hypertension 
• Nicotine use 
OE 5CS have 68.2 
(PDM) – 68.3 (MLM) 
OMEs prescribed higher 
than ON over time 
 
Factors associated with 
higher average OMEs 
over time: 
• Public insurance 
• Anxiety 
• Depression 
• Other drug use 
 
Factors associated with 
lower average OMEs 
over time: 
• Diabetes 
• Hypertension 
 
5CS are predicted to 
have 4.1 daily OMEs 
prescribed 1 year after 
CIR  
5CS median TTD of 
opioids 16.8 months 
(95% CI: 13.1-19.1) 
following end of radiation 
 
NPOU median TTD: 13.0 
months  
 
COU median TTD: 21.4 
months  
 
Factors associated with 
shorter TTD: 
• NPOU 
• Head & neck cancers 
 
Factors associated with 
longer TTD: 
• Surgery 
• Death after >5 years of 
diagnosis 
• Alcohol use 
• Nicotine use 
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Table 6.2: Specific Aim 4 
Specific Aim 4: In cancer survivors who received curative intent radiation therapy for their malignancy, 
examine health disparities that may exist in sex, race, and socioeconomic status in patients with new 
persistent and continued chronic opioid use 
 
 
Table 6.3: Summary of Health Disparities 
 Gender Race Insurance Comorbid Conditions 
Overall 
Opioid 
Use 
Descriptively 
higher OME: 
• Men 
Descriptively 
higher OME: 
• White 
 
Higher 
average 
OME: 
• White 
with VCC 
Descriptively higher 
OME: 
• Public insurance 
 
Higher average OME: 
• Public insurance 
Higher average OME: 
• Anxiety 
• Depression 
• Other drug use 
 
Associated with longer TTD of opioids: 
• Alcohol use 
• Nicotine use 
NPOU  Associated 
with NPOU: 
• African 
American 
Associated with NPOU: 
• Indigent insurance 
• Public insurance 
Associated with NPOU: 
• Arthritis 
• Back pain 
• Depression 
• Lung disease 
• Other Opioid use 
• Nicotine use 
COU   Associated with COU: 
• Indigent insurance 
Associated with COU: 
• Anxiety 
• Back pain 
• Hypertension 
• Nicotine use 
 
Implications 
 
As cancer therapies continue to improve and patients with cancer continue to live 
longer, opioid use considerations should be of greater concern for survivorship care.  Our 
results have demonstrated substantial opioid use in cancer survivors and, as mentioned 
earlier, there are no evidence-based recommendations for treating cancer pain.  There may be 
justifiable instances for CS where long term opioid use may be necessary for chronic pain.  
However, evidence-based recommendations and guidelines are warranted to prevent potential 
misuse and deaths due to high numbers of patients that continue to use opioids long after CIR, 
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risk of NPOU, COU, and high OMEs utilized. Findings from these studies should serve as a 
baseline for identifying patients with cancer that are at greatest risk of opioid use after CIR. 
Opioids are necessary for pain management of cancer and cancer therapies.  However, once 
patients that have undergone caustic cancer therapies have attained remission or no evidence 
of disease, they must be safely weaned off or transitioned to substance use treatment to 
prevent potential poor outcomes such as overdose and death.  Assessment of factors 
associated with greater and long term use of opioids can help identify patients that may be 
good candidates for substance use treatment.  Lastly, our findings provided real-world 
evidence of opioid use in cancer survivors. 
 
Limitations 
 There are several limitations to our studies.  First, this study only included patients at a 
single, urban, academic institution.  Due to access to only institutional medical records, it is 
possible that outside information may have been missed.  For example, access to the Virginia 
Prescription Monitoring Program (PMP) was not permitted, and therefore, access to additional 
opioid prescriptions written by doctors outside of the VCU Health medical network was not 
available.  Providers at our health system may have different pain management practices or 
preferences that may not be nationally representative.  Thus, the results of this study may only 
be generalizable to other academic institutions of similar size, patient population, and 
geography.  Additionally, the results from our analysis can only be generalized to patients with 
cancer that receive CIR. 
Second, we pooled data over ten years. We have shown that the mean opioid dose 
prescribed was different over time (Chapter 2; especially in later parts of this study).  It could 
be that those that had exposure to higher opioid doses from the first half of the study may have 
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been at higher risk for NPOU and COU, had a more difficult time discontinuing opioids at a 
later time, or were transitioned to maintenance methadone. We did not find significant 
differences between types of medications in our results, but we did not investigate differences 
between long- and short-acting opioid formulations.  
Third, this study utilized prescribing data rather than fill data. There exists the possibility 
of patients not filling prescriptions, or missing prescriptions due to lack of access to opioid 
prescriptions written by doctors outside of the institution. Therefore, missed prescriptions could 
have resulted in underestimation of opioid use if patients received outside opioid prescriptions. 
Conversely, if prescriptions were not filled by the patient, opioid use could have been 
overestimated. In order to address this, we conducted the subgroup analysis with VCC 
patients for which we have all prescribing data. However, patients in this group were sicker 
than the entire sample with a higher proportion of comorbidities and, as a result, may be at 
higher risk for higher opioid use. 
A prescription specific limitation was that there was a large amount of missing 
prescription data information necessary to calculate accurate daily OME doses. In order to 
accurately calculate a daily OME dose, a medication name, medication strength, tablet or 
quantity amount (number of doses), daily frequency, and the OME conversion factor were 
needed. Due to the inherent limitations of documentation of the prescriptions from the 
electronic medical record, 59.6% of prescriptions were missing at least one component of the 
OME dose calculation. This could have resulted in underestimation of opioid use. The authors 
considered imputing missing data to address this issue, however, it was ultimately decided that 
imputation was not necessarily needed due to the large sample size of available prescriptions 
for which all data was available to calculate 30-day average daily OME dose. Patients were 
retained in our sample while prescriptions with missing data were dropped. This likely resulted 
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in underestimations of opioid dose in our sample, suggesting our dose estimates are 
conservative.  
Another prescription limitation was due to the inherent flexibility that prescribers often 
use when writing prescriptions for patients, particularly for “as needed” (i.e. PRN) dosing. 
Ranges were often provided in prescriptions for dose and frequency (i.e. 1-2 tablets every 4-6 
hours per day). Therefore, daily OME doses were calculated based on patients using the 
highest possible dose at the greatest frequency for the ranges given in a prescription.  As a 
result, it is possible that 30-day average daily OME doses may be overestimated. However, 
minimum daily OME doses were also calculated for all prescriptions and differences in results 
were negligible.  
Lastly, we could not differentiate whether the indication for an opioid prescription was 
for cancer or non-cancer pain. Opioid prescriptions due to cancer pain would be, in theory, 
easier to discontinue than those for non-cancer pain after CIR from decreasing or eliminating 
the source of the underlying cancer pain.  
 
Future Directions 
This study assessed opioid utilization in cancer survivors. Future research should 
examine the association of palliative radiotherapy with opioid burden among patients in the last 
6 months of life. While we observed that almost one-fifth of patients develop NPOU, there may 
be a lower incidence of NPOU in cancer survivors receiving radiation due to the potential of 
radiation alleviating some cancer pain.  Additionally, we saw that 5CS utilize high doses of 
opioids, which decreased over time, but were still significantly higher for those with a baseline 
opioid prescription. Addressing opioid trends in the palliative radiotherapy space may indicate 
a lower opioid dose requirement.   
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This study specifically excluded inpatient and acutely prescribed opioids.  Examining the 
association of inpatient opioid administration with long-term opioid utilization in these patients 
should be explored.  We also did not assess prevalence of opioid use disorder (OUD) in our 
patients.  As patients are surviving longer after CIR, risk of OUD should be assessed and 
guidelines for transitioning patients to substance use treatment should be recommended. 
Further, there is a significant need to assess opioid related outcomes in cancer survivors. 
Lastly, our study did not assess health-related quality of life or costs associated with opioid use 
for these patients. 
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